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SUMMARY
This PhD thesis consists of several retrospective and prospective studies in molecular 
epidemiology as well as in genotype and phenotype relationships of Mycobacterium 
tuberculosis. The studies presented in chapters 2 and 3 aimed to uncover the genetic 
diversity and population structure of M. tuberculosis and to formulate a strain-typing 
strategy for M. tuberculosis in Singapore. We analyzed 364 consecutively collected drug-
susceptible M. tuberculosis isolates using IS6110 restriction fragment length 
polymorphism (RFLP) typing, spoligotyping, and mycobacterial interspersed repetitive 
unit-variable number tandem repeat (MIRU-VNTR) typing. We found that all the seven 
major worldwide prevalent families of M. tuberculosis, i.e. the Beijing family (53.8%), 
the East-African-Indian (EAI) family (21.7%), the Haarlem family (8%), the Latin-
American-Mediterranean (LAM) family (1.6%), the Central Asia (CAS) family (0.5%), 
the T family (9.1%), and the X family (0.8%), were present in Singapore. Moreover, a 
novel evolutionary clone was identified and designated as “S” family (4.5%). These data 
showed the high genetic diversity of M. tuberculosis and the predominance of the Beijing 
genotype in Singapore. Among the three typing methods, no single method could 
differentiate all unique isolates. We then analyzed the discriminatory power of different 
combinations of the three methods. The combination of IS6110 RFLP and MIRU-VNTR 
typing showed the highest discriminatory power. A two-step strain-typing strategy has 
therefore been proposed that uses MIRU-VNTR typing as first line screening method and 
IS6110 RFLP typing as secondary typing modality for MIRU-VNTR defined clusters. 
This typing strategy would greatly reduce typing workload and provide ‘real-time’ results 
for most isolates. 
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The study presented in chapter 4 aimed to examine the relationship between M. 
tuberculosis Beijing genotype strains and tuberculosis relapse. Our results showed that 
the Beijing genotype was associated with tuberculosis relapse in Singapore (odds ratio, 
2.64; p = 0.005).
The study presented in chapter 5 aimed to understand the transmission dynamics 
of drug-resistant tuberculosis and relationships between genotypes and drug-resistant 
phenotypes of M. tuberculosis. We analyzed a population sample of 234 drug-resistant 
isolates using genotyping methods. We found that the Beijing genotype (odds ratio, 2.61; 
p = 0.017) and resistance to streptomycin (odds ratio, 2.01; p = 0.044) were risk factors 
for clustering and that only about 11% of drug-resistant tuberculosis was due to recent 
transmission. In addition, we also found that there were several significant positive and 
negative associations between M. tuberculosis genotypes and drug-resistant phenotypes. 
These data suggest that the transmission of drug-resistant tuberculosis is low in Singapore 
and different genotypes of M. tuberculosis may have different preference in the 
development of drug-resistant patterns. 
The study presented in chapter 6 aimed to investigate whether Beijing genotype 
strains elicit a weaker Th1 immunity and are clinically more virulent in human 
tuberculosis. By clinically and immunologically comparing tuberculosis associated with 
Beijing and non-Beijing strains, we found that patients in the Beijing group were 
characterized by significantly lower frequency of fever (odds ratio, 0.12; p = 0.008) and 
pulmonary cavitation (odds ratio, 0.2; p = 0.049). Night sweats were also significantly 
less frequent by univariate analysis, and the duration of cough prior to diagnosis was 
longer in Beijing compared to non-Beijing groups (medians, 60 versus 30 days, p = 
x0.048). The plasma and gene expression levels of IFN-  and IL-18 were similar in the 
two groups. However, patients in the non-Beijing group had significantly increased IL-4 
gene expression (p = 0.018) and lower IFN- : IL-4 cDNA copy number ratios (p = 0.01). 
These findings suggest that patients with tuberculosis caused by Beijing strains appear to 
be less symptomatic than those who have disease caused by other strains. Th1 immune 
responses are similar in patients infected with Beijing and non-Beijing strains but non-
Beijing strains activate more Th2 immune responses compared with Beijing strains, as 
evidenced by increased IL-4 expression.
xi
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                                                              CHAPTER 1
LITERATURE REVIEW
21.1 History and Epidemiology
Tuberculosis is an ancient human disease caused by bacterial infection and remains 
among the top 10 causes of death in the world today (Bleed et al., 2000). Molecular 
evidence from the Egyptian and South American mummies date it back to thousands of 
years ago (Salo et al., 1994; Nerlich et al., 1997). The disease became epidemic first in 
Europe about 400 years ago. Europe became the epicenter of many tuberculosis 
epidemics from the 16th century onwards due to population expansion, industrialization, 
and development of large urban centers. In the 18th-19th centuries, tuberculosis was the 
major cause of death in Europe. It is estimated that one-quarter of Europeans died of the 
disease. In 1882, Robert Koch first identified the etiological agent of tuberculosis, 
Mycobacterium tuberculosis, from patient’s sputum. It has been long thought that 
tuberculosis was spread into Europe followed the immigration of Indo-European cattle 
herders who were infected by tubercle bacillus, M. bovis or an adaptor, from cattle (Bates 
and Stead, 1993). However, this hypothesis has been refuted by a very recent study in 
which the new findings suggest that M. bovis is the final evolutionary member of a 
diverged lineage from M. tuberculosis which includes M. africanum, M. microti, and M. 
bovis. This novel evolutionary scenario for M. tuberculosis complex suggests that M. 
tuberculosis is the progenitor of M. bovis (Brosch et al., 2002).
Tuberculosis peaked in Europe in the first half of the 19th century. It declined in 
the latter half of the 19th century largely because of socioeconomic improvements and 
possibly also because of the isolation of infectious cases. The declining trend was 
maintained throughout most of the 20th century and accelerated by the widespread 
vaccination of an attenuated Bacille Calmette-Guerin (BCG) vaccine and the application 
3of antituberculosis agents in the latter half of the 20th century. This resulted in neglect to 
the epidemic and the wane of necessary public health infrastructure for tuberculosis 
control for a period of time in developed countries (Maher and Raviglione, 2005) despite 
it was still a problem in the developing world.
Tuberculosis was spread to the other regions of the world by European 
immigration and colonization in the 400 years from the 16th-19th centuries. It reached 
peak about a century later in Asia than was in Europe, even later in some other areas, 
such as, Papua New Guinea, Indonesia, and the sub-Sahara of Africa (Bates and Stead, 
1993; Smith, 2003). The epidemic has since been a public health problem in developing 
countries.
The declining trend in developed countries, however, has been reversed since the 
mid-1980s and the disease has re-emerged as a major killer worldwide. In 1993, the 
World Health Organization (WHO) declared tuberculosis a global emergency. It is 
estimated by the WHO that one third of the global population is infected by M. 
tuberculosis, with approximately 8 million new tuberculosis cases and 2 million deaths 
reported annually (Corbett et al., 2003). Developing countries bear the brunt of the 
tuberculosis epidemic, about 95% of the world’s tuberculosis cases and 98% of the 
tuberculosis deaths occur in the developing countries (Maher and Raviglione, 2005). The 
top 22 high-burden countries accounted for roughly 80% of the world’s tuberculosis 
cases in 2002 (WHO, 2004; Maher and Raviglione, 2005). For example, India alone takes 
20% of the burden. Poverty, HIV pandemic, malnutrition, poor health care, and lack of 
adequate tuberculosis control are among the factors that are responsible for this heavy 
burden in the developing world. HIV infection has emerged as the most important risk 
4factor for progression of dormant M. tuberculosis infection to active disease and for 
contracting the disease from new infection in the sub-Sahara Africa and some other areas 
of the world (Maher and Raviglione, 2005). In developed countries, tuberculosis is a 
disease occurring mostly in some specific groups of persons, such as the homeless, 
foreign-born immigrants from countries with high tuberculosis incidence, and also 
HIV/AIDS patients.
To effectively control the epidemic, the WHO has promoted a global five-element 
strategy, called directly observed treatment by standard short-course anti-tuberculosis 
therapy (DOTS) in 1993 (Maher and Mikulencak, 1999; WHO, 2002). The five elements 
of DOTS include:
1. Sustained government commitment to tuberculosis control;
2. Diagnosis based on quality-assured sputum-smear microscopy mainly among 
symptomatic patients presenting to health services;
3. Standardized short-course chemotherapy for all cases of tuberculosis, under 
proper case-management conditions including direct observation of treatment;
4. Uninterrupted supply of quality-assured drugs;
5. A standard recording and reporting system enabling program monitoring by 
systematic assessment of treatment outcomes of all patients registered.
Despite the global efforts, the two targets of the DOTS program (to detect at least 
70% of all smear-positive tuberculosis cases, and to treat successfully at least 85% of the 
detected smear-positive tuberculosis case) set for the period of 1993 to 2000 was not 
reached and has been re-set to 2005 (WHO, 2000a). The achievement of the two target 
percentages of the DOTS would eventually reduce both the prevalence of infectious 
5tuberculosis cases and the number of infected contacts by about 40% and would lead to 
an expected decline in annual tuberculosis incidence rate of 6% to 7% per year, and by 
2015 to have halted and begun to reverse the incidence and death rates of tuberculosis 
(Maher and Raviglione, 2005).
1.2 The M. tuberculosis Complex
The M. tuberculosis complex (MTC) consists of a group of acid-fast mycobacteria which 
cause tuberculosis diseases in a wide range of mammalian hosts (Cole, 2002). It 
comprises five classical species. The species M. tuberculosis and M. africanum are 
human pathogens, but infections by the two species have also been found in other 
primates and animals (Cole, 2002); unlike M. tuberculosis, M. africanum is prevalent 
only in equatorial Africa (Aranaz et al., 1999), although it has recently been isolated from 
African and Vietnamese immigrants in Europe and the United States (Viana-Niero et al., 
2001; Desmond et al., 2004); M. bovis is the causative agent of bovine-type tuberculosis, 
infects a wide range of animal species and man (Morris et al., 1994; O’Reilly and 
Daborn, 1995); M. bovis BCG is a laboratory-attenuated vaccine strain of M. bovis, has 
been used extensively as a vaccine against human tuberculosis; M. microti is the cause of 
vole tuberculosis, almost exclusively a rodent pathogen and has been successfully used as 
a live vaccine (Frota et al., 2004). Recently, three new members of the MTC, M. canettii
(van Soolingen et al., 1997), M. pinnipedii (Cousins et al., 2003), and M. capare (Aranaz 
et al., 1999, 2003) have been reported, and were found to affect a variety of mammals, 
but mainly cause diseases in humans, seals, and goats respectively. The MTC members 
therefore differ greatly in their host tropisms, phenotypes, epidemiology, pathogenesis, 
6and in some biochemical characteristics; for example, M. bovis isolates are naturally 
resistant to pyrazinamid, whereas M. capare isolates are sensitive to the drug (Aranaz et 
al., 1999).
Genetically, however, there has been extensive experimental evidence showing 
that the MTC bacilli are highly conserved. At individual gene level, the nucleotide 
sequences of 16S rRNA gene (Böddinghaus et al., 1990; Rogall et al., 1990, van 
Soolingen et al., 1997), the dnaJ gene (Takewaki et al., 1993), the 65 kDa heat-shock 
protein gene (Telenti et al., 1993), the internal transcribed spacer (ITS) region between 
16S rRNA and 23S rRNA (Frothingham et al., 1994; Glennon et al., 1994), and many 
more other genes (Sreevatsan et al., 1997) are identical among the members of the MTC. 
At whole genome level, the species of the MTC share greater than 99% of DNA identity 
(Brosch et al., 2000). Furthermore, DNA sequence analysis of the MTC isolates have 
revealed that allelic polymorphism is extremely restricted, occurring in 1 in 10,000 base 
pairs, significantly less compared to other pathogenic bacteria (Sreevatsan et al., 1997). 
As such, it has been suggested that the species of the MTC should be re-classified as 
subspecies of M. tuberculosis (van Soolingen, 2001; Mostowy et al., 2002).
1.3 DNA Fingerprinting Methods of M. tuberculosis
There have been a great number of methods for M. tuberculosis genotyping developed in 
the last fifteen years (Kremer et al., 1999; van Soolingen, 2001; Mazars et al., 2001). 
Among them, IS6110 restriction fragment length polymorphism (RFLP) typing (van 
Embeden 1993), spoligotyping (Kamerbeek et al., 1997), and mycobacterial interspersed 
7repetitive unit-variable number tandem repeat (MIRU-VNTR) typing (Mazars et al., 
2001) are the most widely used.
1.3.1 IS6110 RFLP Typing
The mobile insertion sequence IS6110 was first identified from the chromosome of M. 
tuberculosis in 1990 (Thierry et al., 1990a; McAdam et al., 1990) and was found to be 
specific to the members of the MTC (Hermans et al., 1990; Thierry et al., 1990b; Cave et 
al., 1991). It has since been widely used as a PCR diagnostic marker for tuberculosis 
(Hermans et al., 1990; Thierry et al., 1990b; Brisson-Noel et al., 1991) and a DNA 
fingerprinting marker of MTC isolates (Hermans et al., 1990; Thierry et al., 1990b; Cave 
et al., 1991).
IS6110 RFLP typing is based on the difference of copy numbers, ranging from 0 
to about 25, and variability in chromosomal positions of IS6110 inserts between strains 
(Hermans et al., 1990; Cave et al., 1991). Three underlying mutational mechanisms, 
including IS6110 insertion, chromosomal mutation, and deletion, may drive the IS6110
RFLP diversity (Warren et al., 2000). IS6110 RFLP typing is reproducible and highly 
discriminatory on population level (Kremer et al., 1999), and currently serves as a “gold 
standard” strain-typing technique for M. tuberculosis (van Soolingen 2001). However, 
IS6110 RFLP typing has several disadvantages. It is a slow, cumbersome, labour 
intensive and technically demanding technique requiring relatively large amounts ( 2 
g) of high quality bacterial DNA, an amount that can only be extracted from a large 
number of bacteria obtained from subcultures of M. tuberculosis. The time to grow the 
bacteria usually takes weeks. Also, this method has very poor discriminatory power for 
8isolates with fewer than 6 of IS6110 copies, and is not informative for isolates, though 
very rare, which do not have IS6110 insert (Das et al., 1995; van Soolingen 2001). 
Finally, to facilitate interlaboratory comparison of IS6110 RFLP patterns, a 
internationally standardized methodology has been recommended (van Embeden et al., 
1993); despite this, it remains difficult to compare IS6110 RFLP results between 
laboratories as sophisticated computer software are required to analyze IS6110 RFLP 
patterns.
Therefore, in order to increase the discriminatory power of IS6110 RFLP typing, 
a secondary strain-typing method is needed for the isolates with fewer than 6 IS6110
copies. The most used methods for this purpose are spoligotyping (Bauer et al., 1999; 
Yang et al., 2001; Kwara et al., 2003), MIRU-VNTR typing (Cowan et al., 2002; Kwara 
et al., 2003), and the polymorphic GC-rich sequence (PGRS) RFLP typing (Yang et al., 
2001).
1.3.2 Spoligotyping
Spoligotyping is based on the hybridization detection of the presence or absence of 43 
distinct direct variant repeats (DVRs) in the direct repeat (DR) region of the bacillary 
genome, each DVR consists of an identical 36-bp direct repeat sequence and a variable 
(both in length, 35 to 41 bp, and in nucleotide sequences) spacer DNA sequence 
(Kamerbeek et al., 1997).
Spoligotyping is a PCR-based strain-typing method, thus need only a few bacteria 
that can be obtained from either the primary culture of the bacilli or directly from clinical 
specimens (Heyderman et al., 1998), or even from slides of Ziehl-Neelsen staining (van 
9der Zanden et al., 1998), making it a “real-time” analysis tool. Furthermore, this method 
is highly reproducible and easy to perform (Kremer et al., 1999); particularly 
spoligotypes can be digitized into binary or octal code formats (Dale et al., 2001) which 
greatly facilitate the management and interlaboratory comparison of spoligotyping data. 
An international spoligotyping database (SpolDB) has been set up in the Unite de la 
Tuberculose et des Mycobacteries, Institut Pasteur de Guadeloupe (http://www.pasteur-
guadeloupe.fr/tb). By decoding the spoligotypes in the database, worldwide prevalent M. 
tuberculosis isolates have been classified into seven major families and some minors 
(Filliol et al., 2002). With more spoligotyping data available, novel families have been 
and will be defined (Garcia de Viedma et al., 2005). However, the discriminatory power 
of spoligotyping is generally poor, not able to provide sufficient discrimination between 
isolates, especially for the Beijing genotype strains, this method is not informative as vast 
majority of Beijing strains share an identical spoligotype (van Soolingen et al., 1995, 
Kremer et al., 2004).
1.3.3 MIRU-VNTR Typing
The genome of M. tuberculosis contains many minisatellite-like variable number tandem 
repeat (VNTR) loci (Frothingham and Meeker-O’Connell, 1998; Supply et al., 2000), 
some of these VNTR loci are named as mycobacterial interspersed repetitive unit 
(MIRU) loci due to some specific genetic features of the loci in mycobacteria (Supply et 
al., 2000). The repeat sequences of each locus are either identical or slightly variable in 
sequence or length (Frothingham and Meeker-O’Connell, 1998; Supply et al., 2000). 
MIRU-VNTR typing makes use of 12 such loci which are variable between strains in the 
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number of repeats; after PCR amplification of the 12 locus DNA sequences, the length of 
the PCR amplicons is converted into repeat numbers in term of every specific repeat 
length (Marzas et al., 2001).
Similarly as spoligotyping, MIRU-VNTR typing is a PCR-based typing method, 
therefore needs only 103 to 106 times less DNA than does IS6110 RFLP, hence can 
provide ‘real-time’ typing results. But, this technique is highly reliable and the most 
reproducible, easy to perform, and MIRU-VNTR patterns are documented in 12 digital 
numbers. More importantly, MIRU-VNTR typing is comparable to IS6110 RFLP typing 
in discriminatory power (Mazars et al., 2001), and performs greatly better than IS6110
RFLP for strains with low IS6110 copies, particularly for strains with one or zero IS6110
copy (Mazars et al., 2001; Cowan et al., 2002). Moreover, this method can achieve 
substantially better discrimination for Beijing strains than does spoligotyping which is 
not discriminatory (Supply et al., 2001; Kam et al., 2005). MIRU-VNTR typing has been 
adapted high-throughput automation using gel-electrophoresis-based genescan analysis 
(Supply et al., 2001) which makes this method suitable for the global study of the 
molecular epidemiology of M. tuberculosis.
1.4 Epidemiological Applications of M. tuberculosis DNA Fingerprinting
The development of DNA fingerprinting techniques for typing M. tuberculosis isolates 
has led to an increasing number of studies of the molecular epidemiology of tuberculosis. 
The principal basis of molecular epidemiology of tuberculosis is to determine the genetic 
relatedness between clinical M. tuberculosis isolates by DNA fingerprints, and then use 
this to determine the clinical or epidemiological relationships of the isolates. Due to the 
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nature of clonal expansion of M. tuberculosis, epidemiologically-related isolates have 
identical or nearly identical DNA fingerprints, whereas epidemiologically-unrelated 
isolates show distinct DNA fingerprints from each other. Thus, the relationships between 
clinical isolates can be inferred from their DNA fingerprints (van Soolingen, 2001). In 
this application, however, the genetic marker used for strain-typing is pivotal. IS6110
RFLP has been the most used on the basis of assumption that IS6110 RFLP patterns in 
epidemiologically unrelated M. tuberculosis strains are sufficiently variable to label each 
strain as unique one, whereas epidemiologically related M. tuberculosis strains show 
identical or highly similar (one or two band difference) patterns. The validity of this 
assumption depends on the evolutionary speed of IS6110; it should be fast enough to 
generate substantial diversities of IS6110 RFLP to distinguish unrelated strains yet stable 
enough in a certain time interval to identify isolates of the same strains in 
epidemiological events (Yeh et al., 1998). A number of studies have analyzed the 
stability of IS6110 RFLP patterns of M. tuberculosis clinical isolates with > 5 IS6110
copies and shown that IS6110 insert is at a suitable evolutionary speed to be used in this 
connection (Cave et al., 1994; de Boer et al., 1999; Niemann et al., 2000; Warren et al., 
2002a). For example, a study conducted in The Netherlands using 544 serial isolates from 
patients found that the half-life of IS6110 RFLP patterns was 3.2 years (de Boer et al., 
1999). This means that on average half of the stains exhibit a band shift in their IS6110
RFLP patterns in a period of 3-4 years. This interval is sufficient for distinguishing 
epidemiologically-related and -unrelated isolates. This has been supported by many 
application studies in different settings over the years (Alland et al., 1994; Small et al., 
1994; Borgdorff et al., 1998; van Soolingen et al., 1999; Garcia-Garcia et al., 2000a; van 
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Deutekom et al., 2004). In the study by van Soolingen et al. (1999), the authors found 
that 2 years may be a suitable study period to analyze transmission, shorter than that 
would underestimate transmission, longer than that would overestimate transmission.
However, IS6110 RFLP is not suitable for isolates with  5 IS6110 copies, 
especially for isolates with one or zero copies (Hermans et al., 1991; Yuen et al., 1993; 
Borgdorff et al., 1998). In this case, a secondary typing method, such as the polymorphic 
GC-rich sequence (PGRS) RFLP (van Soolingen et al., 1993; Borgdorff et al., 1998), 
spoligotyping (Goguet-de-la-Salmoiere et al., 1997; Bauer et al., 1999), and MIRU-
VNTR typing (Mazars et al., 2001; Kwara et al., 2003), is needed to increase resolution. 
The PGRS RFLP typing is also a complicated method and difficult to be standardized, 
thus not be often used. Spoligotypes are too stable to yield satisfactory discrimination, 
often overestimate clustering rate; especially in the areas with high proportions of Beijing 
genotypes strains, spoligotyping is almost not informative whether used as first-line or 
secondary typing method (van Soolingen et al., 2001). MIRU-VNTR typing has been 
shown a suitable secondary typing method (Mazars et al., 2001; Cowan et al., 2002; 
Kwara et al., 2003; Blackwood et al., 2004), and some studies have suggested using 
MIRU-VNTR typing as first-line method either as alternative of IS6110 RFLP typing 
(Blackwood et al., 2004) or in combination with IS6110 RFLP typing (Mazars et al., 
2001; Supply et al., 2001; Cowan et al., 2002; Kwara et al., 2003). On the other hand, 
some studies have also cast doubt to the suitability of MIRU-VNTR typing towards its 
application in molecular epidemiology because it can split clusters consisting of isolates 
with high number of IS6110 copies (Kam et al., 2005; Scott et al., 2005). Therefore, more 
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studies based on confirmed epidemiological events are needed to further evaluate MIRU-
VNTR typing in settings with different M. tuberculosis population structures.
1.4.1 Identification of Outbreaks and Transmission Analysis of M. tuberculosis
Tuberculosis is a disease spread by transmission from person to person. A major 
tuberculosis control measure is to interfere with the transmission of the bacilli by 
identifying foci of transmission. DNA fingerprinting has been used in many settings to 
define outbreaks and to estimate the extent of recent transmission (Alland et al., 1994; 
Small et al., 1994; van Soolingen et al., 1999; van Deutekom et al., 2004). In this regard, 
molecular epidemiological analysis of tuberculosis has proven markedly more effective 
than conventional epidemiological tools, which have very limited value in this situation 
(Small et al., 1994; van Deutekom et al., 2004). In the population-based study by 
Deutekom et al. (2004), as high as 86% of epidemiologically-related patients were not 
identified by conventional contact tracing.
1.4.2 Differentiation of Endogenous Reactivation and Exogenous Reinfection
Recurrent tuberculosis may result from the reactivation of endogenous primary infection 
(relapse) or from a recent exogenous reinfection (van Rie et al., 1999). DNA 
fingerprinting serves as a conclusive method to differentiate these two events from each 
other by fingerprinting M. tuberculosis isolates of the primary and recurrent episodes. If 
the paired isolates of primary and recurrent episodes of one patient are identical (or 
nearly identical, with one or two band difference) in their DNA fingerprints (usually 
IS6110 RFLP), the recurrent event is regarded as a reactivation; otherwise, if the paired 
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isolates exhibit different DNA fingerprints, the recurrent event is considered to be 
reinfection. Studies in this connection have changed the traditional perspective that 
recurrent tuberculosis could be only a result of endogenous reactivation of primary 
infection. It is now considered that even in areas with low incidence of tuberculosis, 
reinfection could contribute to tuberculosis recurrence (Bandera et al., 2001; Garcia de 
Viedma et al., 2002). An accurate differentiation of reactivation and reinfection is 
essential for the determination of treatment failure rate and transmission level.
1.4.3 Identification of Laboratory Cross-contamination
Laboratory cross-contamination can lead to incorrect diagnosis and it has been reported 
in a prospective multicenter study that about 2% of all positive cultures are due to 
laboratory cross-contaminations (Jasmer et al., 2002). Therefore, it is important to 
identify cross-contamination as a regular practice. DNA fingerprinting has been used to 
identify or to confirm laboratory cross-contaminations. In this regard, IS6110 RFLP 
typing seems more powerful due to its faster evolutionary speed (Small et al., 1993; 
Bauer et al., 1997); but a recent study has also demonstrated the utility of MIRU-VNTR 
typing in this aspect (Allix et al., 2004).
1.4.4 Identification of Simultaneous Infection with Multiple Strains
Simultaneous infections with multiple strains have been reported and documented by 
both IS6110 RFLP typing (Yeh et al., 1999; Das et al., 2004) and MIRU-VNTR typing 
(Allix et al., 2004). Mixed infection could be confused with exogenous reinfection and 
laboratory cross-contamination.
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1.5 Other Applications of DNA Fingerprinting of M. tuberculosis
1.5.1 Improving Speciation of M. tuberculosis Complex Isolates
DNA fingerprinting has led to improvements in identification and recognition of 
subspecies of the MTC that do not fit the previous classifications based on biochemical 
tests and growth characteristics. For example, in a study in Guinea-Bissau, Källenius et 
al. (Källenius et al. 1999) found that 140 out of 229 MTC strains could be allocated into 
one of three biovars, representing a spectrum between the classical bovine and human 
tubercle bacilli, using biochemical criteria. Although phenotypically heterogeneous these 
strains were genomically homogeneous and it was proposed that these strains constitute a 
distinct branch of the MTC tree between classical M. bovis and classical M. tuberculosis
(Koivula et al., 2004) based on genetic markers. In another study by Niemann et al., 
(Niemann et al., 2002), the authors found that phenotypically-defined M. africanum
subtype II is the main cause of human tuberculosis in Kampala, Uganda; by using genetic 
markers these strains has recently been reclassified as modern M. tuberculosis strains 
(Mostowy et al., 2004).
1.5.2 Uncovering of Population Structures of M. tuberculosis
Studying changes in population structure of M. tuberculosis is important to understand 
the adaptation of infectious agents to control measures. Strain-typing of isolates has 
revealed that the population structure of M. tuberculosis varies geographically. In low-
incidence areas, IS6110 RFLP patterns were highly polymorphic (Small et al., 1994; van 
Soolingen et al., 1999; Blackwood et al., 2005), reflecting the importance of reactivated 
disease, whereas the M. tuberculosis isolates in high-incidence areas showed much more 
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homogeneous IS6110 RFLP patterns (Das et al., 1995; Bhanu et al., 2002), reflecting the 
active occurrence of ongoing transmission. DNA fingerprinting studies have also 
revealed that many local dominant clones of M. tuberculosis were endemic in different 
areas (van Soolingen et al., 1995; Bhanu et al. 2002; Douglas et al., 2003). This local 
dominance of specific M. tuberculosis clones suggests their selective advantages over 
others (van Soolingen et al., 1995), and may be related to local human biological and/or 
environmental factors (Hirsh et al., 2004).
1.5.3 Phylogenetic and Evolutionary Analysis
DNA fingerprinting generated huge amount of genetic data which have been used to 
study the phylogeny and evolution of the MTB members. Analyses by various genetic 
markers indicate that M. tuberculosis evolves and disseminates by clonal expansion 
(Warren et al., 2001; Supply et al., 2003; Baker et al., 2004) which results in great 
geographic variations in the distribution of M. tuberculosis evolutionary lineages (Sola et 
al., 2002; Filliol et al., 2002; Baker et al., 2004).
Spoligotyping is the most useful typing technique for phylogenetic study. Based 
on spoligotype, the global M. tuberculosis isolates can be well assigned into seven major 
evolutionary lineages and some minor ones, each family is defined by common family 
characteristics of spoligotype (Filliol et al., 2002; Sebban et al., 2002, Kremer et al., 
2004). Grouping of M. tuberculosis isolates by spoligotype can reveal useful information 
for understanding of the evolutionary history, the phylogeographical distribution, the 
global transmission of the bacilli (Sola et al., 1999, 2001; Warren et al., 2002b; Dale et 
al., 2003; Filliol et al., 2003, Baker et al., 2004), and family-specific disease phenotypes 
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and pathogenesis (Glynn et al., 2002; Bifani et al., 2002, Baker et al., 2004). This 
application has been widely used to identify Beijing genotype strains for studying their 
relationships with various phenotypes (Anh et al., 2000; van Crevel., 2001; Lan et al., 
2003; Toungoussova et al., 2003; Drobniewski et al., 2005).
1.6 Human Immunity to Tuberculosis
1.6.1 Innate Immunity
Whether an individual infected with M. tuberculosis does or does not develop clinical 
disease is determined by the complex immune interplay between host and the pathogen. It 
is estimated that in the infected population only 5-10% progress to active tuberculosis, 
90-95% never develop active disease but remain lifelong asymptomatic latent infection; 
and among the diseased, about 85% of cases involve exclusively the lungs only (Boom et 
al., 2003; North and Jung, 2004).
It is generally believed that the initial immune defense to M. tuberculosis is the 
local innate immunity in lung, mediated primarily by alveolar macrophages. Inhaled 
mycobacteria are engulfed by alveolar macrophages through phagocytosis, and the 
macrophages can inhibit their growth and kill them via a variety of antimicrobial 
mechanisms. The degradation of phagocytosed mycobacteria by intralysosomal acidic 
hydrolases upon phagolysosome fusion constitutes a significant antimicrobial mechanism 
of phagocytes (Cohn and Wiener, 1963). Macrophages can kill mycobacteria through 
effector functions by producing reactive oxygen intermediates (ROI), such as H2O2
(Flesch and Kaufmann, 1987), and reactive nitrogen intermediates (RNI), such as nitric 
oxide (NO) and related RNI via inducible nitric oxide synthase (iNOS) (Nicholson et al, 
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1996; MacMicking et al., 1997). These effector functions are believed to be upon the 
activation of phagocytes by interferon- (IFN-) and tumor necrosis factor-α (TNF-α). 
Another potential mechanism involved in macrophage defense against M. tuberculosis is 
apoptosis of infected cells (Placido et al., 1997). This TNF-α mediated programmed cell 
death can limit outgrowth of M. tuberculosis (Placido et al., 1997), reduce viability of 
intracellular mycobacteria (Molloy et al., 1994).
In addition to lung macrophages, natural killer (NK) T lymphocytes also involve 
in host innate immunity against mycobacteria. T lymphocytes can be recruited to the 
macrophages and further stimulate it, possibly by producing IFN- (Iho et al., 1999), to 
inhibit growth of or kill mycobacteria. Cytotoxic T lymphocytes can ingest macrophages 
that have engulfed mycobacteria (Stenger et al., 1997) and kill them through apoptosis.
Toll-like receptors (TLRs) are phylogenetically conserved mediators of innate 
immunity which are essential for microbial recognition on macrophages and dendritic 
cells (Medzhitov and Janeway Jr., 1997). The importance of TLRs in tuberculosis 
immunity is that they can recognize the wall components of M. tuberculosis, such as 
lipoarabinomanan (LAM), and through this specific route M. tuberculosis can activate
macrophages and dendritic cells. The specific TLRs so far identified for M. tuberculosis
are TLR-2 and TLR-4 (Means et al., 1999).
But the fate of ingested bacilli in macrophages depends on the virulence of 
individual mycobacterial isolates and the intrinsic microbicidal capacity of host 
phagocytes. A recent study has shown the substantial variability in the capacity of clinical 
tuberculosis isolates to replicate in host cells in the face of innate host immunity
(Janulionis et al., 2005). The importance of the intrinsic microbicidal capacity of host 
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phagocytes has been shown by the associations between the polymorphisms of some 
human genes which encode various macrophage products, such as the natural resistance-
associated macrophage protein (NRAMP1) gene, the interleukin 1 (IL-1) gene cluster, the 
vitamin D receptor gene and mannose-binding lectin gene, and the susceptibility to M. 
tuberculosis (Bellamy et al., 2000). Individuals with certain polymorphisms in these 
genes may render them susceptible to mycobacterial infection. However, to what extent 
these genes can affect the susceptibility is unknown. A case-control study on vitamin D 
deficiency in the Gujarati population in London showed that such effect is likely small 
(Wilkinson et al., 2000).
1.6.2 Acquired Immunity
If innate immune responses fail to eliminate ingested bacilli, the surviving bacilli will 
multiply and stimulate the immune system to develop adaptive immunity. In fact, the 
ubiquitous acquisition of anti-tuberculosis specific adaptive immunity in the diseased and 
the latently infected suggest that the innate cellular immunity often fail to eliminate the 
bacteria.
Humoral immunity. It is generally assumed that acquired humoral immune response is 
not relevant with protection in tuberculosis, but maybe there are some antibodies are 
protective (Teitelbaum et al., 1998).
Cellular immunity. Cell-mediated immune responses are pivotal in tuberculosis, which 
can be protective or detrimental. The protective immunity against tuberculosis is called 
Th1 immune response, which is characterized by Th1 cytokines, primarily IFN-, IL-2, 
and IL-12. The detrimental immunity in tuberculosis is called Th2 immune response, 
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which is characterized by Th2 cytokines, mainly IL-4, IL-5, and IL-13 (reviewed by 
Rook et al., 2001).
IFN-. The role IFN- for a protective immunity in tuberculosis has been well 
established. In children who have genetic defects in IFN-γ receptor gene which result in 
deficiency of IFN-γ receptor, BCG vaccination, which is widely used to protect 
tuberculosis infection, can cause severe disseminated disease (Jouanguy et al., 1996; 
Newport et al., 1996). In gene knock-out (KO) mice incapable of making IFN-γ fail to 
acquire the ability to inhibit M. tuberculosis growth in their lungs and other organs 
(Cooper et al., 1993; Flynn et al., 1993). in vitro IFN-γ production upon mycobacterial 
antigen-specific stimulation has been substantially investigated and used as a surrogate 
diagnostic marker for M. tuberculosis infection (van Crevel et al., 1999).
IL-2. IL-2 can induce lymphocyte expansion in the context of antigen-specific 
stimulation. It has been demonstrated that IL-2 can influence the course of mycobacterial 
infection either alone or in combination with other cytokines (Blanchard et al., 1989).
IL-12. The central role of IL-12 is to induce the production of IFN-γ. It is a key player in 
host defense against M.  tuberculosis in both innate and adaptive immunity. IL-12 KO 
mice are highly susceptible to mycobacterial infections (Cooper et al., 1997). In humans 
who have genetic defects in IL-12 receptor gene and contracted mycobacterial infections, 
the effect of IL-12 receptor deficiency is due to the significant reduced production of 
IFN-γ by NK cells and T cells which is induced by IL-12 (Altare et al., 1998; de Jong et 
al., 1998). This further emphasizes the importance of IFN-γ.
IL-18. In addition to IL-12, IL-18 is another important IFN-γ-inducing cytokine (O’Neill 
and Greene, 1998), and it can stimulate the production of other proinflammatory 
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cytokines (Netea et al., 2000b). Synergistically IL-12 and IL-18 strongly favor 
development of Th1 cytokine responses.
IL-4. IL-4 is a major Th2 cytokine which can suppress IFN-γ production and macrophage 
activation (van Crevel et al., 2002), and switch of signaling via TLR-2 and potently down 
regulate iNOS (Bogdan et al., 1994). In mice infected with M. tuberculosis, progressive 
disease and reactivation of latent infection are both associated with increased production 
of IL-4 (Hernandez-Pando et al., 1996; Howard and Zwilling, 1999), and overexpression 
of IL-4 intensified tissue damage in experimental infection (Lukacs et al., 1997). In 
humans, overproduction of IL-4 has been associated with more extensive radiological 
disease (Seah et al., 2000), with cavitary tuberculosis (van Crevel et al., 2000), and with 
progression from latent infection to active disease (Ordway et al., 2004). All these 
findings suggest that IL-4 may be a major pathogenic factor in tuberculosis (Rook et al., 
2005a). The increased production of IL-4 has been thought to result in the imbalance of 
Th1 and Th2 cytokines, and this imbalance may play a major role in the pathogenesis of 
tuberculosis (Howard and Zwilling, 1999; Barnes and Wizel, 2000).
TNF-α. TNF-α is a prototype proinflammatory cytokine which plays a key role in 
granuloma formation (Kindler et al., 1989; Senaldi et al., 1996), activates macrophage 
inhibiting growth of intracellular mycobacteria (Barnes and Modlin, 1996). On the other 
hand, TNF-α also contributes to immunopathology of tuberculosis by participating in 
host-mediated destruction of lung tissue. The switch from protective to deleterious role of 
TNF-α is believed to be associated with IL-4 (Rook et al., 2005a).
T-cell subtypes involved in adaptive immunity. Studies in humans and animals 
demonstrate that adaptive immunity to M. tuberculosis requires contributions by multiple 
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T cell subsets, which include α/ CD4+ and CD8+ cells, / T cells, and CD1-restricted 
T cells. These cells can only control or maintain the infection, cannot eradicate the 
bacteria (reviewed by Boom et al., 2003).
α/ CD4+ T cells. This subset of T lymphocytes is the central player in acquired 
tuberculosis immunity. This can be well reflected by HIV positive individuals. HIV 
positive persons, who have defective CD4+ cellular immunity, are at markedly increased 
risk to contract tuberculosis either from new infection or from reactivation of latent 
infection (Corbett et al., 2003). Mice with CD4+ T cell deficiency are greatly susceptible 
to M. tuberculosis (Caruso et al., 1999), and in a murine model of chronic persistent M. 
tuberculosis infection, CD4+ T cell depletion caused rapid reactivation of the infection 
(Scanga et al., 2000).
The primary effector function of CD4+ T cells is the production of IFN-γ and 
TNF-, essential cytokines to activate macrophages. M. tuberculosis antigen activated 
CD4+ T cells are cytotoxic to macrophages infected by M. tuberculosis and help 
macrophages control intracellular mycobacteria (Boom et al., 2003).
α/ CD8+ T cells. CD8+ T cells can secret IFN-γ and IL-4 and thus may play a role in 
regulating the balance of Th1 and Th2 immunity. Increased production of IL-4 by CD8+ 
cells and / T cells is associated with progression from latent infection to active disease 
in health-care workers (Ordway et al., 2004). M. tuberculosis antigen activated CD8+ 
cells can lyse M. tuberculosis-primed macrophages and thus help macrophages to control 
the infection (de Libero et al., 1988).
/ T cells. / T cells are cytotoxic, can kill M. tuberculosis-infected macrophages and 
reduce the viability of intracellular bacteria (Rook et al., 2001). / T cells selectively 
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expand when stimulated in vitro by live M. tuberculosis (Barnes and Modlin, 1996). In
addition, / T cells from tuberculin-negative individuals and from newborns proliferate 
in response to M. tuberculosis, suggesting they also participate in innate immunity 
(Barnes and Modlin 1996).
1.7 The Beijing Genotype of M. tuberculosis
1.7.1 Definition of Beijing Genotype Strains
In 1995, van Soolingen et al. identified a group of genetically highly conserved M. 
tuberculosis strains from the Beijing area of China. In the patterns of IS6110, IS1081, 
and the polymorphic GC-rich repeat sequence (PGRS) RFLP, these strains were distinct 
from then-known M. tuberculosis strains but closely related within the group; moreover, 
in the direct repeat (DR) region, all the strains exhibited an identical spoligotype that in 
the 43 spacer format of spoligotype had spacers 1 to 34 deleted and 35-43 conserved. 
Because this group of M. tuberculosis strains were first discovered and highly prevalent 
(> 85%) in the Beijing area, strains in this group were designated the Beijing genotype 
(van Soolingen et al., 1995).
With more global genotyping data available, it is found that the identical 
spoligotype is specific to the Beijing genotype strains. It is also found however that the 
nine spacers 35 to 43 are not invariably present in all Beijing strains, some Beijing-like 
spoligotypes (lacking one or more of the last 9 spacers in addition to spacers 1 to 34) 
were uncovered in some areas of the world (Diaz et al., 1998; Chan et al., 2001; van 
Crevel et al., 2001; Kremer et al., 2004). Kremer et al. (2004) have recently characterized 
the strains with Beijing-like spoligotypes and proven that they belong to the Beijing 
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genotype; a new definition for the Beijing genotype strains thereby has been 
recommended which defines Beijing strains as strains hybridizing to at least three of the 
nine spacers 35 to 43 and with absence of hybridization to spacers 1 to 34 by 
spoligotyping. Those which hybridize with all the nine spacers of 35 to 43 are termed 
“typical Beijing strains”, otherwise, called “atypical Beijing strains”. By this definition, 
spoligotyping can serve as a “gold standard” method to identify Beijing lineage strains 
(Kremer et al., 2004).
The W strain (Bifani et al., 1996), a MDR clone associated primarily with 
institutional outbreaks in New York City (Valway et al., 1994; Frieden et al., 1996; Moss 
et al., 1997), is a variant of Beijing family strains (Bifani et al., 1999). Therefore, the 
Beijing genotype is also known variously as Beijing\W or W-Beijing in some studies 
(Bifani et al., 2002; Glynn et al., 2002; Kremer et al., 2004).
1.7.2 Global Dissemination of the Beijing Genotype Strains
In addition to the Beijing area, the M. tuberculosis Beijing genotype strains were found to 
be also predominant in other Asian areas, such as Mongolia (van Soolingen et al., 1995), 
Korea (Park et al., 2000), Vietnam (Anh et al., 2000), Hong Kong (Chan et al., 2001), 
and in Russia (Pfyffer et al., 2001; Drobniewski et al., 2002; Toungoussova et al., 2002, 
2003), and highly prevalent in some states of the United States (Yang et al., 1998; Bifani 
et al., 1999, 2001; Soini et al., 2000), Thailand (Prodinger et al., 2001), Malaysia (Dale et 
al., 1999), Indonesia (van Crevel et al., 2001). In 2002, Bifani et al. and Glynn et al. 
independently made systematic reviews of published papers in which Beijing strains 
could be identified based on different genetic markers, it was showed that Beijing strains 
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are widely distributed worldwide (Bifani et al., 2002; Glynn et al., 2002). The reason for 
the selective expansion of the Beijing genotype strains over other genotype strains has 
been speculated as that Beijing strains may be able to escape from the protection of BCG 
vaccination but other genotype strains are inhibited by the protection of BCG vaccination 
(van Soolingen et al., 1995). Limited supportive data for this hypothesis have been 
obtained from an animal study in which pre BCG vaccination seemed to inhibit the 
multiplication of M. canettii and M. tuberculosis laboratory strain H37Rv but not Beijing 
strains (López et al., 2003). However, no supportive evidence for this hypothesis has 
been obtained from molecular epidemiological studies (Bifani et al., 2002; Glynn et al., 
2002).
Beijing strains have been found to be more likely involved in DNA fingerprint 
defined cluster (Toungoussova et al., 2002, 2003) which is generally assumed as a result 
of recent active transmission (Small et al., 1994; Glynn et al., 1999). In addition to the 
higher rate of clustering, Beijing strains were also found to spread rapidly in a 
community from 5.5% to 27% in 3 years (Caminero et al., 2001). This suggests that 
Beijing strains are highly transmissible.
1.7.3 Clinical and Epidemiological Phenotypes of Tuberculosis Associated with the 
Beijing Genotype
In addition to the wide dissemination, Beijing strains have been frequently reported to be 
associated with drug-resistance in Vietnam (Anh et al., 2000), New York (Bifani et al., 
1996), Cuba (Diaz et al., 1998), Estonia (Kruuner et al., 2001), and some areas of Russia 
(Pfyffer et al., 2001; Drobniewski et al., 2002; Toungoussova et al., 2002, 2003). 
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Whereas in other areas, such as Hong Kong (Chan et al., 2001), Thailand (Prodinger et 
al., 2001), and Indonesia (van Crevel et al., 2001), this association was not observed. In 
Vietnam, Beijing strains were also found to be associated with younger patients (Anh et 
al., 2000) but this was not demonstrated in other areas (Glynn et al., 2002). Therefore, the 
relationship of the Beijing genotype with drug-resistance and with patient’s age remains a 
matter of debate. In addition, also in Vietnam the Beijing genotype was found to be 
associated with treatment failure and tuberculosis relapse (Lan et al., 2003), and in 
Indonesia it was associated with febrile response to treatment (van Crevel et al., 2001). 
Very recently, Warren and colleagues have found that Beijing strains are involved in 
most of multiple infections in a single episode (Warren et al., 2004).
1.7.4 Potential Virulent Genetic Factors of the Beijing Genotype
The bacterial factor(s) that is responsible for the differential epidemiological and clinical 
phenotypes of tuberculosis remains largely unknown. One potential genetic factor is the 
pks1-15gene encoding polyketide synthase-derived phenolic glycolipid (PGL), which 
confers Beijing strains with the ability to inhibit the release of key inflammatory effector 
molecules by the cells of the host’s innate immune response (Reed et al., 2004). The 
pks1-15 gene is unable to encode PGL in non-Beijing strains due to a frameshift mutation 
resulting from 7-base-pair deletion of the gene, but Beijing strains have an intact pks1-15
gene, thereby being able to produce PGL. The mobile element IS6110 is another possible 
virulent genetic factor. Most of Beijing genotype strains contain high numbers of IS6110
copy compared to non-Beijing strains, and all Beijing strains share IS6110 insertion sites. 
One of them is in the bacterial chromosomal origin of replication, and many of them are 
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within coding regions which result in disruption of the coding genes (Bifani et al., 2002). 
A recent study has shown that IS6110 can up-regulate downstream genes through an 
outward-directed promoter in its 3’ end which may alter the expression of adjacent genes 
to favor the specific phenotypes (Safi et al., 2004). The whole genome sequencing of M. 
tuberculosis Beijing strain 210 is in progress in The Institute for Genomic Research 
(TIGR, http://www.tigr.org). The availability of this whole genomic sequence will shed 
more light into the relationship between genomic structure of Beijing strains and the 
phenotypes.
1.7.5 Specific Immunological Pathogenesis of the Beijing Genotype Strains
The associations of Beijing genotype strains with the specific phenotypes of tuberculosis 
have attracted increasing research attention to virulence of Beijing genotype and immune 
response against this genotype strains. In an interesting study (López et al., 2003) which 
compared immune response, pathogenesis and BCG protection in mouse model of 
pulmonary tuberculosis induced by four genotypes of M. tuberculosis strains, Beijing 
strains were characterized by significantly higher bacillary burdens, extensive 
pneumonia, and significantly higher and earlier mortality. Previous BCG vaccination 
protects less effectively against infection with Beijing strains than against the laboratory 
strain H37Rv. However, the patterns of cytokine secretion are intriguing. INF-γ gene 
expression in lungs of mice infected with Beijing strains is delayed and remarkably 
weaker than those infected with laboratory strain H37Rv, showing some correlation with 
bacterial loads and disease phenotypes. In contrast, although M. canettii strains induce 
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similar INF-γ gene expression level as Beijing strains, the disease phenotypes, 
particularly mortality, between the two genotypes differ markedly.
Similarly, in another animal study which characterized a Beijing strain, HN878, 
the high early death of infected mice with HN878 was associated with failure to induce 
INF-γ production by spleen and lymph node cells from infected mice. Moreover, the 
expression of INF-γ, TNF-α, IL-6 and IL-12 were significantly lower in lungs of HN878-
infected mice (Manca et al., 2001). This is in contrast with an outbreak strain CDC1551, 
a well characterized non-Beijing strain, which induces earlier and strikingly higher level 
expressions of INF-γ, TNF-α, IL-6 and IL-12 genes in lungs of mice infected with 
CDC1551 which are associated with long term survival of the mice (Manca et al., 1999). 
Furthermore, in humans, infection with CDC1551 also induced strong immune responses 
characterized by very large skin test responses to purified protein derivative of tuberculin 
(PPD) and more latent infections than active diseases (Valway et al., 1998).
Although CDC1551 grew much faster than laboratory strain Erdman in lungs of 
mice, this was not found when compared to strains HN878 and H37Rv. In addition, the 
growth rates of CDC1551 and H37Rv in human monocytes were also the same. 
However, another outbreak strain, strain 210 (a Beijing family member), was found to 
grow markedly faster than CDC1551 and other clinical isolates but they all produced 
similar amounts of TNF-α, IL-6, IL-10, and IL-12, and were equally susceptible to 
reactive nitrogen intermediates in human macrophages (Zhang et al., 1999).
1.8 Molecular Epidemiology of Drug-resistant Tuberculosis
1.8.1 Types of Drug Resistance
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The phenomenon of resistance of M. tuberculosis to anti-tuberculosis drugs was observed 
shortly after the introduction of effective antituberculosis agents into clinical practice in 
50 years ago (Crofton and Mitchison, 1948; Szyblaski and Bryson, 1952), but only 
received international attention in the early 1990s when drug-resistant M. tuberculosis
strains were frequently found to be involved in outbreaks in patients with HIV infection 
in the United States and Europe (Pablos-Mendez et al., 1998).
Drug resistance of M. tuberculosis is classified as primary or acquired. When 
resistance occurs in a patient who has never undertaken anti-tuberculosis therapy 
previously, it is termed primary resistance. The acquisition of primary resistance results 
from the transmission of drug-resistant M. tuberculosis isolate from a patient to another 
person. The level of primary resistance in a community is therefore an indicator of 
transmission within the community. Acquired resistance is that which occurs as a result 
of unsuccessful anti-tuberculosis treatment due to a number of man-made factors, such as 
improper medical management, inappropriate prescription, or poor adherence of patients 
to treatment, etc.. The level of acquired resistance reflects the performance of on-going 
tuberculosis control program (WHO, 1997, 2000b). However, the two proxies “resistance 
among new cases” and “resistance among previously treated cases” have now been 
adopted to replace the terms acquired and primary resistance respectively (WHO, 2000b; 
Espinal et al., 2001).
1.8.2 Burden of Drug-resistant Tuberculosis
Being launched in 1994, the global project of resistance surveillance to antituberculosis 
drugs conducted by WHO/IUATLD has obtained considerable information on the global 
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burden and trends of drug-resistant tuberculosis over the last 10 years (WHO, 1997, 
2000b, 2004; Pablos-Mendez et al., 1998; Espinal et al., 2001). The incidences vary 
significantly between geographic settings. The very recent WHO report showed that the 
prevalence rates ranged from the lowest 0% in some Western European countries to the 
highest 57.1% (median = 10.2%) in Kazakhstan among new cases, and a wider range 
from 0% to 82.1% (again in Kazakhstan) among previously treated cases, with a median 
18.4%; the higher prevalence rates were seen in Central Asia and some provinces of 
China and Russian Federation. With respect to prevalence trends, data from settings with 
at least two observation points showed significant increase in Botswana, New Zealand, 
Poland, and Tomsk Oblast of Russian Federation; on the other hand, significant deceases 
in prevalence were also observed in quite number of settings implementing tuberculosis 
control according to international guidelines over the years (WHO, 2004).
Overall, drug-resistant tuberculosis continues to be a serious threat to global 
tuberculosis control. Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to 
at least the two most potent anti-tuberculosis drugs, i.e., isoniazid (INH) and rifampin 
(RIF), is a major threat since MDR-TB is significantly more difficult and expensive to 
treat than is drug-susceptible tuberculosis, and causes higher treatment failure, relapse 
and mortality (Mahmoudi and Iseman, 1993; Espinal et al., 2000; Garcia-Garcia et al., 
2000a, 2000b; Quy et al., 2003). Although globally MDR-TB is low (median 1.1%), but 
in many specific regions of the world it is at levels of incidence greater than 10% (WHO, 
2004; Espinal, 2003; Maher and Raviglione, 2005). MDR-TB may spread from those 
areas with high incidence to other areas with low incidence. Other resistance to 
antituberculosis drugs also possesses threat to tuberculosis control though maybe at a less 
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extent than does MDR. Streptomycin resistance, isoniazid resistance or polyresistance 
(resistance to more than two drugs but not MDR) has been found to be risk factors 
secondary to MDR for treatment failure or relapse in Vietnam (Quy et al, 2003). In 
addition, drug-resistant tuberculosis is usually to be infectious for a longer period than is 
drug-susceptible tuberculosis.
1.8.3 Transmission of Drug-resistant Tuberculosis
Molecular epidemiological studies in New York City showed that resistance to any drug 
(Alland et al., 1994) or MDR (Friedman et al., 1995) were important risk factors for 
patients being in a cluster. Similar finding was obtained from a study performed in 
Poland that patient with MDR disease was more likely to cluster (Sajduda et al., 2004). 
However, in Mexico (Garcia-Garcia et al., 2000a, 2000b) and in South African gold-
mining community (Godfrey-Faussett et al., 2000), patients with MDR tuberculosis were
significantly associated with a decreased likelihood of being clustered. Similarly, in San 
Francisco, patients with MDR tuberculosis were not likely to produce secondary drug-
resistant cases (Burgos et al., 2003). In addition, in the Netherlands, van Soolingen et al. 
(1999) have found that INH-resistant strains were less likely to be in a cluster. 
Corroborating with this, Burgos et al. (2003) found that even clustered strains that were 
resistant to isoniazid alone or in combination with other drugs were less likely to result in 
secondary cases than were drug-susceptible strains. The discrepancy among these studies 
may be due to different population structures of M. tuberculosis in these areas because 
different genotypes of M. tuberculosis may have different propensities to develop drug-
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resistance as reviewed in section 1.8.4, or maybe the studies in New York City involved 
in more high virulent drug-resistant strains.
1.8.4 M. tuberculosis Genotypes and Drug-resistant Phenotypes
The genetic basis of drug-resistance in M. tuberculosis is the resistance-conferring 
mutations in variety of genes in relation to antituberculosis agents (Ramaswamy and 
Musser, 1998). Spontaneous mutations leading to drug resistance occur rarely in the 
bacilli, man-made factors are responsible for the occurrence of drug-resistant mutants. 
However, molecular epidemiological studies in recent years have revealed increasing 
evidence that some drug-resistant patterns are not equally occurred among the family 
members of M. tuberculosis (Anh et al., 2000; Chan et al., 2001; Toungoussova et al., 
2002, 2003; Baker et al., 2004; Hillemann et al. 2005; Jou et al., 2005). In Vietnam, 
resistance to isoniazid or streptomycin was found to more likely occur in Beijing 
genotype strains (Anh et al., 2000).  In Russia, resistance to streptomycin, rifampin, or 
ethambutol but not to isoniazid was found to be associated with Beijing strains 
(Toungoussova et al., 2002, 2003). In the UK, resistance to streptomycin was associated 
with both Beijing and Delhi strains, but resistance to rifampin was not associated with 
any genotype (Baker et al., 2004). An association between resistance to isoniazid or 
ethambutol and Beijing genotype was also demonstrated in Taiwan (Jou et al., 2005). 
However, resistance to isoniazid was inversely associated with Beijing genotype in Hong 
Kong (Chan et al., 2001).
Moreover, by correlating resistance-conferring mutations with the genotypic 
lineages of M. tuberculosis, Baker et al. (2004) found that the streptomycin resistance-
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conferring mutation rpsLA128G was positively associated with Beijing strains, but 
inversely associated with Haarlem strains; the isoniazid resistance-conferring mutation 
katG A944C was positively associated with Delhi strains, and the inhA C15T promoter 
mutation positively associated with East-African-Indian (EAI) strains. In a very recent 
study in Germany, Hillemann et al. (2005) found that the isoniazid resistance-conferring 
mutation katG S315T and the rifampin resistance-conferring mutation rpoB S531L were 
associated with Beijing strains. These findings suggest that the resistance-conferring 
mutations in M. tuberculosis may not independently and randomly occur in different 
genotype strains but genotype-related, further suggesting possible role of intrinsic 
bacterial factors of the bacillium in the development of the resistance-conferring 
mutations.
1.9 Tuberculosis in Singapore
Singapore is a small island situated on the southernmost tip of the Malaysian peninsular. 
During the past few decades, Singapore has become industrialized and developed as a 
globalized city state. The overall incidence of tuberculosis in Singapore (per 100,000 
population) has declined from > 200 in 1960s to about 100 in early 1980s and further to 
about 50 in 1990s (Figure 1.1). The incidence has reached its lowest ever rate at 39 in 
2004 (Ministry of Health Singapore, 2005). However, the remarkable decrease in 
tuberculosis incidence is mainly due to the rapid increase in size of the Singaporean 
population, whereas the absolute number of tuberculosis cases notified did not change 
much over the period of 1987 to 2004 (Figure 1.2; data from Communicable Disease 
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Surveillance Report 2004, the Department of Clinical Epidemiology, Communicable 
Disease Centre, Tan Tock Seng Hospital and Ministry of Health).
In 1997, Singapore embarked the Singapore Tuberculosis Elimination Program 
(STEP) (Chee and James, 2003). The key component of the STEP is early diagnosis and 
proper treatment of patients with tuberculosis. This can cure and prevent further 
transmission of the disease and emergence of drug-resistant tuberculosis. The concerted 
efforts carried out under the STEP and by the medical community have contributed to the 
recent decline in tuberculosis cases in Singapore.
     Fig. 1.1. Incidence of tuberculosis among Singapore residents, 1960-2001. 





























































Fig. 1.2. Total number of tuberculosis cases notified among Singapore residents, 1987-
2004. 
Drug-resistant tuberculosis has been a persistent problem with an incidence in 
local residents fluctuating between 4.2% to 6.7% in the last decade (Communicable 
Disease Surveillance Report 2004, the Department of Clinical Epidemiology, 
Communicable Disease Centre, Tan Tock Seng Hospital and Ministry of Health). Lee 
and colleagues have done a series of studies (Lee et al., 1999, 2001, 2005) to examine 
drug-resistant mechanisms of M. tuberculosis in Singapore. However, little is known to 
date on the genetic diversity and molecular epidemiology of M. tuberculosis in this urban 
country.
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1.10 Aims of the Present Project
In this PhD program, we designed several retrospective and prospective studies aimed to 
study the molecular epidemiology of tuberculosis in Singapore and to investigate clinical 
and immunological characteristics of tuberculosis associated with the M. tuberculosis
Beijing and non-Beijing family strains. Our specific aims were:
1. To uncover the genetic diversity and population structure of M. tuberculosis in 
Singapore using three major genotyping methods, IS6110 RFLP typing, spoligotyping, 
and MIRU-VNTR typing, as well as other minor typing methods.
2. To evaluate and compare the performances of the three major strain-typing methods 
and to formulate a genotyping proposal based on the local population structure of M. 
tuberculosis and the performances of the three major typing modalities.
3. To examine the relationship between Beijing strains and tuberculosis relapse in 
Singaporean patients. 
4. To study the transmission dynamics of drug-resistant tuberculosis and relationships 
between genotypes and drug-resistant phenotypes of M. tuberculosis.
5. To clinically and immunologically characterize the tuberculosis associated with the 
Beijing and non-Beijing families of M. tuberculosis.
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CHAPTER 2




Tuberculosis remains a leading cause of death due to bacterial infection, with 
approximately 8 million new cases and 2 million deaths each year worldwide. It is 
estimated that one third of the world’s population is infected with M. tuberculosis, the 
causative agent of tuberculosis (Corbett et al., 2003). Singapore has moderate 
tuberculosis incidence (40 per 100,000) in local residents (citizens and permanent 
residents). But an increasing burden has come from foreigners who work and study in 
this country. The effort to control the epidemic has been so far clinically oriented (Chee 
and James, 2003).
Molecular epidemiology of tuberculosis has been widely used in developed 
countries to study and to trace tuberculosis transmission (van Soolingen et al., 2003). It 
has been shown that molecular epidemiology is greatly more effective than is 
conventional contact tracing (van Deutekom et al., 2004). DNA fingerprinting of M. 
tuberculosis has gained increased acceptance as a useful tool for molecular 
epidemiological investigations (Alland et al., 1994; Small et al., 1994; Borgdorff et al., 
1998; van Soolingen et al., 1999; Garcia-Garcia et al., 2000a; van Deutekom et al., 2004). 
During the past 15 years, a large number of DNA fingerprinting methods based on 
various genetic markers have been developed (van Soolingen, 2001; Mazars et al., 2001). 
As no single method however has defined all unique isolates so far, multistep typing 
strategies are needed for a better performance (Alland et al., 1994; Bauer et al., 1999; 
Yang et al., 2001; Cowan et al., 2002; Kwara et al., 2003).
The purposes of the present study were to discover the genetic diversity and 
population structure of M. tuberculosis in Singapore, to compare the novel MIRU-VNTR 
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typing with the more established spoligotyping and IS6110 RFLP typing, and finally to 
define an optimal typing strategy for molecular epidemiological analysis of tuberculosis 
in Singapore.
2.2 Materials and Methods
2.2.1 Mycobacterial DNA samples
We used a bank of mycobacterial DNA samples that had been extracted from drug-
susceptible M. tuberculosis clinical isolates consecutively collected between August and 
December 1994 from the Central Tuberculosis Laboratory, Singapore General Hospital. 
Isolates from 10 residential postal districts were collected and analyzed. The DNA 
samples were extracted using a standard protocol that is described elsewhere (van 
Soolingen et al., 1991). Briefly, mycobacterial culture was resuspended in 400 l TE 
buffer (10 mM Tris/HCl, 1 mM EDTA, pH8.0) in a microcentrifuge tube and heated at 
800C for 30 minutes to kill the bacteria. Lysozyme was added to a final concentration of 
1 mg/ml, and the tube was incubated for 1 h at 37 0C. Followed by adding 70 l of 10% 
SDS and 6 l of proteinase K at concentration of 10 mg/ml and incubated for 10 min at 
650C. After adding 80 l of N-acetyl-N,N,N-trimethyl ammonium bromide (CTAB) and 
votexing briefly, the tube was incubated for 10 minutes at 650C. An equal volume of 
chloroform/isoamyl alcohol was added, and the mixture was votexed for at least 10 
seconds. After centrifugation at 14,000 rpm for 5 minutes, 0.6 volume of isopropanol was 
added to the supernatant to precipitate DNA. After 30-minute incubation at -200C, DNA 
was pelleted by centrifugation at 14,000 rpm for 15 minutes, and washed with 70% 
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ethanol. The final DNA pellet was air-dried and dissolved in 20 l of TE buffer. Samples 
were kept in -200C freezer until the current analysis.
2.2.2 Spoligotyping
A detailed spoligotyping protocol has been previously described (Kamerbeek et al., 
1997). In this study, we used a commercial spoligotyping kit (Isogen Bioscience BV, The 
Netherlands), and the manufacturer’s protocol was followed.
Spoligotyping PCR. Primers DRa (5’-GGT TTT GGG TCT GAC GAC-3’) and DRb (5’-
CCG AGA GGG GAC GGA AAC-3) flanking the DR region were used for 
spoligotyping PCR. Primer DRa is biotinylated at 5’ end. PCR was performed using 
microwell PCR plate in 50 l reaction volume mixture which contained 20 pmol of each 
of primer (DRa and DRb), 0.2 mM each of dATP, dCTP, dGTP, and dTTP, 1.5 mM of 
MgCl2, 1x Q solution, 1x PCR buffer, 1 U of HotStartTaq DNA polymerase (Qiagen, 
Germany), and approximately 5 to 50 ng of DNA. The PCR was carried out using a PCR 
thermocycler (Biometra, Austria) starting with a denaturing step of 3 minutes at 96°C, 
followed by 40 cycles of 1 minute at 96°C, 1 minute at 55°C, and 30 seconds at 72°C. 
The reactions were terminated by incubation for 5 minutes at 72°C. Positive controls 
using M. tuberculosis strain H37Rv and M. bovis BCG P3 and negative control using 
water were performed in parallel.
Hybridization and membrane development. PCR products were diluted by mixing 20 l 
of PCR product and 150 l 2x SSPE/0.1% SDS. The diluted PCR products were 
denatured at 99°C for 10 min and then immediately cooled on ice. The PCR products 
were added to a miniblotter which sandwiched a membrane with 43 synthetic 
oligonucleotides immorbilized in parallel rows. The 43 oligonucleotides represent the 
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unique variable spacer sequences between DR units in the DR region. After incubated at 
60°C for 60 min, samples were removed from the miniblotter and the membrane was 
washed twice in 250 ml 2xSSPE/0.5% SDS for 10 minutes at 60°C. The membrane was 
then placed in a rolling bottle and incubated with 2.5 l streptavidin-peroxidase 
(Amersham Bioscience, Sweden) in 10 ml 2xSSPE/0.5% SDS for 60 minutes at 42°C in 
a hybridization oven (Hybaid, UK). After the incubation, the membrane was washed 
twice in 250 ml 2xSSPE/0.5% SDS for 10 minutes at 42°C and subjected to 
chemiluminescence development using the ECL chemiluminescent detection kit for 
labeled nuclei acids. The membrane was exposed to a light sensitive ECL Hyperfilm 
(Amersham Bioscience) for 40 minutes and then developed using Kodak X-ray film 
developer and fixer. This generated a characteristic spoligotype pattern for each isolate, 
where a positive hybridization signal was indicative of the presence of a particular spacer.
2.2.3 MIRU-VNTR typing using genescan analysis
MIRU-VNTR PCR. This PCR has been previously described (Supply et al., 2001). The 
fluorescent-labeled PCR primers flanking each polymorphic MIRU-VNTR locus and 
multiplex mixtures are shown in Table 2.1. Each MIRU-VNTR locus was individually 
amplified using a 50 μl reaction volume in 96-well PCR plates. The reaction mixture 
contained 0.4 μM each of primer, 0.2 mM each of dATP, dCTP, dGTP, and dTTP, 1.5 
mM of MgCl2, 1x Q solution, 1x PCR buffer, 1 U of HotStartTaq DNA polymerase 
(Qiagen, Hilden, Germany), and approximately 5 to 50 ng of DNA. The thermocycler 
programs for the four multiplex reactions were identical. The PCRs were carried out 
using a PCR thermocycler (Biometra, Austria) starting with a denaturing step of 
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15 minutes at 95°C, followed by 40 cycles of 1 minute at 94°C, 1 minute at 59°C, and 
1 minute 30 seconds at 72°C. The reactions were terminated by incubation for 10 minutes 
at 72°C. Negative controls consisted of the PCR performed on reaction mixtures lacking 
mycobacterial DNA. PCR products were appropriately diluted and pooled together by 
each multiplex mixture for genescaning. However, those samples that were not properly 
analyzed in the pooled sets were then diluted for individual capillary electrophoresis.







Primer sequence (5’-3’) (labeling)
A 4 77 GCGCGAGAGCCCGAACTGC (FAM) 
GCGCAGCAGAAACGCCAGC 
26 51 TAGGTCTACCGTCGAAATCTGTGAC 
CATAGGCGACCAGGCGAATAG (HEX) 
40 54 GGGTTGCTGGATGACAACGTGT (NED) 
GGGTGATCTCGGCGAAATCAGATA 
B 10 53 GTTCTTGACCAACTGCAGTCGTCC 
GCCACCTTGGTGATCAGCTACCT (FAM) 
16 53 TCGGTGATCGGGTCCAGTCCAAGTA 
CCCGTCGTGCAGCCCTGGTAC (HEX) 
31 53 ACTGATTGGCTTCATACGGCTTTA 
GTGCCGACGTGGTCTTGAT (NED) 
C 2 53 TGGACTTGCAGCAATGGACCAACT 
TACTCGGACGCCGGCTCAAAAT (FAM) 
23 53 CTGTCGATGGCCGCAACAAAACG (HEX) 
AGCTCAACGGGTTCGCCCTTTTGTC 
39 53 CGCATCGACAAACTGGAGCCAAAC 
CGGAAACGTCTACGCCCCACACAT (NED) 
D 20 77 TCGGAGAGATGCCCTTCGAGTTAG (FAM) 
GGAGACCGCGACCAGGTACTTGTA 
24 54 CGACCAAGATGTGCAGGAATACAT 
GGGCGAGTTGAGCTCACAGAA (HEX) 
27 53 TCGAAAGCCTCTGCGTGCCAGTAA 
GCGATGTGAGCGTGCCACTCAA (NED)
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MIRU-VNTR Genescan Analysis. One μl of diluted PCR products was mixed with 10 μl 
of deionized formamide and 0.2 μl of Genescan ROX-2500 DNA size standard. 
Denatured samples were subjected to electrophoresis using POP-4 polymer as matrix in a 
36cm long capillary array on an ABI PRISM 3100-Avant Genetic Analyzer. The key 
parameters for the capillary electrophoresis were: run temperature = 60 0C, prerun 
voltage = 15 kvolts, prerun time = 180 seconds, sample injection voltage = 1 kvolts, 
sample injection time = 15 seconds, run voltage = 13 kvolts, run time = 2600 seconds. 
The PCR products were sized by GeneScanTM and GenotyperTM software (Applied 
Biosystems) using the Custom macro program of Supply et al. (2001). The tables used 
for MIRU-VNTR allele scoring are available at http://www.ibl.fr/mirus/mirus.html. 
Samples which could not be automatically sized by the software were manually sized and 
converted to allelic numbers according to the tables.
2.2.4 IS6110 RFLP typing
The recommended international standard protocol for IS6110 RFLP (van Embden et al., 
1993) was followed. Briefly, a 245-bp DNA probe was PCR-amplified using primers 
INS1 (5’-CGT GAG GGC ATC GAG GTG GCC-3’) and INS2 (5’-GCG TAG GCG 
TCG GTG ACA AA-3’) at the 3’-end of IS6110 insert sequence. The probe was labeled 
with Enhanced Chemiluminescence (ECL) Direct Nucleic Acid Labeling and Detection 
System kit (Amersham, Bioscience, Sweden). Genomic DNA was digested with 
restriction endonuclease PvuII (Roche, USA), subjected to electrophoresis separation on 
a 0.8% agarose gel in Tris-borate-EDTA buffer, and vacuum blotted onto nylon 
membrane (Amersham Bioscience). Blotted membrane was hybridized overnight at 420C 
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in ECL hybridization buffer containing the labeled probe in a hybridization oven 
(Hybaid, UK). The membrane was then washed and soaked in mixed ECL detection 
reagents to develop chemiluminescence. The membrane was exposed to a light sensitive 
ECL Hyperfilm (Amersham Bioscience) for 5-120 minutes (depending on the expected 
intensity of the reaction) and then developed using Kodak X-ray film developer and fixer. 
To facilitate the determination of the size of each IS6110-hybridizing fragment in 
computer-assisted analysis for comparison of fingerprints of M. tuberculosis strains, a 
mixture of HindIII-digested X174 DNA as an external marker and a mixture of PvuII-
digested supercoiled DNA ladder and HaeIII-digested X174 DNA as an internal marker. 
The internal marker was added to the wells together with the cleaved mycobacterial DNA
and visualized by reprobing the blots with enhanced chemiluminescence kit labeled 
molecular size marker standards. PvuII-digested DNA of M. tuberculosis reference strain 
Mt.14323 was run in parallel as a standard.
The IS6110 RFLP patterns were analyzed at the National Institute of Public 
Health and the Environment (RIVM), The Netherlands by using the Bionumerics 
software (Applied Maths, Sint-Martens-Latem, Belgium). Similarities between RFLP 
patterns were calculated by using the Dice coefficient and the dendrogram was produced 
with the unweighted pair group method using arithmetic averages (UPGMA) algorithm.
2.2.5 Calculation of discriminatory power
The Hunter-Gaston Discriminatory Index (HGDI) described by Hunter and Gaston 
(1988) was used as a numerical index for the discriminatory power of each typing method 

















where N is the total number of strains in the typing scheme, s is the total number of 
distinct patterns discriminated by each typing method and strategy, and nj is the number 
of strains belonging to the jth pattern.
2.2.6 Definition of clustered isolates
Clustered isolates were defined as isolates with identical DNA fingerprint or fingerprints 
when defined by more than one typing method.
2.3 Results
2.3.1 Genotyping
A total of 364 initial drug-susceptible M. tuberculosis isolates from 364 patients were 
analyzed by spoligotyping, MIRU-VNTR typing, and IS6110 RFLP typing. All the 
isolates were successfully typed by spoligotyping and MIRU-VNTR typing. IS6110
RFLP typing produced 363 readable RFLP patterns.
2.3.2 Genetic diversity by spoligotyping and genotype determination of isolates 
Spoligotyping result is shown in Fig. 2.1 (see Appendix 1). The genotypes of the isolates 
were determined primarily based on their spoligotyping patterns as described before 
(Filliol et al., 2002; Ferddinand et al., 2004; Kremer et al. 2004). There were 179 isolates 
had the typical Beijing spoligotype, 17 isolates had atypical Beijing spoligotypes; thus in 
total there were 196 (53.8%) isolates belonged to Beijing family. Of the remaining 168 
non-Beijing isolates, 79 (21.7%) were EAI isolates, 29 (8%) Haarlem isolates, 2 (0.5%) 
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CAS isolates, 6 (1.6%) LAM isolates, 33 (9.1%) T isolates, and 3 (0.8%) X isolates. Of 
the above isolates, only 3 EAI isolates (patterns 16, 54 and 55) and 1 Haarlem isolate 
(pattern 76) (see Fig. 2.1) could not be determined based only on their spoligotypes,  their 
MIRU-VNTR pattern characteristics were refereed (Supply et al., 2001; Sun et al., 
2004a). There were 16 (4.4%) isolates did not exhibit any characteristic spoligotypes of 
the above families. However, the 16 isolates showed clonal characteristics in IS6110
RFLP and MIRU-VNTR patterns (see Chapter 3 for more details).
As shown in Table 2.2, spoligotyping produced in total 118 distinct patterns; of 
which, 98 were unique patterns, the remaining 20 were clustered patterns. The largest 
cluster belonging to the Beijing family contained 179 isolates. The 196 Beijing isolates 
exhibited only 7 distinct patterns, showing very low discriminatory power (HGDI). But 
spoligotyping showed high discrimination to non-Beijing isolates. The overall 
discrimination power (HGDI) of spoligotyping was 0.743.










Beijing 196 3 4 193 0.165
EAI 79 40 6 39 0.916
CAS 2 2 0 0 1
LAM 6 6 0 0 1
Haarlem 29 18 3 11 0.961
T 33 15 5 18 0.932
X 3 3 0 0 1
S 16 11 2 5 0.967
Overall 364 98 20 266 0.743
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2.3.3 Genetic diversity by MIRU-VNTR typing
The 364 isolates showed 176 distinct MIRU-VNTR typing patterns (Table 2.3; see 
Appendix 2). Of the 176 distinct patterns, 136 were unique patterns, and the remaining 40 
were clustered patterns. The largest cluster contained 58 isolates sharing an identical 
Beijing genotype pattern 223325173533. MIRU-VNTR typing had a better 
discrimination to non-Beijing isolates than to Beijing isolates, and had the best 
performance for EAI isolates. A markedly better discrimination for Beijing isolates was 
achieved by MIRU-VNTR typing than by spoligotyping, although it still clustered 83% 
(163/196) of Beijing isolates in 23 clusters, with a mean of 7 isolates per cluster. In 
addition, this typing modality was highly discriminatory to EAI and T families which are 
known to consist of high number of isolates with low copy numbers of IS6110. The 
overall discrimination power (HGDI) of MIRU-VNTR typing was 0.966 (Table 2.4).










Beijing 196 33 23 163 0.894
EAI 79 53 6 26 0.971
CAS 2 2 0 0 1
LAM 6 6 0 0 1
Haarlem 29 12 6 17 0.946
T 33 16 5 17 0.949
X 3 3 0 0 1
S 16 8 3 8 0.942
Overall 364 136 40 228 0.966
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2.3.4 Genetic diversity by IS6110 RFLP typing 
As shown in Fig. 2.2, the IS6110 copy numbers of the M. tuberculosis isolates ranged 
from 0 to 24, a very wide range nearly covered the full range of 0 to 25 copies (van 
Soolingen, 2001), suggesting the high diversity of M. tuberculosis in Singapore. Isolates 
with high ( 6) IS6110 copies accounted for approximately 85% of the collection. There 
was less than 1% of isolates had zero copy of IS6110, and isolates with single-IS6110
copy were prevalent, accounting for approximately 9.5% of the collection.














Fig. 2.2. Frequency distribution of M. tuberculosis drug-susceptible isolates with 
different number of IS6110 copies. IS6110 copy number ranged from 0 to 24. High ( 6) 
IS6110-copy isolates accounted for approximately 85%. Single IS6110-copy isolates 
accounted for approximately 9.5%.
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Based on the similarity analysis result of IS6110 RFLP patterns, IS6110 RFLP 
typing generated 288 distinct patterns, 34 cluster patterns and 254 unique patterns. Of the 
34 clusters, 30 clusters consisted of in total of 74 high IS6110-copy isolates, 3 clusters 
consisted of in total of 33 single IS6110-copy isolates, the remaining 1 cluster consisted 
of 2 two IS6110-copy isolates. The largest cluster contained 19 single IS6110-copy 
isolates. IS6110 RFLP typing showed the highest discrimination power (HGDI = 0.997) 
for Beijing isolates although it also defined the most clusters (22 out of 34, 65%) in 
Beijing isolates. Due to single IS6110-copy isolates, IS6110 RFLP typing was slightly 
less discriminatory to EAI and T isolates. The overall discrimination power of IS6110
RFLP typing was 0.995 (Table 2.5).
                 Table 2.5. IS6110 RFLP typing results by M. tuberculosis genotypes
2.3.5 Multistep typing
The degree of discrimination by combinations of the three methods is listed in Table 2.6. 










Beijing 195 137 22 58 0.997
EAI 79 49 6 30 0.942
CAS 2 2 0 0 1
LAM 6 6 0 0 1
Haarlem 29 23 3 6 0.993
T 33 20 2 13 0.894
X 3 3 0 0 1
S 16 14 1 2 0.942
Overall 363 254 34 109 0.995
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strains, the combination of the two methods improved a little in discrimination. The 
combination of IS6110 RFLP and spoligotyping had very similar discrimination with the 
combination of IS6110 RFLP and MIRU-VNTR; the latter was slightly better. The 
combination of all three methods did not improve further compared to the combination of 
IS6110 and MIRU-VNTR. There were 5 clusters consisted of 14 isolates with high 
number IS6110 copies (9 to 22 copies) were further discriminated into 8 unique patterns 
and 3 clustered patterns by MIRU-VNTR typing, and only one of the 5 clusters was 
further resolved by spoligotyping.
               Table 2.6. Typing results by different combinations of the three methods
2.4 Discussion
2.4.1 Genetic diversity and population structure
We have described the genetic diversity and population structure of M. tuberculosis in 
Singapore. Using spoligotyping as the reference method, we found that the seven major 
worldwide prevalent M. tuberculosis families, as defined by decoding an international 
spoligotyping database (Filliol et al., 2002), were all present in this country. The Beijing 












363 165 34 198 0.970
IS6110 & 
spoligotyping
363 280 32 83 0.999
IS6110 & MIRU-
VNTR
363 295 29 68 0.999
All three 
methods
363 295 29 68 0.999
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ancestral EAI strains, accounting for 22% of the isolates. The closely related Haarlem 
and T families accounted for 17%. Isolates from the LAM, the CAS, and the X families 
were responsible for very small proportion of cases and the CAS was associated with new 
immigrant from India where the CAS strains are endemic (Bhanu et al., 2002). 
In addition to these M. tuberculosis families, we have identified a novel clone 
which showed clonal characteristics in IS6110 RFLP and MIRU-VNTR patterns but not 
in spoligotyping patterns, a feature that is different from other genotype strains. This 
clone has not been systematically described before according to our knowledge, it has 
therefore been designated as ‘S’ family and described in Chapter 3.
These proportions of the different M. tuberculosis genotypes are based on 
consecutive samples from 10 residential postal districts in Singapore over a 5-month 
period in 1994. During this time period there were a total of 519 initial isolates from 519 
patients were collected at the Central Tuberculosis Laboratory. Hence the samples used 
in this study comprise the majority (70%) of samples over a defined time period. 
Therefore, they are likely to be representative of the whole M. tuberculosis population at 
that time. Although drug-resistant isolates were not included in the study sample, a study 
based on a collection of all drug-resistant isolates from August 1994 to December 1996 
showed that the M. tuberculosis genotypes distributed in the similar proportions among 
drug-resistant isolates (see Chapter 5). Therefore, exclusion of drug-resistant isolates 
from this study sample is unlikely to have distorted the population structure.
It is not surprising for the predominant prevalence of the Beijing genotype strains 
because the majority of the Singaporean population is of Chinese race, and that 
tuberculosis affects the elderly, many of whom are first or second generation immigrants 
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from mainland China where the Beijing genotype is highly prevalent (van Soolingen et 
al., 1995; Qian et al., 1999). But in Malaysia and Indonesia, Singapore’s closest 
geographical neighbors, the Beijing genotype represents 24% and 34% of the strains, 
respectively (Dale et al., 1999; van Crevel et al., 2001). This reflects the association of 
tuberculosis with population migration.
In addition to China, Beijing strains are also dominant in other Asian countries, 
such as Mongolia, Vietnam, South Korea, and Thailand (van Soolingen et al., 1995; Anh 
et al., 2000; Park et al., 2000; Chan et al., 2001; Prodinger et al., 2001), and some areas 
of Russia (Pfyffer et al., 2001; Drobniewski et al., 2002; Toungoussova et al., 2002, 
2003). This phenomenon suggests that the Beijing genotype has selective advantage to 
spread and/or to establish infection in human over the other genotype strains. van 
Soolingen et al., (1995) has suggested that it may be related with the massive BCG 
vaccination in China and the Beijing genotype may represent an ‘escape variant’ from the 
protection of BCG vaccination. This has been attracting tremendous research interest to 
uncover the answer using animal studies (López et al., 2003; Dormans et al., 2004) and 
molecular epidemiological studies (Anh et al., 2000; van Crevel et al., 2001; Kremer et 
al., 2005). It is also thought that Beijing strains may be more virulent (Manca et al., 2001; 
López et al., 2003; Dormans et al., 2004) than other genotype strains due to some 
intrinsic bacterial factors (Bifani et al., 2002; Manca et al., 2001; Safi et al., 2004; Reed 
et al., 2004).
2.4.2 Comparison of typing methods
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IS6110 RFLP typing revealed considerable diversity in both the IS6110 band number 
pattern and chromosomal position variation. The isolates covered those with zero copy of 
IS6110 to those with 24 copies, nearly covering the full range (0-25 copies) of IS6110
copy number identified worldwide to date (van Soolingen, 2001). Isolates with low 
IS6110 copy number (< 6 copies) accounted for 15% of the collection, most of them were 
single-copy isolates (10%) belonging to either the EAI or T family. This low number of 
IS6110 copies, particularly single- or zero-copy, renders IS6110 RFLP typing inefficient 
to discriminate strains of these families, as shown by the relatively low discriminatory 
powers to these two family isolates (Table 2.5). For Beijing genotype isolates, IS6110
RFLP typing showed the highest discriminatory power because the strains of this family 
have high number (> 9) of IS6110 copies, and was superior to MIRU-VNTR typing or 
spoligotyping.
Among the three typing methods, spoligotyping is the most simple and economic 
method. It can be easily adapted by either research or clinical laboratories. By decoding a 
spoligotyping database, major worldwide prevalent strains have been defined with seven 
evolutionary lineages (Filliol et al., 2002). In this study we have shown its excellent 
performance in genotype defining of isolate; the vast majority of our isolates could be 
assigned to each of the M. tuberculosis families based on spoligotype alone. This has 
made it a useful tool for phylogenetic studies (Sola et al., 2001, 2002; Warren et al., 
2001). It has been also shown that spoligotyping is useful in molecular epidemiological 
investigations in the areas where the Beijing genotype is not prevalent (Goguet de la 
Salmoniere et al., 1997; Sola et al., 1998). Our results showed that it had high 
discrimination on non-Beijing isolates, therefore support its application to non-Beijing 
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genotypes. But spoligotyping had very poor resolution to Beijing genotype strains as 
demonstrated in other studies (van Soolingen et al., 1995; Chan et al., 2001). Due to the 
high prevalence of Beijing strains in our setting, spoligotyping has limited value to be 
used as strain-typing method in Singapore.
On population level, MIRU-VNTR typing performed better than spoligotyping, 
but was not as efficient as IS6110 RFLP typing. To non-Beijing isolates, MIRU-VNTR 
typing had a comparable discriminatory power with that of IS6110 RFLP typing and 
performed better than IS6110 RFLP typing for EAI and T family isolates. This agrees 
with previous studies in developed countries with low tuberculosis incidences and 
without or with very low proportion of Beijing strains (Mazars et al., 2001; Blackwood et 
al., 2004) and supports that MIRU-VNTR typing could be an alternative for IS6110
RFLP typing in these areas (Blackwood et al., 2004). Whereas for Beijing isolates, 
although MIRU-VNTR typing showed better discrimination than spoligotyping, it still 
clustered a very significant proportion of Beijing isolates. Thus, MIRU-VNTR typing 
alone cannot provide sufficient discrimination power in our setting.
The present study represented the first performance of using a genetic analyzer 
equipped with capillary electrophoresis system for MIRU-VNTR typing analysis. MIRU-
VNTR typing based on such a detection system offers high sensitivity, convenience, 
automation, short turnaround time, and high throughput, and had perfect reproducibility. 
The digital format of the MIRU-VNTR pattern makes direct inter-laboratory comparisons 
possible and easy (Sun et al., 2004a).
2.4.3 Strain-typing strategy
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As discussed above, no single method could define all unique isolates in our setting; 
therefore, a multistep typing strategy is needed. We evaluated the combinations of the 
three typing modalities. The PCR-based combination of MIRU-VNTR typing and 
spoligotyping clustered more than 50% of the isolates, thus is not applicable in our 
setting. But this combination may be useful in other areas without or with low Beijing 
genotype strains (van Deutekom et al., 2005). The combinations of IS6110 RFLP typing 
with either MIRU-VNTR typing or spoligotyping showed very similar and the highest 
discrimination power on the M. tuberculosis isolates in our setting. But MIRU-VNTR 
typing could further subdivide 5 clusters defined by high copy number of IS6110 RFLP 
patterns. Although we were unable to demonstrate the relationship of these isolates in the 
absence of epidemiological data of the patients from whom these isolates were obtained, 
this case very likely indicates that these isolates are epidemiologically unrelated as 
demonstrated by a recent Dutch study (van Deutekom et al., 2005). In that study, the 
authors found that MIRU-VNTR typing can subdivide IS6110 RFLP and PGRS RFLP 
defined clusters which consisted of epidemiologically-unrelated patients (van Deutekom 
et al., 2005). This suggests that MIRU-VNTR typing is more discriminatory than these 
RFLP typing methods in this case and clusters defined by both IS6110 RFLP and MIRU-
VNTR typing can more accurately reflect transmission event. These findings emphasize 
the potential use of MIRU-VNTR typing to refine IS6110 RFLP typing in order to better 
understand transmission routes and support contact tracing. Furthermore, MIRU-VNTR 
typing had a better performance in subdividing single-IS6110 isolate clusters than 
spoligotyping.
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In view of the advantages and the excellent discrimination power of the 
combination of IS6110 RFLP typing and MIRU-VNTR typing, this combination could be 
a suitable modality for M. tuberculosis strain-typing in Singapore using MIRU-VNTR 
typing as a first-line screening method. 
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CHAPTER 3
              IDENTIFICATION AND CHARACTERIZATION OF A NOVEL M. 
TUBERCULOSIS CLONE BY MULTIPLE GENETIC MARKERS
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3.1 Introduction
In the past 15 years, a considerable amount of information has been obtained on the 
genetic diversities and population structures of M. tuberculosis worldwide. Analyses by 
various genetic markers indicate that M. tuberculosis evolves and disseminates by clonal 
expansion (Warren et al., 2001; Supply et al., 2003; Baker et al., 2004) which results in 
great geographic variations in the distribution of M. tuberculosis evolutionary lineages 
(Sola et al., 2002; Filliol et al., 2002; Baker et al., 2004).
Thus far, the most optimal phylogenetic marker for defining the evolutionary 
clonalities of M. tuberculosis is the direct repeat (DR) locus of the bacillary genome 
which is conserved only in the subspecies of M. tuberculosis complex (Hermans et al., 
1991). Based on spoligotype, a type of DNA fingerprint of the DR region generated by 
spoligotyping (Kamerbeek et al., 1997), the global M. tuberculosis isolates can be well 
assigned into seven major evolutionary lineages and some minor ones, each family is 
defined by common family characteristics of spoligotype (Filliol et al., 2002; Sebban et 
al., 2002, Kremer et al., 2004). Studies based on grouping of M. tuberculosis isolates by 
spoligotype has revealed useful information for understanding of the evolutionary 
history, the phylogeographical distribution, the global transmission of the bacilli (Sola et 
al., 1999, 2001; Warren et al., 2002a; Dale et al., 2003; Filliol et al., 2003, Baker et al., 
2004), and family-specific disease phenotypes and pathogenesis (Glynn et al., 2002; 
Bifani et al., 2002, Baker et al., 2004).
However, in our study samples of drug-susceptible (Chapter 2) and drug-resistant 
M. tuberculosis (Chapter 5) collected from Singapore, there were 27 isolates (16 
susceptible and 11 resistant isolates) which showed clonal characteristics in IS6110
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RFLP and MIRU-VNTR patterns, but not in spoligotyping patterns. These isolates 
represent a novel M. tuberculosis family clone, and therefore have been designated as the 
“S” family of M. tuberculosis.
3.2 Materials and Methods
3.2.1 Mycobacterial isolates
Twenty-seven clinical M. tuberculosis isolates (16 drug-susceptible isolates and 11 drug-
resistant isolates) were selected from the collections of drug-susceptible and drug-
resistant M. tuberculosis as described in Chapters 2 and 5.
3.2.2 DNA fingerprinting
IS6110 RFLP typing, spoligotyping, and MIRU-VNTR typing was performed as 
described in Chapter 2.
3.2.3 Genomic insertion and deletion analysis
The isolates were analyzed for the insertion of IS6110 copy at the A1 position of the 
dnaA-dnaN intergenic region of M. tuberculosis genome, and the region of difference 9 
(RD9) and flanking the M. tuberculosis specific deletion 1 (TbD1) region as described 
before (IS6110 insertion in dnaA-dnaN region analysis was described by Kurepina et al., 
1998 and Milan et al., 2004; RD9 and TbD1 analysis was described by Brosch et al., 
2002).
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3.2.4 katG463 and gyrA95 single nucleotide polymorphism (SNP) analysis
The katG463 and gyrA95 single nucleotide polymorphism (SNP) analysis has been 
previously described (Sreevatsan et al., 1997). After PCR amplification, each PCR 
product was subjected to cycle DNA sequencing using the sequencing primer and ABI 
PRISM® BigDyeTM V3.0 Cycle Sequencing kit (Applied Biosystems, Foster City). The 
cycle sequencing products were purified using Dye-terminator removal kit (Qiagen) and 
ethanol precipitation before being analyzed using ABI PRISM® 3100-Avant Genetic 
Analyzer. DNA sequencing was performed using ABI PRISM 3100-Avant Genetic 
Analyzer (Applied Biosystems).
3.2.5 Phylogenetic analysis
PAUP (Phylogenetic Analysis Using Parsimony and other methods) software 4.0 beta 
version (Sinauer Associates, Inc., Sunderland, Mass) was used to perform phylogenetic 
analysis using the UPGMA (unweighted pair group method using arithmetic averages) 
algorithm based on MIRU-VNTR typing data. TreeView (version for Windows, available 
at http://taxonomy.zoology.gla.ac.uk/rod/treeview.html) was used to print out the 
dendrogram generated by PAUP analysis.
3.2.6 Allelic diversity
The MIRU-VNTR locus allelic diversity (h) was calculated as h = 1-∑xi2, where xi is the 




IS6110 RFLP fingerprints showed that 25 of the 27 SG clone isolates carried 13 to 17 
IS6110 copies. Of the remaining 2 drug-resistant isolates, one (I08) had 20 bands and the 
other (ISE1) had 21 bands. A number of bands were shared by all or by most of the 
isolates (Fig. 3.1). The patterns were highly homogenous. IS6110 RFLP similarity 
analysis showed that these isolates shared greater than 70% of similarity. In spite of this, 
IS6110 RFLP typing still generated 25 distinct patterns.

















































   
   
   
   

















































































   
   
   
   












































Fig. 3.1. IS6110 RFLP patterns of the S clone isolates. Twenty-six of the 27 isolates the S 
clone contained 13 to 17 IS6110 copies, and multiple IS6110 bands are shared by all or 
most of the isolates. Sizes of standard DNA fragments are indicated to the right in 
kilobase pair.
Similarly, as shown in Table 3.1, the MIRU-VNTR patterns were also highly 
homogenous and restricted. The 27 isolates exhibited 14 distinct MIRU-VNTR patterns. 
In 6 of the 12 MIRU-VNTR loci (loci 2, 4, 20, 23, 24, 27), the allelic numbers were 
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invariable. The most variable MIRU-VNTR locus was locus 10 (allelic diversity = 0.74), 
which alone could define 7 of the 14 distinct patterns. Moreover, the locus 10 was 
characterized by a high repetitive allele number; all but one of the isolates had  5 allelic 
copies.
  
As shown in Fig. 3.2, spoligotyping generated a total of 15 distinct spoligotypes, 
3 clustered patterns (P1, P2, and P6) and 12 unique patterns (P3-P4, P7-P15). The pattern 
P1 which had all the 43 spacers conserved was previously identified as a spoligotype of 
Isolates 2 4 10 16 20 23 24 26 27 31 39 40
12-22 2 2 7 2 2 5 1 7 3 4 3 3
16-26 2 2 7 2 2 5 1 7 3 4 3 3
23-02 2 2 7 2 2 5 1 7 3 4 3 3
I08 2 2 7 2 2 5 1 7 3 4 3 3
I14 2 2 7 2 2 5 1 7 3 4 3 3
I42 2 2 7 2 2 5 1 7 3 4 3 3
I76 2 2 7 2 2 5 1 7 3 4 3 3
I81 2 2 7 2 2 5 1 7 3 4 3 3
IRE3 2 2 7 2 2 5 1 7 3 4 3 3
12-36 2 2 7 2 2 5 1 7 3 4 3 4
18-17 2 2 5 2 2 5 1 7 3 4 3 3
19-11 2 2 5 2 2 5 1 7 3 4 3 3
19-24 2 2 5 2 2 5 1 7 3 4 3 3
16-08 2 2 6 2 2 5 1 7 3 4 3 3
I15 2 2 6 2 2 5 1 7 3 4 3 3
23-23 2 2 3 2 2 5 1 7 3 4 3 3
27-10 2 2 9 2 2 5 1 7 3 4 3 3
IS08 2 2 10 3 2 5 1 7 3 4 3 3
IS09 2 2 10 3 2 5 1 7 3 4 3 3
ISE1 2 2 7 3 2 5 1 7 3 4 3 3
12-55 2 2 8 2 2 5 1 7 3 4 3 2
14-14 2 2 8 2 2 5 1 7 3 4 3 3
20-20 2 2 8 2 2 5 1 7 3 4 4 3
20-55 2 2 8 2 2 5 1 7 3 4 4 3
20-57 2 2 8 2 2 5 1 7 3 4 2 2
14-07 2 2 8 2 2 5 1 6 3 4 3 3
I58 2 2 8 2 2 5 1 6 3 3 3 3
Table 3.1. MIRU-VNTR patterns of the S clone isolates
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an M. africanum strain (strain number 960762) in the study by Viana-Niero et al. (2001). 
The pattern P6 was also previously identified from M. tuberculosis strains in Houston, 
the United States (Soini et al., 2000). Despite the high homogeneity of the S clone 
isolates in both IS6110 RFLP and MIRU-VNTR patterns, no common family 
characteristics could be drawn from the spoligotypes of these isolates (Fig. 3.2). 
Therefore in this regard, the S clone is different from the other M. tuberculosis families 
characterized in previous studies (Filliol et al, 2002; Sebban et al., 2002; Douglas et al., 
2003; Sun et al., 2004b).
                




I76    ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■
I81    ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■ P1
IS08   ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■
IS09   ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■
12-22  ■■■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■
12-36  ■■■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■ P2
23-02  ■■■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■
14-07  ■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■ P3
27-10  ■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■ P4
IRE3   ■■■■■■■■■■■■■■■■■■■■■■□■■■■■■■■■■■■■■■■■■■■ P5
19-24  ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■
I08    ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■
I14    ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■
I15    ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■ P6
I42    ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■
I58    ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■
20-57  ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□■■ P7
ISE1   ■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■□■■■ P8
20-20  ■■■■■□□□□■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■ P9
16-08  □□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■■■■■■■□□■■ P10
20-55  □□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■■□■■■■□■■■ P11
23-23  □□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■■■■■■■■■■■ P12
14-14  □□□□□□□□□□□■■■■■■■□□□□□■■■■□■■■■■■■■■■■■■■■ P13
16-26  ■■■■■■■■■■■■■■■■■■■■■■■■□□□□□□□□□□□□□□□□□□□ P14
12-55  ■■■□□□■■■■■■■■■■■■□□□■■■■■■■■■■■■■■■■■■■■■■ P15
Fig. 3.2. Spoligotypes of the S clone isolates. The 43 spacer formats of spoligotypes of 
the 27 S clone isolates are shown. ■ denotes the presence of the spacer and □ indicates 
the absences of the spacer. Shared spoligotype patterns (P1, P2, and P6) were seen within 
several subgroups of isolates, but no common spoligotype characteristics could be drawn 
for all the isolates.
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In other genetic markers, at the A1 position of the dnaA-dnaN region of M. 
tuberculosis genome, an IS6110 insert was detected in all the 27 isolates, and all the 
isolates had RD9 conserved and TbD1 deleted. In regard to the SNP of katG463 and 
gyrA95, all the isolates showed katG463 CTG (Leu) and gyrA95 ACC (Thr) 
polymorphisms, corresponding to the principal genetic group 1 (Sreevatsan et al., 1997). 
3.3.2 Phylogenetic analysis
To explore the phylogenetic position of the S clone in the M. tuberculosis complex, we 
built a genetic tree (Fig. 3.3) based on pooled MIRU-VNTR typing data of the S clone 
isolates (Table 3.1) and that of a global collection of M. tuberculosis complex strains 
(Kremer et al., 1999) which have been typed in a previous study (Supply et al., 2001). On 
the dendrogram, all the S family isolates fell into a clade belonging to one of the modern 
M. tuberculosis branches. The S clone, the Beijing family, and the clades of the CAS 
family are diverged from the same branch which represents the modern M. tuberculosis
of principal genetic group 1 of the M. tuberculosis complex (Sreevatsan et al., 1997). 
Interestingly, another M. africanum strain in the global collection of M. tuberculosis
complex strains (strain 100) fell into the clade of the S clone and shared an identical 
MIRU-VNTR pattern (226225173433) with the S clone strains 16-08 and I15.
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Fig. 3.3.  Phylogenetic position of the S clone. This dendrogram was generated using the 
UPGMA algorithm based on pooled MIRU-VNTR typing data of this study (Table 3.1) 
with that of a global collection of M. tuberculosis complex strains which were previously 
MIRU-VNTR typed (Supply et al., 2001). M. canettii (strain 116) was used as an 
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The discovery of the S genogroup has added information to the genetic diversity of M. 
tuberculosis. Due to the small proportion of the S isolates and limited demographic and 
epidemiological data that were available, we did not find any clinical or epidemiological 
significance of these isolates. The proportions of the S isolates in drug-sensitive and -
resistant M. tuberculosis were the same, suggesting that they were not more related with 
drug-resistance.
However, the S genogroup provides an interesting evolutionary model for 
investigating the evolution of the DR region of M. tuberculosis genome. Spoligotyping is 
based on the polymorphism of the DR region and currently serves as a reference method 
for defining evolutionary lineages of M. tuberculosis because family characteristics of 
spoligotype are well conserved among strains of each family (Filliol et al., 2002; Sebban 
et al., 2002, Douglas et al., 2003; Kremer et al., 2004). However, although a number of 
clonal characteristics in IS6110 RFLP and MIRU-VNTR patterns suggest that the 27 
isolates were derived from a common progenitor, these isolates did not show any family 
characteristics in their spoligotypes that can be used to group these isolates as a family 
like the other known M. tuberculosis families. This represents an exception from a 
common evolutionary mechanism. In addition, it has been suggested that the 
polymorphism of the DR region results from the irreversible deletion of direct variable 
repeat (DVR) (van Embden et al., 2000; Warren et al., 2002a; Sampson et al., 2003) and 
the deletion may be mediated by IS6110 insertion (Warren et al., 2002a; Sampson et al., 
2003). Most of the S isolates had the 43 DVRs conserved or only lost 1 to 3 DVRs, 
therefore, these isolates are valuable for investigating this potential evolutionary 
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mechanism. Thus, further studies on the structure of the DR locus of these isolates would 
shed more light into the evolutionary mechanism of the DR region.
The S family isolates were genetically close to the Beijing genotype as 
demonstrated by genetic relatedness in their IS6110 RFLP and MIRU-VNTR patterns 
with that of Beijing strains, and by the presence of a IS6110 insert in the dnaA-dnaN
region of the S family isolates because all Beijing strains have a IS6110 copy inserted in 
this region (Kremer et al., 2004). However, the spoligotypes of the S isolates indicate that 
these isolates did not belong to the Beijing family. Furthermore, the high allelic diversity 
and the high repetitive allele number in MIRU-VNTR locus 10 were very different 
features from those of Beijing strains.
Phylogenetic analysis suggests that the S family might share a common 
progenitor with the Beijing and CAS families as they are diverged from the same branch 
of the MIRU-VNTR genetic tree (Fig. 3.3). In phylogenetic markers of TbD1 and the 
SNP of katG463 and gyrA95, the S family isolates exhibited the same evolutionary traits as 
Beijing and CAS strains did. TbD1 is deleted from the genomes of modern evolutionary 
lineages of M. tuberculosis, including the known families of Beijing, CAS, LAM, 
Haarlem, T, and X, but conserved in the ancestral EAI family strains of M. tuberculosis
and the other taxons of the M. tuberculosis complex (Brosch et al., 2002), thus a specific 
marker to differentiate ancestral and modern M. tuberculosis. Based on the SNP of 
katG463 and gyrA95, the M. tuberculosis complex isolates are divided into three principal 
genetic groups (Sreevatsan et al., 1997). The M. tuberculosis families of Beijing, CAS, 
and EAI belong to the principal genetic group 1. Taken together, all the results suggest 
that the S clone is a member of the modern M. tuberculosis of the principal genetic group 
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1 (Sreevatsan et al., 1997), and the Beijing family is the closest evolutionary lineage to 
the S family.
Interestingly, two previously characterized M. africanum strains, the strain 
960762 in the study by Viana-Niero et al. (2001) and the strain 100 in the Kremer’s 
collection (Kremer et al., 1999; Supply et al., 2001), were found to share either an 
identical spoligotype or an identical MIRU-VNTR pattern with isolates of the S clone. 
The strain 100 in the Kremer’s collection was originally identified as a representative of 
M. africanum, designated so was based solely on its biological phenotype (Kremer et al. 
1999). However, this strain was genetically distant from another M. africanum strain 
(strain 92) in the same collection based on their IS6110 RFLP patterns (Kremer et al., 
1999) and MIRU-VNTR patterns (Supply et al., 2001, and Fig. 3.3 in this study), and the 
allelic number of MIRU-VNTR locus 24 of the strain 92 indicates that it belonged to an 
ancestral taxon of the M. tuberculosis complex, whereas that of the strain 100 indicates 
that it belonged to a modern evolutionary lineages of M. tuberculosis (Supply et al., 
2001; Sun et al., 2004a). Findings from another study (Brosch et al., 2002) also suggest 
that the strain 100 was a M. tuberculosis strain instead of a M. africanum strain because 
the strain 100 was different from a group of M. africanum strains in two critical genomic 
deletion markers, RD9 and TbD1. RD9 is absent from M. africanum, M. bovis, and M. 
microti, but present in M. tuberculosis and M. canettii. TbD1 is present in M. africanum, 
M. bovis, M. microti and M. canettii, as well as the ancestral M. tuberculosis EAI strains, 
but absent from the modern family strains of M. tuberculosis (Brosch et al., 2002). The 
strain 100 was RD9 positive but TbD1 negative. These molecular evidence unanimously 
indicate that the strain 100 is a member of modern M. tuberculosis. Accordingly, some 
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members of the M. tuberculosis S family may phenotypically present as M. africanum, an 
interesting phenomenon that deserves further investigation.
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CHAPTER 4




The M. tuberculosis Beijing genotype family constitutes a group of genetically 
homogeneous strains, presumably due to recent clonal expansion (van Soolingen et al., 
1995). Beijing genotype strains are globally widespread with dominant prevalence in a 
number of East Asian countries, and associated with drug-resistance in Vietnam, New 
York, Cuba, and Estonia (van Soolingen et al., 1995; Bifani et al., 2002; Glynn et al., 
2002). Moreover, in Vietnam the Beijing genotype was found to be associated with 
younger patients, and based on this, it has been proposed that the Beijing genotype is an 
emerging pathogen in this country (Anh et al., 2000). But the relationship of the Beijing 
genotype with patient’s age remains a matter of debate because the association has not 
been found in other areas (Glynn et al., 2002). Also in Vietnam, the Beijing genotype was 
recently reported to be associated with treatment failure and tuberculosis relapse (Lan et 
al., 2003). All these findings are important for understanding the Beijing genotype, it is 
therefore necessary to confirm the findings in different settings because epidemiological 
studies may be biased by many potential confounding factors.
We have described the dominant prevalence of Beijing strains in Singapore in 
Chapter 2. In this retrospective study, we aimed to demonstrate the relationships of 
Beijing strains with tuberculosis relapse and with patient’s age in our setting.
4.2 Materials and Methods
4.2.1 Study subjects and mycobacterial isolates
Study subjects were the 364 patients who had drug-susceptible tuberculosis and their 
isolates have been analyzed in Chapter 2. Demographic data of age, sex, and ethnicity as 
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well as the information of current episode (recurrence or first episode) were obtained 
retrospectively from the National Tuberculosis Registry database. Mycobacterial isolates 
were the same as described in Chapter 2 and the genotyping results were used in this 
chapter.
4.2.2 Definitions for recurrent, relapsed, and reinfected tuberculosis
Patients who had tuberculosis and were completely bacteriologically negative with anti-
tuberculosis treatment 2 years prior to the current episode were categorized as recurrent 
cases. Recurrent cases who were infected with clustered M. tuberculosis isolates by 
IS6110 and MIRU-VNTR typing were defined as exogenously re-infected patients, the 
remaining recurrent cases who were infected with a unique strain determined by IS6110
and MIRU-VNTR typing were defined as relapsed cases. The non-recurrent and re-
infected cases were categorized as non-relapsed cases.
4.2.3 Statistical analysis
2 test was used to analyze categorical variables, and Spearman’s correlation test was 
used to analyze trend correlation of categorical variables. Odds ratio (OR) with 95% 
confidence interval (CI) was calculated.  Student’s t test was used to compare normally 
distributed continuous variables. Multivariate logistic regression was used to adjust for 
potential confounding factors. A p value of <0.05 was considered statistically significant.
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4.3 Results
Of the 364 patients, 196 (53.8%) were infected with Beijing genotype isolates. 
Information on patient’s age, sex, ethnicity, and current episode were available for 335 
patients. The 29 patients with missing data had a similar proportion of Beijing genotype 
strains to the others, and the dates of specimen acquisition were evenly distributed 
throughout the sampling period. Therefore, the exclusion of the 29 patients from the total 
sample is unlikely to introduce bias into the study.
The 335 patients (243 males, 72.5%) ranged in age from 6 to 91 years, with a 
mean age of 50 years (SD = 19). Fifty-two of the 335 patients had recurrent tuberculosis, 
the remaining 283 had first episode disease. Of the recurrent cases, 7 (5 were infected 
with Beijing strains, 2 with non-Beijing strains) were regarded as having exogenous re-
infection as they were members of seven IS6110 and MIRU-VNTR fingerprint defined 
clusters, the remaining 45 recurrent patients (37 males, 82.2 %) were categorized as 
relapsed cases. Beijing strains were found in 32 (71.0%) of the 45 relapsed cases and in 
148 (51.0%) of the 290 non-relapsed (283 first episode and 7 re-infected) cases. As 
shown in Table 4.1, univariate analysis revealed that there was an association between 
Beijing strains and tuberculosis relapse (OR, 2.36; 95% CI, 1.20-4.64; p = 0.019). The 
mean age was 61 years (SD = 16) in the relapsed group, but it was 48 years (SD = 19) in 
the non-relapsed group, the difference is statistically significant (t test, p = 0.0001). All 
but one relapsed case were older than 30 years, and about a half of relapsed cases were ≥ 
65 years. Tuberculosis relapse was found to be strongly associated with older patients by 
univariate analysis (p < 0.001). However, no significant association of tuberculosis 
relapse with sex (p = 0.166) and ethnicity (p = 0.375) was observed.
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Multivariate logistic regression analysis, which included genotypes (dichotomous 
as Beijing and non-Beijing) and age (continuous variable), confirmed the significant 
association of Beijing genotype with tuberculosis relapse (OR, 2.64; 95% CI, 1.30-5.34; 
p = 0.005). Patient’s age was also independently associated with tuberculosis relapse, the 
odds that an older patient had relapsed tuberculosis increased 4% over that of a younger 
patient with each year of age (OR, 1.04; 95% CI, 1.02-1.06; p < 0.001).
The relationship between M. tuberculosis Beijing genotype and patient’s age was 
also examined.  The mean ages were 49 (SD = 20) and 51 (SD = 18) for the patients 
infected with Beijing and non-Beijing strains respectively. There was no association 
between the Beijing genotype and patient’s age in our study (p = 0.244).
4.4 Discussion
Recurrent tuberculosis may develop as the result of reactivation of the endogenous 
primary infection (relapse) or as a result of a recent exogenous infection (re-infection) 
(van Rie et al., 1999). The conclusive method to differentiate these two events from each 
other is to fingerprint M. tuberculosis isolates of the primary and recurrent episodes. If 
the paired isolates of primary and recurrent episodes of one patient are identical (or very 
similar) in their DNA fingerprints, the recurrent event is regarded as a reactivation; 
otherwise, if the paired isolates exhibit different DNA fingerprints, the recurrent event is 
considered to be re-infection. As strain-typing was not done in the previous episodes of 
tuberculosis for the recurrent cases in this study, we were unable to define these cases as 
relapse or re-infection by this method. Nevertheless, re-infection is an event of recent 
transmission from person to person; isolates involved in this event are epidemiologically 
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Table 4.1. Analysis of relapsed and non-relapsed tuberculosis cases based on the
M. tuberculosis genotypes and demographic factors
                          a2 and Spearman’s correlation. OR, odds ratio; CI, confidence interval. 
                          bLogistic regression analysis. OR for genotype and age is adjusted by each other. 
                          cUsed as continuous variable in Logistic regression analysis. OR (1.04) indicates that the odds of relapse
                   increases 4% every one year older.
Patient (%) Univariate analysisa Multivariate analysisbGenotypes No. of
patients Relapsed Non-relapsed OR (95% CI) p OR (95% CI) p
Genotype
   Beijing














   < 25
   25-44
   45-64









  34 (97.1)
104 (94.5)
  86 (83.5)






Age (y)c 335 45 (13.4)     290 (86.6) 1.04 (1.02-1.06) 0.000
Sex
   Male












   Malay
   Indian






  8 (14.8)
  5 (23.8)
    0 (0)
216 (87.1)
  46 (85.2)








related, thus likely showing identical or nearly identical DNA fingerprints. Isolates from 
reactivated cases are likely to be distinct from each other. Based on this notion, we have 
defined each of the recurrent cases as relapse or re-infection and found that M. 
tuberculosis Beijing genotype was associated with tuberculosis relapse in Singapore. This 
observation agrees with the finding of the Vietnamese study (Lan et al., 2003).
The limitation of our definitions for relapse and non-relapse is the risk of 
misclassification of true relapsed cases into re-infection or true re-infected cases into 
relapse. However this possibility seems unlikely to counter the association between the 
Beijing genotype and tuberculosis relapse for several reasons. Firstly, the relative 
contribution of exogenous re-infection to recurrent tuberculosis depends on the incidence 
of tuberculosis in a community (van Rie et al., 1999; Jasmer et al., 2004). Although the 
incidence in Singapore was moderate (49 per 100,000 people) in 1994, re-infection 
appeared to be not significant because in 21 drug-resistant tuberculosis patients who had 
multiple isolates (the time intervals between the first and last isolates for a given patient 
ranged from 45 to 815 days, with a mean of 258 days) sampled during the period of 
August 1994 to December 1996, all subsequent isolates had identical or nearly identical 
(only one band difference) IS6110 RFLP patterns and identical MIRU-VNTR patterns 
with the respective initial isolate (data not shown), indicating that none of these patients 
had exogenous reinfection. Secondly, the findings that the mean age of the relapsed 
group was significantly older than that of the non-relapsed group and relapse was 
strongly correlated with older patients suggest that the recurrences in the relapsed group 
were more likely due to endogenous reactivation rather than exogenous reinfection. 
Thirdly, by our definition of re-infection, more recurrent cases infected with Beijing 
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strains (5 cases) were classified as re-infected cases compared to those infected with non-
Beijing strains (2 cases).
We did not find an association between Beijing strains and patient’s age in this 
study. This observation is consistent with previous ones obtained from Hong Kong, 
Thailand, Indonesia, and Estonia (Glynn et al., 2002), but disagrees with the previous 
study performed in Vietnam (Anh et al., 2000). The disparity between the studies was 
possibly due to variations in overall population structure in these settings; for example, 
the < 30-year population accounted for approximately 47% of the total population in 
Singapore in 1994, the same age group of population accounted for about 62% of the 
total population in Vietnam in 2000 (U.S. Census Bureau, 2005) 
http://www.census.gov/ipc/www/idbpyr.html). Thus, the association between Beijing 
strains and younger patients in Vietnam might be because it had higher proportion of 
younger population. As such, when comparing such data from different settings, study 
samples should be standardized with respective national population data.
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CHAPTER 5
MOLECULAR EPIDEMIOLOGY OF DRUG-RESISTANT TUBERCULOSIS: 
TRANSMISSION ANALYSIS AND ASSOCIATIONS BETWEEN DRUG-
RESISTANT PHENOTYPES AND GENOTYPES OF M. TUBERCULOSIS
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5.1 Introduction
Drug-resistant tuberculosis is a major threat to global control of the epidemic. According 
to a recent WHO report (WHO, 2004), drug-resistant tuberculosis is highly prevalent and 
emerging in multiple areas of the world. Drug-resistant tuberculosis can be disseminated 
with population immigration from areas with high incidence to areas with low incidence 
(Granich et al., 2005).
“Resistance among new cases” results from the transmission of drug-resistant M. 
tuberculosis isolate from a patient to another person. The incidence of “resistance among 
new cases” in a community is an indicator of transmission within the community. 
“Resistance among previously treated cases” results from man-made factors, such as 
improper medical management, inappropriate prescription, or poor adherence of patients 
to treatment, etc.. The level of “resistance among previously treated cases” reflects the 
performance of on-going tuberculosis control program (WHO, 1997, 2000b).
Drug-resistant tuberculosis has been a persistent problem in Singapore with an 
incidence fluctuating in a range of 4.2% to 6.7% from 1994 to 2004 (Boudville et al., 
1997; Communicable Disease Surveillance Report 2004, the Department of Clinical 
Epidemiology, Tan Tock Seng Hospital). However, little is known about the transmission 
dynamics of drug-resistant tuberculosis in this large urban center. In this population-
based study, we estimated the relative contribution of recent transmission to drug-
resistant tuberculosis on the basis of molecular genotyping analysis, and examined the 
relationships between drug-resistant phenotypes and genotypes of M. tuberculosis. 
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5.2 Materials and Methods
5.2.1 Mycobacterial DNA samples
A DNA sample bank of 271 drug-resistant M. tuberculosis isolates was used for M. 
tuberculosis genotyping. These isolates were consecutively collected between August 
1994 and December 1996 from the Central Tuberculosis Laboratory, Singapore General 
Hospital, Singapore. The collection of isolates represented the population of drug-
resistant M. tuberculosis in Singapore during the study period. Drug-susceptibility testing 
was performed using the BACTEC 460 radiometric method (Becton Dickinson, Towson, 
Md). The concentrations tested were 0.1 g/ml for isoniazid, 2 g/ml for rifampin, 6 
g/ml for streptomycin, and 7.5 g/ml for ethambutol. The drug-susceptible isolates 
described in Chapter 2 were used as a control sample.
5.2.2 Genotyping analysis
The genotyping methods of spoligotyping, MIRU-VNTR, and IS6110 RFLP, as well as 
the similarity analysis of IS6110 RFLP patterns are the same as described in Chapter 2. 
The genotype of the isolates was determined as described in Chapter 2. The definition of 
transmission cluster is the same as described in Chapter 2 and transmission clusters were 
defined using both IS6110 RFLP and MIRU-VNTR patterns.
5.2.3 Statistical analysis
Differences between groups were tested by 2 test (or Fisher’s exact test) and 
multivariate logistic regression. Odds ratio (OR) with 95% confidence interval (CI) was 
calculated. A p value of < 0.05 was considered statistically significant.
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5.3 Results
5.3.1 Frequencies of isolates by drug-resistant patterns
A total of 271 drug-resistant isolates (244 initial isolates and 27 subsequent isolates) were 
collected, which were from 244 patients. Among the 244 initial isolates, 10 isolates (8 
monoresistance to INH, 1 monoresistance to STR, 1 resistance to both INH and STR) 
were excluded because DNA samples were not available. Table 5.1 shows the drug-
resistant patterns of the remaining 234 initial isolates and the frequencies of isolates of 
each resistant pattern. A total of 168 (71.8%) isolates were resistant to at least INH, 103 
isolates (44.0%) were resistant to at least STR, 48 (20.5%) isolates were resistant to at 
least RIF, and 16 (6.8%) isolates were resistant to at least EMB. Forty-one (17.5%) 
isolates were MDR. 
Table 5.1. Drug-resistant patterns of 234 M. tuberculosis isolatesa
       
Note. aData shown are absolute numbers with percentage of the group total in brackets. 
INH, isoniazid; RIF, rifampin; STR, streptomycin; EMB, ethambutal





INH, RIF 21 (9.0)
INH, RIF, EMB 5 (2.1)
INH, RIF, STR 10 (4.3)
INH, RIF, STR, EMB 5 (2.1)
INH, STR 30 (12.8)
INH, EMB 3 (1.3)
INH, STR, EMB 1 (0.4)
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5.3.2 Genotype determination of isolates
Among the 234 initial isolates, 216 had typing results for all the three typing modalities. 
Of the remaining 18 isolates, 9 had only IS6110 RFLP typing results (one isolate carried 
single IS6110 copy, 8 isolates carried  9 IS6110 copies), the remainder had both 
spoligotyping and MIRU-VNTR typing results. Each of the 224 isolates which had 
spoligotyping and MIRU-VNTR typing results was assigned to one of the eight M. 
tuberculosis genotypes as described in Chapters 2 and 3. The genotypes of the 8 isolates 
that had only IS6110 RFLP typing results were determined based on their IS6110 RFLP 
patterns by similarity comparison with the isolates with known genotypes. There were 
142 (60.1%) isolates belonged to the Beijing genotype, 45 (19.2%) isolates belonged to 
the EAI genotype. In the remaining 48 isolates, 2 (0.9%) belonged to the CAS family, 11 
(4.7%) belonged to the S family, 13 (5.6%) belonged to the Haarlem family, 3 (1.3%) 
belonged to the LAM family, and 17 (7.3%) belonged to the T family. No X genotype 
isolate was found from this drug-resistant sample.
5.3.3 Transmission analysis of drug-resistant tuberculosis
Of the 234 isolates, 3 Beijing isolates which had shared MIRU-VNTR patterns but did 
not have IS6110 RFLP typing result and 1 EAI isolate which had shared single IS6110
band pattern but did not have MIRU-VNTR and spoligotyping results were excluded 
from clustering analysis because the status of these isolates, i.e., whether they were 
unique or clustered, could not be determined. In the remaining 230 isolates, 180 were 
unique isolates, 50 were clustered isolates in 21 clusters.
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The characteristics of the clustered isolates are listed in Table 5.2. Sixteen (76%) 
of the 21 clusters were comprised of Beijing isolates. The largest cluster (cluster 12) 
contained 6 isolates. Drug-resistant patterns of isolates within 15 clusters (1 through 11 
and 18 through 21) were identical. Drug-resistant patterns of isolates within 3 clusters 
(clusters 13, 16, and 17) were entirely different, and those of isolates in clusters 14 and 
15 differed for one drug. Cluster 12 can be subdivided into two clusters based on the 
resistant patterns of the isolates, isolates 12A and 12B as one cluster, the remaining 12C 
through 12F as the other.
By assuming that there is one source case in each cluster and the rest case (s) in a 
cluster is due to transmission (Small et al., 1994), we calculated the transmission rates of 
drug-resistant tuberculosis. However, it is apparent that the transmission events for 
clusters 13, 16, and 17 occurred before the development of drug-resistance in these 
isolates. In addition, in cluster 12, 12A and 12B might be due to one transmission event 
of a drug-resistant strain, whereas 12C through 12F obviously resulted from different 
drug-resistant transmission event(s). Therefore clusters 13, 16, and 17 were excluded 
from the calculation, and cluster 12 was treated as two clusters. After these adjustments, 
there were 25 drug-resistant isolates in 19 clusters were due to transmission. The overall 
transmission rate of drug-resistant tuberculosis was 10.9% (25/230), the transmission rate 
of drug-resistant Beijing isolates was 15% (21/140), and the transmission rate of drug-
resistant non-Beijing isolates was 4.4% (4/90). These data suggest that the recent 
transmission of drug-resistant tuberculosis in Singapore was low and Beijing strains were 
more transmissible than were non-Beijing strains.
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          Table 5.2. Characteristics of clustered drug-resistant isolates
Resistant patternsc  Cluster 
No.a





















































































































































































































































































































































Notes to Table 5.2. aClusters are numbered 1 through 21. bIsolates in each cluster are labeled with A, B, C, 
D, E, or F, after cluster number. cINH, isoniazid; RIF, rifampin; STR, streptomycin; EMB, ethambutol; R, 
resistant; S, sensitive. dn = 10.
5.3.4 Assessment of resistant pattern and Beijing genotype as clustering factors
The clustering risk of drug-resistant M. tuberculosis isolates with different resistant 
patterns and of Beijing isolates were examined (Table 5.3). INH-resistant (resistance to at 
least INH) isolates were inversely associated with clusters OR (95% CI), 0.20 (0.10-
0.38), p < 0.001. When stratified by INH-monoresistance and INH-polyresistance/MDR, 
only INH-monoresistant isolates remained inversely associated with clusters OR (95% 
CI), 0.25 (0.12-0.54), p < 0.001, whereas INH-polyresistant/MDR isolates were not 
associated with clusters OR (95% CI), 0.70 (0.36-1.41), p = 0.324. On the contrary, 
STR-resistant (resistance to at least STR) isolates were positively associated with clusters 
OR (95% CI), 2.56 (1.35-4.86), p = 0.004; when stratified by STR-monoresistance and 
STR-polyresistance, the association between STR-monoresistant isolates and clusters 
became stronger OR (95% CI), 3.03 (1.59-5.80), p < 0.001, but no significant 
association between STR-polyresistant isolates and clusters was observed OR (95% CI), 
0.62 (0.26-1.43), p = 0.263. Neither RIF-resistant isolates nor MDR were associated 
with clusters (p > 0.05). The drug-resistant isolates of the Beijing genotype were 
significantly associated with clusters OR (95% CI), 3.20 (1.52-6.70), p = 0.002.
Multivariate logistic regression analysis was performed to adjust any potential 
confounding effect between Beijing isolates and STR-resistant or STR-monoresistant 
isolates because Beijing isolates were associated with STR-resistance or STR-
monoresistance. After the adjustments, the association remained between Beijing 
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genotype strains and clusters no matter of being adjusted by STR-resistant isolates OR 
(95% CI), 2.61 (1.19-5.73), p = 0.017 or by STR-monoresistant isolates OR (95% CI), 
2.42 (1.10-5.31), p = 0.028. Similarly, although the associations remained between STR-
resistant isolates and clusters as well as between STR-monoresistant isolates and clusters, 
Beijing isolates showed a negative adjustment to the association of STR-resistant isolates 
with clusters OR (95% CI), 2.01 (1.02-3.96), p = 0.044, but a positive adjustment to the 
association between STR-monoresistant isolates and clusters OR (95% CI), 3.43 (1.71-
6.89), p < 0.001.
                         Table 5.3. Clustering risk of isolates with different resistant
                                                 patterns and of Beijing  isolates
a2 test. bLogistic regression. OR, odds ratio; CI, confidence interval. cAdjusted by resistance to at least 
STR. dAdjusted by monoresistance to STR. eIncluding the 7 MDR isolates in this table.
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5.3.5 Relationships of drug-resistant phenotypes with M. tuberculosis genotypes
The relationships between drug-resistant phenotypes and M. tuberculosis genotypes were 
analyzed by comparing with the 364 drug-susceptible isolates which have been described 
in Chapter 2. As shown in Table 5.4, monoresistance to INH was inversely associated 
with Beijing isolates OR (95% CI), 0.494 (0.31-0.788), p = 0.003 but positively 
associated with EAI isolates OR (95% CI), 1.804 (1.099-2.961), p = 0.019. However, 
when considered all the INH-resistant patterns (resistance to at least INH), INH-
resistance was neither associated with Beijing isolates nor EAI isolates (p > 0.05). On the 
contrary, monoresistance to STR was positively associated with Beijing isolates OR 
(95% CI), 4.571 (2.208-9.452), p < 0.001 but negatively associated with EAI isolates 
OR (95% CI), 0.131 (0.035-0.499), p = 0.001. STR-resistance remained positively 
associated with Beijing isolates OR (95% CI), 3.306 (1.969-5.549) p < 0.001 and 
negatively associated with EAI isolates OR (95% CI), 0.307 (0.145-0.649) p = 0.001
when considered all the STR-resistant patterns (resistance to at least STR). Either MDR 
OR (95% CI), 2.657 (1.282-5.501), p = 0.008 or all RIF-resistant patterns OR (95% 
CI), 2.883 (1.442-5.759), p = 0.002 was associated with Beijing isolates.
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                          Table 5.4. Distribution of drug-resistant and drug-susceptible isolates by M. tuberculosis genotypesa
                  aTwo monoresistant isolates to EMB were excluded, and comparison of frequencies between drug-resistant and drug-susceptible groups
                       is by 2 or Fisher’s exact test.                                                                                           bOR (95% CI), 0.494 (0.31-0.788), p = 0.003.
                                 cOR (95% CI), 1.804 (1.099-2.961), p = 0.019.                                                   dOR (95% CI), 4.571 (2.208-9.452), p < 0.001.
                                 eOR (95% CI), 0.131 (0.035-0.499), p = 0.001.                                                   fOR (95% CI), 2.657 (1.282-5.501), p = 0.008.
                                  gOR (95% CI), 3.306 (1.969-5.549), p < 0.001.                                                  hOR (95% CI), 0.307 (0.145-0.649), p = 0.001.
                                  iOR (95% CI), 2.883 (1.442-5.759), p = 0.002.                                                   jData from Chapter 2.
No. of isolates (%) by genotypes Resistant
patterns
No. of
isolates Beijing EAI CAS S Haarlem LAM T X
Mono-
resistance
    INH
    STR
    RIF
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364  196 (53.8) 79 (21.7) 2 (0.5) 16 (4.4) 29 (8.0) 6 (1.6) 33 (9.1) 3 (0.8)
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5.4. Discussion
5.4.1 Transmission of drug-resistant tuberculosis
Drug-resistant tuberculosis could result either from transmission (resistance among new 
cases) or from inadequate treatment (resistance among previously treated cases). Thus, a 
better understanding of the relative contribution of the two situations has practical 
implications for assessing and improving tuberculosis control programs. In this study, we 
have demonstrated that only about 11% of patients with drug-resistant tuberculosis were 
due to recent transmission. This observation suggests that recent transmission contributes 
only a small part to the incidence of drug-resistant tuberculosis in Singapore. 
Since 1953, it has been recognized by animal studies that INH-resistant strains are 
less virulent than drug-susceptible strains as demonstrated by causing less disease in 
guinea pigs (Middlebrook and Cohn, 1953). Molecular epidemiological studies have 
shown that INH-resistant isolates were less likely to be in a cluster defined by DNA 
fingerprint in the Netherlands (van Soolingen et al., 1999) and to cause secondary cases 
in San Francisco (Burgos et al., 2003) than INH-sensitive ones. In the present study, we 
also found that INH-resistant isolates were less likely to be in a cluster compared to 
isolates with other resistant patterns. But this was restricted only to INH-monoresistant 
isolates not INH-polyresistant/MDR isolates. INH-polyresistant/MDR isolates were not 
related with clusters. Taken together, these findings suggest that INH-monoresistant 
strains have reduced transmissibility, perhaps because some INH-resistance conferring 
gene alterations reduce the virulence of the bacilli (Barnes and Cave, 2003).
In New York City (Friedman et al., 1995) and Poland (Sajduda et al., 2004), 
MDR strains were more likely to cluster. However, in Mexico (Garcia-Garcia et al., 
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2000a, 2000b) and South African gold-mining community (Godfrey-Faussett et al., 
2000), patients with MDR-TB were significantly associated with a decreased likelihood 
of being clustered. In San Francisco (Burgos et al., 2003), MDR-TB cases were not likely 
to produce new, incident drug-resistant tuberculosis cases. It is possible to be more likely 
in clusters if some individual MDR strains are high virulent. In the present study, no 
association was observed between MDR isolates and clusters. This might be due to our 
small MDR sample size or because our comparison was performed within drug-resistant 
population instead of between drug-resistant and drug-susceptible populations as the 
other studies did. This is because our drug-sensitive sample was collected in a short 
period (5 months) which is not long enough to reflect the extent of recent transmission 
(van Soolingen, 2001), thus not suitable for transmission analysis.
In addition to STR-monoresistant isolates, Beijing genotype isolates were also 
found to be more likely in a cluster than were non-Beijing isolates. This observation 
agrees with that of studies performed in Russia (Toungoussova et al., 2002, 2003). 
Because STR-resistance was strongly associated with Beijing genotype strains, 
multivariate analysis was then performed to adjust for any potential confounding effect 
between the two factors. Although these two risk factors for clustering remained 
independent from each other after multivariate analysis, because of as high as 84% of the 
STR-monoresistant isolates belonging to the Beijing genotype, it remains difficult to 
ascertain an independent role for STR-monoresistance in clustering. 
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5.4.2 M. tuberculosis genotypic preference to drug-resistant phenotypes
Although drug-resistant tuberculosis among previously treated cases results from man-
made factors, increasing evidence suggest that drug-resistant phenotypes are not equally 
distributed among M. tuberculosis genotypes, suggesting that different M. tuberculosis
genotypes may have different preference for developing drug-resistant phenotypes (Anh 
et al., 2000; Chan et al., 2001; Toungoussova et al., 2002, 2003; Baker et al., 2004; Jou et 
al., 2005). In this population-based study with a substantial number of resistance among 
previously treated cases, we demonstrated that there were significant positive/negative 
associations between M. tuberculosis genotypes and drug-resistant patterns. For example, 
INH-monoresistance was found to be more frequent in EAI strains but less often in 
Beijing strains; in contrast, STR-monoresistance occurred with a significant high 
proportion in Beijing strains, but less likely occurred in EAI strains.
So far the findings are discrepant on the relationship between INH-resistance and 
Beijing genotype strains. In Hong Kong, an inverse association between INH-resistance 
and Beijing genotype strains was observed (Chan et al., 2001), but in Vietnam (Anh et 
al., 2000) and in Taiwan (Jou et al., 2005), the association was found to be positive. In 
this study, the inverse association between INH-monoresistance and Beijing strains as 
well as the positive association between INH-monoresistance and EAI strains were 
resolved when considered all INH resistant patterns including MDR, suggesting that 
INH-polyresistance and MDR have introduced negative confounding effect to the 
significant associations. In supportive of this suggestion, the Hong Kong study (Chan et
al., 2001) did not find significant association between Beijing genotype strains and MDR. 
This could be inferred that the confounding effect of INH-polyresistance and MDR were 
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at less extent compared to the present study in which a strong significant association 
between Beijing isolates and MDR was observed. The confounding effect suggests that 
the INH-monoresistant Beijing strains and the INH-polyresistant/MDR Beijing strains 
may represent different subgenotypes of the Beijing family. Baker et al. (2004) have 
provided supportive evidence that the INH resistance-conferring mutation katG A944C was 
positively associated with Delhi strains, and the inhA C15T promoter mutation positively 
associated with EAI strains.
However, studies performed in different settings have reported consistent results 
on the relationship of STR-resistance with Beijing genotype strains that Beijing strains 
are positively associated with STR-resistance (Anh et al., 2000; Toungoussova et al., 
2002, 2003; Baker et al., 2004). This association was also detected in the present study. 
The inconsistent or complex findings in INH-resistance and the consistent 
findings in STR-resistance may be related with their complexity of drug-resistance 
conferring mutations. INH-resistance has been found to be involved in multiple genes 
and mutations, but STR-resistance has been only related to two mutations of two genes 
and one of them is predominant (Ramaswamy and Musser, 1998). This has been the case 
for this study sample. Previous studies have shown that 64% of the INH-resistant isolates 
of the present study carried potential drug-resistance conferring mutations and/or 
deletions in genes katG, inhA, oxyR, ahpC, kasA, and ndh, and the remaining 36% of 
isolates did not show any of the targeted genetic alterations in these genes (Lee et al., 
1999, 2001). On the other hand, as high as 90% of our STR-resistant isolates carried 
drug-resistance conferring mutations only in the codon 43 (82%) and codon 88 (8%) of 
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rpsL gene, and only 10% of isolates did not show the targeted mutations (Lee et al., 
unpublished data).
In summary, these data showed that recent transmission makes a small 
contribution to the incidence of drug-resistant tuberculosis in Singapore, suggesting a 
limited transmission of drug-resistant tuberculosis. The disequilibrium in distribution of 
resistant patterns among M. tuberculosis genotypes suggests that bacterial factor(s) also 
have a role to play in the development of drug-resistance.
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CHAPTER 6
CLINICAL AND IMMUNOLOGICAL COMPARISON OF
TUBERCULOSIS ASSOCIATED WITH M. TUBERCULOSIS BEIJING
AND NON-BEIJING GENOTYPE STRAINS
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6.1 Introduction
Molecular epidemiology has greatly advanced the understanding of population structure 
and geographic distribution of Mycobacterium tuberculosis worldwide. An important 
finding is the high prevalence of the M. tuberculosis Beijing genotype strains (Bifani et 
al., 2002; Glynn et al., 2002). The Beijing genotype was first described in 1995 because 
of its predominance in the Beijing area of China, the high similarity of IS6110 RFLP 
patterns and the identical polymorphism pattern of the direct repeat region of M. 
tuberculosis genome between isolates (van Soolingen et al., 1995). Thereafter, it has been 
shown that strains of this genotype are predominant in other East Asian areas (Anh et al., 
2000; Park et al., 2000; Chan et al., 2001; Sun et al., 2004) and prevalent all over the 
world (Bifani et al., 2002; Glynn et al., 2002). In Vietnam, it is an emerging pathogen 
associated with younger patients, and hence with active transmission (Anh et al., 2000). 
The selective advantage of the Beijing genotype has led to the postulation that it may be 
an “escape variant” of mass BCG vaccination (van Soolingen et al., 1995).
In addition to the wide dissemination and local predominance, Beijing strains 
have been reported to be associated with various phenotypes. The association with drug-
resistance is the most frequently reported, such as in Vietnam (Anh et al., 2000), New 
York (Bifani et al., 1996), Cuba (Diaz et al., 1998), Estonia (Kruuner et al., 2001), and in 
Russia (Toungoussova et al., 2003). In addition, the Beijing genotype was also found to 
be associated with treatment failure and tuberculosis relapse in Vietnam (Lan et al., 
2003), and with febrile response to treatment in Indonesia (van Crevel et al., 2001).
Two animal studies have been performed in mice comparing the infections 
associated with selected Beijing and non-Beijing strains (Manca et al., 2001; López et al., 
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2003). In the study by Manca et al. (2001), the Beijing genotype strain HN878 was found 
to be hypervirulent. Mice infected with this strain failed to induce a Th1 immune 
response, as evidenced by lower levels of IFN- and TNF- in the lungs than mice 
infected by other strains. In the study by López et al. (2003), mice infected with Beijing 
strains were characterized by extensive pneumonia, early but transient TNF- expression, 
and higher bacillary loads in the lungs, and significantly higher earlier mortality. 
Expression of IFN- was faint, similar to the infection of M. canettii strains but lower 
than the infection of M. tuberculosis laboratory strain H37Rv.
All these findings suggest that the Beijing genotype clone of M. tuberculosis
behaves differently from the others. However, there has been no study performed to 
compare the immune responses associated with infections caused by Beijing and non-
Beijing strains in patients. M. tuberculosis Beijing strains accounted for >50% of 
tuberculosis cases and were associated with tuberculosis relapse and drug-resistance in 
Singapore (Chapters 2-5) and this is therefore a good study setting for comparison study 
of tuberculosis caused by Beijing and non-Beijing strains. In this prospective study, we 
aimed to determine whether there are clinical and biological differences in the host 
response to infections caused by Beijing and non-Beijing strains. In particular we 
hypothesized that Beijing strains elicit a weaker Th1 immune response, as shown by a 
reduced production of IFN-.
6.2 Patients and Methods
6.2.1 Patients and setting
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Inpatients with pulmonary tuberculosis were prospectively and consecutively enrolled 
from the Departments of Infectious Diseases and General Medicine, Tan Tock Seng 
Hospital (TTSH), and the Department of Medicine, National University Hospital (NUH), 
from September 2004 to May 2005. Subject inclusion criteria were: (1) clinical 
presentation and radiographic findings considered to be strongly suggestive of pulmonary 
tuberculosis by the primary physicians, (2)  18 years old, (3) antituberculous treatment 
naïve or not longer than 48 hours, (4) able and willing to give informed consent. Patients 
who had a past history of tuberculosis, who were known to have HIV infection or other 
coexisting systemic diseases, such as chronic renal failure, diabetes mellitus, and 
neoplastic diseases, and pregnant or breastfeeding women were excluded. Approval for 
this study was granted by the Ethics Committee of the National Healthcare Group 
(NHG), Singapore. Written informed consent was obtained from all study subjects.
6.2.2 Demographic and clinical data collection.
Demographic, clinical, and routine laboratory testing data were collected by interview of 
patients or from medical records. Demographic characteristics included date of birth, 
place of birth, sex, and race. The data of BCG scar, BCG vaccination history, TB contact 
history, and risk factors for HIV infection were collected by interview of the subjects. 
The information of clinical symptoms and their durations, including cough (productive or 
not, sputum color), fever, night sweats, haemoptysis, weight loss, appetite loss, and chest 
pain, were first collected from medical records and confirmation of the information was 
sought during interview of patients. Routine temperature charts were examined covering 
the time of admission until the time of enrolment. Axillary temperature was recorded in 
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both hospitals using a digital thermometer every 6 hours. The patient was defined having 
fever if there was a recorded temperature of greater than 37.5 0C at any time. Routine 
laboratory test data including white blood cells, differential counts of white blood cells, 
serum hemoglobin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), AFB 
smear results, bacillary culture and drug-susceptibility test results were collected from 
medical records. Anemia was defined when hemoglobin < 13 g/dL in males and < 11.8 
g/dL in females. All patients were screened for risk factors of HIV infection and offered 
HIV serology testing.
6.2.3 Assessment of chest X-ray (CXR) presentation
Chest X-ray (CXR) films were reviewed at each institution by a single clinician 
experienced in the diagnosis and management of tuberculosis who were blinded to M. 
tuberculosis genotyping results. The disease extent on CXR was classified as: (1) 
unilateral disease, (2) bilateral disease, (3) cavitary disease, (4) pleural effusion, and (5) 
miliary disease.
6.2.4 DNA extraction from sputum
Sputum specimens were collected from each subject at enrolment. To decontaminate and 
liquefy sputum samples, 1 to 2 ml of sputum samples were incubated for 20 minutes with 
equal volume of 1% N-Acetyl-L-Cysteine (NALC)-2% NaOH, votexed every 5 minutes 
and then centrifuged at 14,000 rpm for 10 minutes. The supernatants were decanted, and 
the sediment was resuspended in 400 l of digestion buffer (100 mM NaCl, 10 mM Tris-
HCl, 25 mM EDTA, 0.5% Tween 20, pH8.0, containing 100 g/ml of proteinase K). The 
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digestion was allowed to proceed overnight at 56 0C with rigorous shaking. After the 
digestion, DNA was extracted using phenol-chloroform/isoamyl alcohol, precipitated 
with absolute ethanol and washed with 70% ethanol according to standard protocol 
(Moore and Dowhan, 1998). DNA was finally dissolved in 50 l distilled water.
To assess the integrity of the extracted DNA and the presence/absence of PCR 
inhibitor, 2 l DNA samples were analyzed using PCR which amplifies 268-bp human 
genomic globin DNA with forward primer 5’-GAA GAG CCA AGG ACA GGT A-3’ 
and reverse primer 5’-CAA CTT CAT CCA CGT TCA CC-3’. Samples which were 
positive for the amplicon were stored at -20 0C for M. tuberculosis genotyping as 
described below, samples which were negative for the amplicon were re-extracted and 
purified as described above.
6.2.5 Genotyping of M. tuberculosis
M. tuberculosis was genotyped using spoligotyping and MIRU-VNTR typing as 
described in Chapter 2 except that DNA sample for PCR amplification was 2 l of the 
above DNA extraction for each PCR reaction and the MIRU-VNTR allele number was 
manually converted according to amplicon size.
6.2.6 Isolation of plasma
Fifteen ml of venous blood samples were collected using heparinized tubes. The blood 
samples were centrifuged at 300x g for 10 minutes to separate plasma and blood cells. 
Upper phase plasma was recovered and further centrifuged at 14,000 rpm for 15 minutes 
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at 4 0C using a refrigerated centrifuge. Plasma was then recovered and aliquoted in 0.5 ml 
of volume and stored in -800C freezer until use.
6.2.7 Isolation of PBMC
After removal of plasma as described above, the precipitated blood cells were gently 
resuspended in appropriate volume of RPMI 1640 Media to make the final volume to 12 
ml. Added 6 ml of Ficoll-Paque Plus media (Amersham) to each of two 15 ml centrifuge 
tubes and carefully laid (do not disturb the Ficoll-Paque surfaces) 6 ml of the blood cells 
onto each of the Ficoll-Paque layers. The tubes were centrifuged at 400x g for 40 min at 
room temperature using swing rotor without brake. After centrifuge, the upper liquid 
phases were carefully removed and the buffy layers (leukocytes) were recovered into a 
fresh 15 ml centrifuge tube. Appropriate volume of RPMI 1640 was added to make the 
final volume to 12 ml and the cells were gently mixed by inversion and then equally 
divided into two centrifuge tubes. After centrifuge at 300x g for 15 minutes, the 
precipitated cells were resuspended in 2 ml of RPMI 1640 and then pooled together for a 
further centrifuge at 300x g for 15 min. The final cell palette was resuspended in 1 ml of 
RPMI 1640. Fifty l of the cell suspension was diluted in 450 l of Trypan Blue for cell 
counting using a haemocytometer. The cells were aliquoted at 2 x106 cells for RNA 
isolation.
6.2.8 Cytokine ELISA
Plasma level of IFN-, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-18, TGF-1,
and TNF- were measured using quantitative ELISA kits (Bender MedSystems, Austria). 
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The detection limits of the above ELISA kits were 0.66 pg/ml (kit BMS228INST) (IFN-), 
2.3 pg/ml (kit BMS221INST) (IL-2), 0.66 pg/ml (kit BMS225INST) (IL-4), 1.45 pg/ml (kit 
BMS278INST) (IL-5), 0.92 pg/ml (BMS213INST) (IL-6), 0.66 pg/ml (kit BMS215INST) 
(IL-10), 0.93 pg/ml (kit BMS238INST) (IL-12), 0.99 pg/ml (kit BMS231INST) (IL-13), 
9.2 pg/ml (kit BMS267/2) (Il-18), 23.76 pg/ml (kit BMS249/2) (TGF-1), and 1.65 pg/ml 
(kit BMS223INST) (TNF-), respectively. A high sensitivity ELISA kit (BMS228HS) for 
IFN- from the same manufacturer was used to measure some samples with very low 
level of IFN-. The sensitivity of this kit was 0.06 pg/ml. The manufacturer’s protocols 
were followed and each sample was assayed in duplicate. Absorbance was read using an 
anthos 2020 ELISA reader (Anthos Labtech Instruments, Austria) at wavelength 450 nm 
and 620 nm was used as reference wavelength.
6.2.9 Total RNA isolation from
Total RNA isolation from PBMC was performed using TRIZOL® reagent (Invitrogen) 
according to the manufacturer’s protocol. Cells (2 x 106 cells) were lysed in 1 ml of 
TRIZOL® reagent by repetitive pipetting. The lysed cell samples were incubated for 5 
minutes at room temperature (RT) to permit the complete dissociation of nucleoprotein 
complexes. Following the incubation, 0.2 ml of chloroform was added to the tubes and 
vigorously shook the tubes for 15 seconds with hand. After incubation 2-3 minutes at RT, 
the tubes were centrifuged at 12,000x g for 15 minutes at 40C to separate RNA containing 
phase. After the centrifuge, the upper RNA containing supernatant was recovered into a 
fresh tube and RNA was precipitated by incubation with 0.5 ml of isopropyl alcohol for 
10 minutes at RT. The tubes were then centrifuged at 12,000x g for 10 minutes at 40C to 
101
pellet RNA. The RNA pellets were washed with 1ml of 75% ethanol and centrifuged 
again at 7,500x g for 5 minutes at 40C. After removal of the ethanol, the RNA samples 
were briefly air-dried and dissolved in 10 l of RNase free water. The purity and quantity 
of the RNA samples were measured using spectrophotometer at wavelength 260 nm and 
280 nm.
6.2.10 cDNA synthesis by RT-PCR
cDNA was reverse transcribed from total RNA using the 1st Strand cDNA Synthesis Kit 
for RT-PCR (AMV) (Roche). Briefly, 0.5 to 1 g of total RNA was incubated with 1x 
reaction buffer, 5 mM of MgCl2, 1 mM dNTP, 1.6 g (2.0 l) of oligo-p(dT)15 primer, 50 
units (1l) of RNase inhibitor,  20 units (0.8 l) of AMV reverse transcriptase in a final 
volume of 20 l at 250C for 10 minutes and then at 420C for 60 minutes. Followed the 
incubation, the AMV reverse transcriptase was inactivated by incubation the reaction at 
990C for 5 minutes. All the incubations were performed on a thermocycler (Biometra, 
Germany). The resulting cDNA was diluted to a final volume of 200-500 l with PCR-
grade water. A negative control without RNA was performed in parallel.
6.2.11 Quantification of cDNA by Real-Time PCR
The cDNA of reverse-transcribed cytokine genes was relatively quantified using 
quantitative real-time PCR. The real-time PCR primers and standards for cytokine genes 
IFN-γ, IL-2, IL-4, IL-13, and IL-18, and for housekeeping gene -actin were 
commercially obtained from Search-LC GmbH (Heidelberg, Germany). All the primers 
are located on exons, thus do not amplify potential contaminating genomic DNA. Real-
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time PCR amplification was performed using the LightCyclerTM FastStart Master 
Sybr®Green I kit (Roche) on the Roche LightCycler apparatus. Quantitative analysis was 
performed with the LightCycler software (version 3.5). Background fluorescence was 
removed manually by setting a noise band at crossing line = 0.6, quantification was based 
on log-linear standard curve. Melting curve analysis was performed to confirm the 
identity and specificity of the PCR products. All cytokine cDNA copies were 
standardized to the housekeeping gene -actin. Negative control without any cDNA was 
performed in each real-time PCR run.
6.2.12 Statistical analysis
2 test and Fisher’s exact test were used to analyze categorical variables. Student’s t test 
was used to compare normally distributed continuous variables and those variables which 
were normally distributed after log-transformation. Mann-Whitney test was used to 
compare continuous but not normally distributed variables. Multivariate logistic 
regression was used to adjust for potential confounding factors. A p value of <0.05 was 
considered statistically significant.
Sample size was calculated using parameters from the study of Verbon et al 
(1999), which gave a mean and standard deviation of IFN- levels of 29 pg/ml and 52 
pg/ml respectively. Based on the difference in mean IFN- levels of patients with and 
without fever, we expect that greater than 100% difference in mean IFN- levels between 
Beijing and non-Beijing strains would be biologically meaningful. Therefore, with a 
power of 0.8 and two-sided level of significance of less than 0.05, the required sample 
size is 47 patients per group.
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6.3 Results
6.3.1 Patient enrolment and determination of M. tuberculosis genotypes
A total of 54 patients were enrolled in this study (35 from TTSH and 19 from NUH) 
between September 2004 and March 2005. Recruitment was discontinued prior to 
completion of the originally planed sample size of 94 patients due to the combination of 
slower-than-projected enrollment, investigator fatigue, and the limiting constraints of 
study funding and time. One of the 54 patients was found to be HIV-infected, and was 
excluded from further analysis. Of the remaining patients, 16 tested negative for HIV 
antibodies. Those who were not tested did not have any apparent risk factors for HIV 
infection nor any evidence of immune suppression noted on physical examination. Two 
further patients were excluded because they were unable to provide a sputum specimen 
for genotyping. Nine patients were culture negative, smear negative and did not have M. 
tuberculosis detected by either spoligotyping or MIRU-VNTR typing. It is uncertain 
whether these patients had tuberculosis, and given that it is not possible to determine the 
genotype, they could not contribute to addressing the study hypothesis and were therefore 
excluded from further analysis.
For the 42 patients with culture-proven pulmonary tuberculosis, all had 
mycobacteria that were fully susceptible to rifampicin, streptomycin, isoniazid, and 
ethambutol. Of these 42, 38 (90.5%) were smear positive. M. tuberculosis DNA was 
detected in the sputum sample and successfully typed by MIRU-VNTR typing in 41
cases, and by spoligotyping in 39 cases. All the cases of failure of genotyping were also 
smear negative. The single case that could not be typed by either method was excluded 
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from further analysis. Therefore, the study analysis concerns 41 patients with genotyping 
data, all of whom had culture-proven tuberculosis.
Twenty-one (51.2%, 21/41) patients were infected with Beijing strains. As shown 
in Fig. 6.1, 19 isolates had the typical Beijing spoligotype which is absent of spacers 1-34 
but present of spacers 35-43 (Filliol et al., 2002; Kremer et al., 2004). One isolate (N04) 
showed Beijing-like spoligotype which has been demonstrated also belonging to the 
Beijing lineage (Kremer et al., 2004). Although the isolate N07 was not detected by 
spoligotyping, MIRU-VNTR typing showed that it had a typical cluster MIRU-VNTR 
pattern (223325173533) specific for Beijing strains. The MIRU-VNTR locus 31 of the 
isolate T38 had two different allele numbers, possibly suggesting mixed infection by two 
Beijing strains.
Based on the spoligotypes and/or MIRU-VNTR patterns, the remaining 20 
isolates were assigned to non-Beijing genotypes: the Haarlem family (6 isolates, 14.6%), 
the Latin American and Mediterranean (LAM) family (1 isolate, 2.4%), the T family (4 
isolates, 9.8%), and the ancestral East-Africa-Indian (EAI) family (9 isolates, 22%). The 
isolate N01 was assigned to the EAI family based on its MIRU-VNTR pattern and the 
allele number of its locus 24, nearly all EAI strains have  2 allele copies in this locus 
(Supply et al., 2001; Sun et al., 2004a).
6.3.2 Demographic and epidemiological characteristics
Table 6.1 presents the demographic and epidemiologic characteristics of the subjects by 
M. tuberculosis Beijing and non-Beijing genotypes. The distributions of sex, ethnicity, 
and age did not differ significantly between the two groups of patients. The frequency of 
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Isolates MIRU-VNTR Patterns Spoligotypes Genotypes
2 4 10 16 20 23 24 26 27 31 39 40
N07 2 2 3 3 2 5 1 7 3 5 3 3 ND Beijing
N08 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T21 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T32 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T38 2 2 3 3 2 5 1 7 3 4/5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T41 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T44 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T45 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T47 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T49 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T55 2 2 3 3 2 5 1 7 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
N14 2 2 3 3 2 5 1 7 3 3 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T51 2 2 3 3 2 5 1 7 3 4 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T18 2 2 3 3 2 5 1 9 3 5 3 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
N05 2 2 3 3 2 5 1 5 3 5 1 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T53 2 2 3 3 2 5 1 6 3 5 3 4 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
N13 2 2 2 3 2 5 1 7 3 5 4 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T11 2 2 2 3 2 5 1 7 3 5 4 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T33 2 2 3 3 2 5 1 7 1 5 3 1 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
T52 2 3 3 2 2 5 1 7 3 4 4 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■ Beijing
N04 2 2 2 3 2 5 1 7 3 5 4 3 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■ Beijing
T34 2 2 2 3 2 5 1 7 3 5 10 3 ■□□□□□□□□□□□□□□□□□□□□□□□■■■□□□□□□□□□□■□□□□□ Haarlem
T03 2 2 2 3 2 5 1 4 3 3 2 3 ■□■■□■■■■□■■■■□■■■■■■■■■□□□□□□□□□□□□■■□■■□■ Haarlem
N26 2 2 2 3 2 5 1 5 3 3 2 3 ■■■■■■■■■□■■■□□□□□■■■■■■□□□■■■□■□□□□■■■■■■■ Haarlem
T50 2 2 6 3 2 5 1 5 3 3 2 3 ■□□■■■■■■■■■■■■■■■■■■■■■■□□□□□□■□□□□■■■■■■■ Haarlem
T12 1 2 2 3 2 5 1 5 3 4 2 3 ■■■■■■■■□□□□□□□□□■□■■■■■□□□□□□□■□□□□■■■■■■■ Haarlem
T19 2 2 2 4 2 5 1 5 3 3 2 4 ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□■□□□□■■■■■■■ Haarlem
N22 2 2 4 3 2 6 1 4 3 3 2 7 ■■■■■■■■■■■■■■■■■■■■□□□□■■□■■■■■□□□□■■■■■■■ LAM
T37 2 2 5 1 2 5 1 1 3 3 2 2 ■■■■■■■■■■■■■■■■■■■■■■■■■■□■■■■■□□□□■■□□□□□ T
T36 2 2 4 2 2 6 1 2 3 3 2 3 ■■■■■■■■■□■■■■■■■■□■□□■■■■□■■■■■□□□□■■■■■■■ T
N28 2 4 2 3 2 5 1 5 2 3 1 2 ■■■■■■■■■□■■■■□■■■■■■■■■□□□■■■■■□□□□■■□□■□■ T
T42 2 3 2 3 2 5 1 4 2 3 2 2 ■■■■■□■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■ T
T24 2 5 5 3 2 6 2 2 2 5 1 3 ■□■■■■■■■□■■■■■■■■■■■■■■■■■■□□□□■□■■■■■■■■■ EAI
T35 2 5 4 3 2 6 2 2 3 4 3 2 ■■□■■■■■■□■■■■■■■■■□□■■■■■■■□□□□■□■■■■■■■■■ EAI
T30 2 7 4 3 2 6 2 2 3 4 3 2 ■■□■■■■■■□■■■■■■■■■□□■■■■■■■□□□□■□■■■■■■■■■ EAI
T54 2 5 4 3 2 6 2 2 3 4 3 2 ■■□■■■■■■■■■■■■■■■■□□■■■■■■■□□□□■□■■■■■■■■■ EAI
N09 2 5 4 2 2 5 2 2 3 5 2 2 ■□□■■■■■■■■■■■■■■■■□□■■■■■■■□□□□■□■■■■■■■■■ EAI
T02 2 5 4 3 2 6 2 2 3 4 3 4 ■□□■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■□■■□□□■■■■ EAI
T40 2 5 4 3 2 6 2 2 3 4 3 2 □□□□□□□□□□□□□□□□□□□□□□□□■■■■□□□□■□■■■■■■■■■ EAI
T48 3 6 4 2 2 5 2 2 3 5 3 3 ■■■■■■■■■■■■■■■■■■□□□□□□□□□□□□□□□□□□□□□□□■■ EAI
N01 2 6 4 3 2 6 2 2 3 4 3 2 ND EAI
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Fig. 6.1 (page105). M. tuberculosis genotyping results of the 41 sputum specimens. M. 
tuberculosis isolates in the 41 sputum specimens were typed by spoligotyping and 
MIRU-VNTR typing. Spoligotyping generated 39 spoligotypes, MIRU-VNTR generated 
41 patterns. Based on the spoligotypes and/or MIRU-VNTR patterns, each isolate was 
assigned to one of the M. tuberculosis genotypes. Beijing, Beijing genotype; Haarlem, 
Haarlem genotype; LAM, Latin American and Mediterranean genotype; T, T genotype; 
EAI, East-African-Indian genotype. ND, not detected.
                 Table 6.1. Characteristics of patients by M. tuberculosis genotypesa
       aData shown are absolute numbers with percentage of the group total in brackets. Comparison of
          frequencies between groups is by 2 or Fisher’s exact test.
              bCitizens and permanent residents
Characteristics Beijing
n = 21 (%) 
Non-Beijing
n = 20 (%)
P
Male sex 14 (66.7) 10 (50.0) 0.297
Ethnicity
   Chinese
   Malay
   Indian
         14 (66.7)
           7 (33.3)
           0 (0)
         12 (60.0)
   6 (30.0)
   2 (10.0)
0.286
Age (y)
    30
   31-59
   ≥ 60
    4 (19.0)
          12 (57.1)
            5 (23.8)
   6 (30.0)
         11 (55.0)
  3 (15.0)
0.325
BCG
   Yes
   No/unknown
   11 (52.4)
   10 (47.6)
13 (65.0)
  7 (35.0)
0.303
Sputum Smear
   Positive
    Median scores





Known contact history    2 (9.5)  2 (10.0) 0.959
Residentships
   Singapore residentb
   Foreigner
  17 (80.9)
    4 (19.1)
12 (60.0)
  8 (40.0)
0.141
Hospitals
   TTSH
   NUH
  15 (71.4)
    6 (28.6)
15 (75.0)
  5 (25.0)
0.796
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past BCG vaccination did not differ between the two groups, and the proportion of smear 
positive cases was similar in each group. The median score for the positive smears was 
3+ in each group. Four patients had known contact history with family members (2 in 
each group). The proportions of Beijing and non-Beijing genotype isolates were similar 
at the two hospitals.
6.3.3 Clinical and radiological features
Table 6.2 shows the clinical and chest radiographic manifestations of the patients by 
Beijing and non-Beijing genotypes. Cough was the most common symptom for the 
pulmonary tuberculosis patients, 38 of the 41 (92.7%) patients had cough. The less 
frequent manifestations were fever (26/41, 63.4%), and weight loss (28/41 68.3%). The 
frequencies of hemoptysis, appetite loss, night sweats, and chest pain were even lower.
Fever was recorded in 9 (42.9%) of the 21 patients infected with Beijing strains 
and 17 (85.0%) of the 20 patients infected with non-Beijing strains OR (95% CI), 0.13 
(0.03-0.57), p = 0.005. In addition to fever, night sweats was also found to be less often 
in patients infected with Beijing genotype strains OR (95% CI), 0.20 (0.04-0.99), p = 
0.049. To further test these associations, we performed multivariate logistic regression 
analysis. Independent variables included sex, age, and ethnicity, though they did not 
differ significantly between the two groups, as well as fever and night sweats. The 
inverse association between the Beijing strains and febrile response remained strong after 
multivariate adjustment OR (95% CI), 0.12 (0.02-0.63), p = 0.008, suggesting that the 
Beijing genotype is an independent factor associated inversely with production of fever. 
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                           Table 6.2. Clinical and chest X-ray manifestations of patients by M. tuberculosis genotypes
Parameters Beijing
n = 21 (%) 
Non-Beijing
n = 20 (%)
Univariate analysisa
        OR (95% CI)        p
Multivariate analysisb
       OR (95% CI)          p
Clinical presentations
   Cough
       Median duration (range)c
   Fever
   Hemoptysis
   Weight loss
   Appetite loss
   Night sweats
   Chest pain
     




      16 (76.2)
6 (28.6)
        2 (9.5)
        2 (9.5)
          20 (100)
30 (2-180)
17 (85.0)
  6 (30.0)
12 (60.0)
  4 (20.0)
  7 (35.0)
  4 (20.0)
     0.00 (0.00-1.27)  0.125
                            0.048
0.13 (0.03-0.57)  0.005
0.55 (0.14-2.22)  0.414
2.13 (0.58-7.87)  0.265
1.60 (0.40-6.39)  0.523
0.20 (0.04-0.99)  0.049
0.42 (0.08-2.29)  0.343
0.12 (0.02-0.63)  0.008
0.20 (0.02-1.75)  0.145
CXR presentationsd
   Unilateral disease
   Bilateral disease
   Pleural effusion
   Cavity
        7 (33.3)
      13 (61.9)
        1 (4.8)
        2 (9.5)
  8 (40.0)
 11 (55.0)
 1 (5.0)
  7 (35.0)
0.75 (0.22-2.61)  0.658
1.33 (0.39-4.52)  0.654
0.95 (0.09-9.75)  0.972
     0.20 (0.04-0.99)  0.049
WBC count (cells/l)
   Total WBC (mean ± SD)e
   Lymphocytes (mean ± SD)
   Monocytes (mean ± SD) 
   Eosinophils (mean ± SD)
   Basophils (mean ± SD)
8629 ± 3331






  901 ± 361
  80 ± 82
  40 ± 43
                            0.150
                            0.496
                            0.014
                            0.193
                            0.474
Anemiaf
Hemoglobin (g/dL)
   Male (mean ± SD)
   Female (mean ± SD)
      14 (66.7)
11.8 ± 1.2




1.08 (0.31-3.81)  0.910
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Notes to Table 6.2. aχ2 or Fisher’s exact test were used for the categorical variables and Student’s was used 
for the WBC counts after they were log-transformed; OR, odds ratio; CI, confidence interval.  bLogistic 
regression. cUnit is in day. dCavity is not exclusive from the other three entries. eSD, standard deviation.  
fHemoglobin < 13 g/dL in males and < 11.8 g/dL in females.
However, the inverse association between night sweats and the Beijing strains was no 
longer significant after the multivariate adjustment OR (95% CI), 0.20 (0.02-1.75), p = 
0.145.
There was no significant difference in the frequency of cough between Beijing 
and non-Beijing infected patients (p = 0.125). However, in the 18 patients who had cough 
and were infected with Beijing strains, the duration of cough before the diagnosis varied 
widely from 14 days to 1440 days (4 yrs) with a median of 60 days, only approximately 
39% (7/18) of such patients were identified and diagnosed within 1 month. While in the 
patients infected with non-Beijing strains, the range of the duration was much narrower, 
from 2 days to 180 days with a median of 30 days; much higher proportion (65%, 13/20) 
of the patients was identified within 1 month. The individual cough duration is shown in 
Fig. 6.2. As the cough duration data had too many ties (identical numbers) hence, the 
non-parametric Mann-Whitney U test does not fit this data. The data were therefore log-
transformed and analyzed by t test. The difference between the two groups is statistically 
significant (p = 0.048). Surprisingly, there were two patients in the Beijing group might 
be as infectious foci for 4 years, because no other obvious cause was found for their 
cough. This finding suggests that patients infected with Beijing strains have longer 
duration of symptoms before being identified/diagnosed.
The CXR abnormalities associated with infections of Beijing and non-Beijing 
strains were compared (Table 6.2). There was significantly less cavitary disease in 
patients infected with Beijing strains OR (95% CI), 0.20 (0.04-0.99), p = 0.049. There 
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was no difference in the frequency of unilateral non-cavitary disease, bilateral non-
cavitary disease, and pleural effusion. We did not find miliary disease in our subjects.






























Fig. 6.2. Cough duration (day) of patients infected with Beijing and non-Beijing strains. 
Cough durations of the pulmonary tuberculosis patients before diagnosis were compared 
by Beijing and non-Beijing groups. Patients infected with Beijing strains had 
significantly longer cough (median, 60 days) compared to those infected with non-
Beijing strains (median, 30 days). The two patients who had coughed for 4 years before 
diagnosis are expressed as > 300 days in the Beijing group. The two groups differed 
significantly (p = 0.048).
6.3.4 Laboratory parameters
The frequency of anemia in total was 65.9% (27/41), and there was no difference 
between the two groups (Table 6.2). Table 6.2 also presents total and differential counts 
of white blood cells of the patients. The mean counts for total white blood cells,
lymphocytes, eosinophils, and basophils were not significantly different in each group. 
The mean monocyte count was significantly higher in non-Beijing group (mean, 901/μl) 
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compared to Beijing group (mean, 656/μl) (p = 0.014). Few patients had CRP and ESR 
tests done, and given the paucity of data we have not analyzed it further.
6.3.5 Plasma cytokine levels in Beijing and non-Beijing genotypes
Of the cytokines analyzed, only IFN-, IL-6, IL-18, and TGF-1 were detectable in 
plasma. There was no statistically significant difference in the mean IFN- levels between 
patients infected with Beijing and non-Beijing strains (20.5 pg/ml, SD = 28.6 versus 33.9 
pg/ml, SD = 95.2, p = 0.994) (Fig. 6.3). The mean plasma level of IL-6 was 13.2 pg/ml 
(SD = 14.7) in patients infected with Beijing strains and 11.1 pg/ml (SD = 15.4) in 
patients infected with non-Beijing strains; the difference was not significant (Fig. 6.4). 
The mean plasma level for IL-18 and TGF-1 was respectively 409.9 pg/ml (SD = 376.1) 
and 99.7 ng/ml (SD = 72.8) in Beijing group, and 598.5 pg/ml (SD = 688.7) and 111.4 
ng/ml (SD = 58.4) in non-Beijing group. Similarly, the differences were not significant 
(Figs. 6.5 and 6.6).
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Fig. 6.3. Plasma levels of IFN- in pulmonary tuberculosis patients. Plasma level of IFN-
 in pulmonary tuberculosis patients was quantified using ELISA assay. Patients infected 
with Beijing and non-Beijing strains had similar mean IFN- level (p = 0.994). Bars 
indicate the log mean levels in each group.
















Fig. 6.4. Plasma levels of IL-6 in pulmonary tuberculosis patients. Plasma level of IL-6 in 
pulmonary tuberculosis patients was quantified using ELISA assay. Patients infected with 
Beijing and non-Beijing strains had similar mean IL-6 level (p = 0.706). Bars indicate the 
log mean levels in each group.
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Fig. 6.5. Plasma levels of IL-18 in pulmonary tuberculosis patients. Plasma level of IL-18 
in pulmonary tuberculosis patients was quantified using ELISA assay. Patients infected 
with Beijing and non-Beijing strains had similar mean IL-18 level (p = 0.341). Bars 
indicate the log mean levels in each group.


















Fig. 6.6. Plasma levels of TGF-1 in pulmonary tuberculosis patients. Plasma level of 
TGF-1 in pulmonary tuberculosis patients was quantified using ELISA assay. Patients 
infected with Beijing and non-Beijing strains had similar mean TGF-1 level (p = 0.219). 
Bars indicate the log mean levels in each group.
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6.3.6 Cytokine gene expression analysis
We further analyzed the cytokine gene expression of PBMCs of the patients. Of the 40 
blood samples collected and prepared for cytokine gene expression analysis, the first 15 
samples had very low RNA yields, thus the cDNA transcribed from these samples was 
too low to be reliably quantified. The results presented below pertain to the 25 samples in 
which satisfactory RNA samples were obtained. The 25 samples were from 12 patients 
infected with Beijing strains (8 males, 66.7%; mean age  SD = 52  14) and 13 patients 
infected with non-Beijing strains (5 males, 38.5%; mean age  SD = 48  21). These 
characteristics were similar between the subgroup patients and the whole group of study 
subjects (refer to Table 6.1).
The gene expression of type 1 cytokines IFN-, IL-2 and IL-18, and type 2 
cytokine IL-4 and IL-13 was quantitatively measured, and standardized as per 105 -actin 
cDNA copies. The expression level of IL-13 was too low to be detected by the 
quantitative real-time PCR. The cDNA copies of IFN-, IL-2 and IL-18 did not differ 
significantly between the Beijing and non-Beijing groups (Figs. 6.7 to 6.9). The median 
cDNA copies for IFN-, IL-2 and IL-18 were respectively 232 (range, 77-691), 7 (range, 
0-78), and 314 (range, 120-715) in patients infected with Beijing strains, and 228 (range, 
39-491), 10 (range, 0-30), 355 (range, 81-1067) in patients infected with non-Beijing 
strains. The cDNA copies of IL-4 were significantly higher in non-Beijing strain (median 
= 26, range, 9-87) versus Beijing strain (median = 16, range, 0-68) infected patients (p = 
0.018) (Fig. 6.10).
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Fig. 6.7. cDNA copies of IFN-. Patients infected with Beijing and non-Beijing strains 
had similarly expressed cDNA copies of IFN- (p = 0.851). Log medians of cDNA copies 
are indicated by bars.







































Fig. 6.8. cDNA copies of IL-2. Patients infected with Beijing and non-Beijing strains had 
similarly expressed cDNA copies of IL-2 (p = 0.503). Log medians of cDNA copies are 
indicated by bars.
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Fig. 6.9. cDNA copies of IL-18. Patients infected with Beijing and non-Beijing strains 
had similarly expressed cDNA copies of IL-18 (p = 0.225). Log medians of cDNA copies 
are indicated by bars.







































Fig. 6.10. cDNA copies of IL-4. Patients infected with non-Beijing strains had 
significantly higher expressed cDNA copies of IL-4 than those infected with Beijing 
strains (p = 0.018). Log medians of cDNA copies are indicated by bars.
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Fig. 6.11. IFN-γ : IL-4 cDNA copy number ratio of pulmonary tuberculosis patients. 
Patients infected with non-Beijing strains had significantly lower ratios than those 
infected with Beijing strains (p = 0.01). The bars indicate log median ratios.
We also compared the IFN- : IL-4 cDNA copy number ratio between the Beijing 
and non-Beijing groups. Two patients who had no detectable IL-4 cDNA copies were 
assumed having 1 cDNA copy in order to calculate the ratios. Patients infected with non-
Beijing strains showed significantly lower IFN- : IL-4 cDNA copy number ratios than 
those infected with Beijing strains (p = 0.01) (Fig. 6.11).
6.3.7 Association between cytokines and fever
The plasma cytokine level of patients was compared by febrile and afebrile disease (Fig. 
6.12). IFN- was significantly higher in patients with fever than in those without fever (p
= 0.004); in addition, significantly higher of TGF-1 was also observed in patients with 
fever (p = 0.048). There was no significant difference was found for IL-6 and IL-18 
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between febrile and afebrile patients. The mean plasma levels of the cytokines in febrile 
and afebrile patients are shown in Table 6.3.
























Fig. 6.12. Plasma cytokine levels of pulmonary tuberculosis patients with and without 
fever. Plasma level of IFN-, IL-6, IL-18, and TGF-1 in pulmonary tuberculosis patients 
was compared by febrile and afebrile condition. Patients with febrile disease had 
significantly higher IFN- (p =0.004) and TGF-1 (p = 0.048). Bars indicate the log mean 
levels in each group.
                       Table 6.3. Plasma cytokine level of patients by febrile
                                       and afebrile disease
Cytokines                Febrile             Afebrile              pa
                             mean  SD       mean  SD
IFN- (pg/ml)        40.0  85.9         6.0  11.1       0.004 
IL-6 (pg/ml)          13.2  14.7       11.1  15.4       0.395  
IL-18 (pg/ml)      599.0  638.7   346.2  345.0     0.084
TGF-1(ng/ml)   114.5  57.1       90.6  77.2       0.048 
                    ap is calculated based on log-transformed data.
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6.3.8 Association between cytokine gene expression and cavitary tuberculosis
Of the 25 patients subjected to cytokine gene expression analysis, 6 were cavitary 
disease, the remaining 19 were non-cavitary disease (Table 6.2). We compared the gene 
expression of IFN-γ and IL-4 in patients with cavitary versus non-cavitary disease. As 
shown in Fig. 6.13, the cDNA copy of IFN-γ was significantly lower in patients with 
cavitary tuberculosis compared to those with non-cavitary tuberculosis (p = 0.028). On 
the contrary, the cDNA copy of IL-4 was significantly higher in cavitary disease than 
non-cavitary disease (p = 0.022).
The log IFN-γ : IL-4 cDNA copy number ratio of patients with cavitary disease 
versus non-cavitary disease is shown in Fig. 6.14. We performed logistic regression 
analysis to determine whether there was correlation between the ratio and cavitary 
disease. Interestingly, IFN-γ : IL-4 cDNA copy number ratio was significantly inversely 
correlated with cavitary disease [OR (95%CI), 0.551 (0.321-0.945), p = 0.0002]. The 
higher the ratio, the less the odds of having cavitary disease. For every one digit number 
increase in the ratio, the odds of having cavitary disease decreased by about 55%.
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Non-cavitary disease (n = 19)
Cavitary disease (n = 6)





























Fig. 6.13. cDNA copy of IFN- and IL-4 in cavitary versus non-cavitary tuberculosis. 
The cDNA copy of IFN- was significantly lower in patients with cavitary disease than 
those with non-cavitary disease (p = 0.028). Conversely, the cDNA copy of IL-4 was 
significantly higher in patients with cavitary disease than those with non-cavitary disease 
(p = 0.022). Log medians of cDNA copies are indicated by bars.




































    (n = 6) (n = 19)
Fig. 6.14. IFN-γ : IL-4 cDNA copy number ratio of patients with cavitary versus non-
cavitary tuberculosis. Cavitary tuberculosis had significantly lower IFN-γ : IL-4 cDNA 




6.4.1 Patients and clinical characteristics
In this study we recruited consecutive patients with clinically defined pulmonary 
tuberculosis to analyze the clinical and laboratory differences between M. tuberculosis
genotypes. All the subjects had microbiologically confirmed tuberculosis, and the manner 
of recruitment and pattern of symptoms suggests that they are likely to be representative 
of the population of tuberculosis patients presenting to a typical general practitioner, 
polyclinic or hospital emergency department in Singapore. In spite of the reluctance of 
some patients to undergo HIV testing, we were able to definitively exclude HIV co-
infection in many of the participants, and establish the absence of risk factors in the 
remainder. Given that the rate of HIV coinfection in tuberculosis patients is less than 1% 
in Singapore (unpublished data), it is unlikely that a significant proportion of the 
remainder would be HIV positive. Although the study population was half the size 
estimated to be necessary to address the primary hypothesis of the study (namely that 
there is a difference in IFN-γ between Beijing and non-Beijing strains), we were 
nonetheless able to make some useful clinical observations that may form the basis of 
future clinical studies.
Fever is a common manifestation of pulmonary tuberculosis and is one of the few 
that can be measured objectively. The frequency with which fever has been observed in 
patients with tuberculosis varies widely from approximately 34% to 94% (Arango et al., 
1973; Kiblawi et al., 1981; Rathman et al., 2003). Patients with fever are more often 
symptomatic, more likely to have advanced disease, more likely to be smear positive, and 
tend to be younger (Kiblawi et al., 1981; Barnes et al., 1987). In this study we made the 
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interesting and potentially very important observation that 85% of patients infected with 
non-Beijing strains had fever, whereas only 43% of those infected with Beijing strains 
had fever, and this large difference is statistically significant.
We used an objective definition of fever that depended on objective observations 
made while patients were hospitalized, and taken by staff who were obviously unaware of 
the genotype of M. tuberculosis with which the patient is infected.  In addition to fever, 
we also found that night sweats were significantly less common in patients infected with 
Beijing strains. This latter finding agrees with the findings of a large study performed in 
Russia by Drobniewski et al. (Drobniewski et al., 2005) to examine differences between 
patients infected with Beijing and non-Beijing strains. In that study, night sweats were 
found significantly less often (OR, 0.7) in patients infected with Beijing strains and the 
association remained significant after multivariate adjustment. However, in that study 
there was no significant difference in the frequency of fever between Beijing and non-
Beijing groups. The definition of fever was not given and the overall rate (approximately 
30% in both groups) suggests that some under-reporting of fever may have occurred. 
Although we found that the frequency of fever and of night sweats differed between the 
Beijing and non-Beijing groups, after multivariate analysis only fever remained 
significant. This is not surprising as the two symptoms often occur together in the same 
patient, and so it is difficult to ascertain an independent effect. The important point is that 
our study agrees with the study from Russia that there is a difference in the clinical 
systemic host response to Beijing and non-Beijing genotype strains.
This study has demonstrated the significantly lower frequency of fever, night 
sweats, and of cavitation in patients infected with Beijing genotype strains, moreover, a 
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number of other symptoms, such as cough, hemoptysis, and chest pain, were also less 
common, although not significant, in tuberculosis caused by Beijing strains. This 
suggests that tuberculosis caused by Beijing strains is less symptomatic and less severe 
compared to disease caused by non-Beijing strains. Symptom, particularly fever, is 
important for patients to recognize that they have a condition that may need medical 
attention, and hence causes them to seek medical attention. The absence of symptom(s) 
and/or less severe disease may therefore lead to delays in consultation and/or make 
patients less identifiable, thus increasing the likelihood of transmission in the case of 
tuberculosis. To examine this hypothesis, we compared the duration of cough of the 
subjects before the diagnosis by Beijing and non-Beijing genotypes, because cough is the 
most common way of spreading the bacteria. We found that patients infected with Beijing 
strains had a significantly longer duration of cough compared to those infected with non-
Beijing strains. This may partially account for why the M. tuberculosis Beijing genotype 
is more prevalent. The data of cough duration was based on the patients’ subjective 
description, and this may not be very accurate. Furthermore, other socioeconomic factors 
may influence patient’s decision for consultation. Therefore, a larger, well-designed 
study is needed to answer questions about the consequences of the differences in 
symptoms on presentation, diagnosis, and transmission of tuberculosis.
The M. tuberculosis Beijing genotype has been recently identified as a bacterial 
factor that is associated with febrile response to treatment in Indonesia (van Crevel et al., 
2001). In the present study, we did not collect the temperature data after the initiation of 
therapy because a high proportion of patients were discharged upon commencing of 
treatment, and hence we are unable to compare our results directly with theirs. In 
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addition, van Crevel et al. (van Crevel et al., 2001) do not elaborate on the presence of 
fever in their subjects prior to treatment, which would have provided useful comparative 
data. It is certainly possible that the pre-treatment and post-treatment inflammatory 
clinical response may differ between M. tuberculosis genotypes, and this represents an 
interesting area for further study.
We found that there was a significant higher frequency of cavitary disease in 
patients infected with non-Beijing strains (OR, 0.2). However, in studies performed in 
Indonesia (van Crevel et al., 2001) and in The Netherlands (Borgdorff et al. 2004) in 
which the CXR presentations of patients infected with Beijing and non-Beijing strains 
were compared, the authors did not find any significant difference between the two 
groups of patients. But in the much larger study by Drobniewski et al. (2005), infection 
with Beijing genotype was associated more commonly with advanced radiological 
abnormalities, defined as multiple lung zones with fibrotic change and widespread 
cavitation, than was non-Beijing genotype, a result that is somewhat contrary to ours.
In contrast to our observation in the present study that patients infected with 
Beijing strains presented with less severe disease, two previous studies (Manca et al., 
2001; López et al., 2003) found that Beijing strains caused more severe disease in mice, 
as demonstrated by higher earlier mortality of infected mice. The hypervirulence of the 
Beijing strains in the mouse studies might be due to the way that the disease was 
presented as a challenge, and that the immunity was unable to arrest the infection; 
especially in the study by López et al. (2003), the mice died before or soon after the 
development of an adaptive immunity which needs 3 weeks to develop in mice and 
actually innate immunity appears to be not protective in mice (North and Jung, 2004). 
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But in patients, active disease is usually a result of reactivation of latent infection in 
which an adaptive immunity is dominant.
6.4.2 Laboratory parameters
We found that patients infected with non-Beijing strains had significantly higher levels of 
peripheral blood monocytes. This proliferation of monocytes in the non-Beijing group 
might be related to higher frequency of febrile disease as the products of monocytes IL-1, 
IL-6, and TNF-α are potent endogenous pyrogens (Netea et al., 2000a). Monocytes are 
key regulators of immune responses, essential for the generation of beneficial 
antipathogen immune reactions. Peripheral blood monocytes are recruited, by signals 
such as chemokines, from the circulation to the sites of inflammation caused by M. 
tuberculosis infection. Upon activation at the sites of inflammation, monocytes can 
modulate the immune reactions by producing a number of cytokines, such as IL-1, IL-6, 
IL-10, IL-12, TNF-α, and TGF- (Wallis et al., 1990; Barnes et al., 1993; Toossi et al., 
1995; Fulton et al., 1996). IL-1, IL-6, IL-12, and TNF-α are proinflammatory cytokines; 
IL-12 is a central player in induction of IFN-γ, favoring the development of Th1 
protective immunity (van Crevel et al., 2002); TNF-α can exhibit both protective and 
pathological effects depending on its production; physiological concentrations of TNF-α 
play a key role in granuloma formation but excessive production of TNF-α may cause 
marked tissue necrosis that is characteristic of progressive disease (Barnes and Modlin, 
1996); IL-10 and TGF- are anti-inflammatory cytokines; they can antagonize the 
proinflammatory cytokine responses, such as suppression of production of IFN-γ and 
TNF-α by down-regulation. In addition, differential proliferation of human T cell subsets 
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in response to in vitro stimulations of mycobacteria or mycobacterial antigens has been 
observed in the presence or absence of monocytes (Esin et al., 1996).
6.4.3 Cytokine response to infection of Beijing and non-Beijing strains
This study has demonstrated that plasma levels of IFN- did not differ significantly 
between patients infected with Beijing and non-Beijing strains. Thus the primary 
hypothesis of this study, namely that IFN- production would be lower in pulmonary 
tuberculosis patients infected with Beijing strains compared with those infected with non-
Beijing strains was not confirmed. However, although the study represents a substantial 
body of work, it is important to note that recruitment was terminated early (for the 
reasons noted in section 6.3.1) after only approximately half the estimated necessary 
numbers of subjects had been recruited. The group mean and standard deviation of the 
IFN- results was similar to that used in the power calculation, and hence the study may 
be underpowered to detecte a difference between groups of the magnitude that was 
originally estimated (100%). Thus, although there appeared to be no major difference in 
IFN- between Beijing and non-Beijing groups in this study, it is possible that this 
represents a Type II error.
We also measured gene expression level for a number of cytokines. The absence 
of a difference in plasma IFN- levels is corroborated by the absence of a difference 
between the two groups of patients in IFN- gene expression level in PBMC. Moreover, 
the plasma level and gene expression level of IL-18, an important inducer for IFN- and 
maybe also for other proinflammatory cytokines (Dinarello et al., 1998), were also not 
different between the two groups of patients. Although we could not detect IL-2 in 
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plasma, its gene expression in PBMC was not different in the Beijing and non-Beijing 
groups. These findings in general do not suggest that Beijing strains elicit a weaker Th1 
immune response in tuberculosis patients, and differ from the observation from mouse 
studies that mice infected with the Beijing strains presented a reduced Th1 immunity 
(Manca et al., 2001; López et al., 2003).
However, we found that patients infected with non-Beijing strains had significant 
higher level of gene expression of IL-4 in PBMC and significant lower IFN- : IL-4 
cDNA copy number ratio compared to those with Beijing strains, suggesting an enhanced 
Th2 immune response in patients infected with non-Beijing strains. This finding to some 
extent agrees with a recent in vitro study (Chacón-Salinas et al., 2005), in which 
macrophages derived from bone marrow of mice were infected with different M 
tuberculosis genotype strains. They found that cells infected with Beijing strains induced 
a Th1 favorable immune response as evidenced by the highest mRNA and protein 
expression of IL-1, TNF-α, and IL-12, and a comparable IL-18 with other M. 
tuberculosis genotype strains, and on the other hand, a reduced Th2 immune response in 
cells infected with Beijing strains as demonstrated by diminished IL-10 mRNA compared 
with other non-Beijing strains. This cytokine pattern is favorable to control infection.
In an in vitro study (Manca et al., 2004) in which PBMC from healthy donors 
were infected with an outbreak Beijing strain HN878 and other Beijing strains as well as 
non-Beijing strains, the infections of the Beijing strains were characterized by Th2-
polarized immunity with preferentially induced IL-4 and IL-13. This differs from the 
findings in the present study, and the reason that was responsible for the difference needs 
to be elucidated.
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Many (IL-2, IL-4, IL-5, IL-10, IL-12p70, IL-13, and TNF-α) of the cytokines 
were not detected in the unstimulated blood of tuberculosis patients by conventional 
ELISA assays in the present study. Some of these negative observations have been 
frequently reported in a number of in vivo studies with human subjects (Barnes et al., 
1993b; Zhang et al., 1994; Verbon et al., 1999; Olobo et al., 2001; Vankayalapati et al., 
2003), though inconsistent results are also observed among these studies. The reasons 
responsible for the disparities in blood cytokine concentrations among studies are 
multiple and complicated. Variations in individual patient, sampling timing, sample 
processing (serum or plasma), assay sensitivity, and experimental personel error, etc. may 
account for some of the differences. But some constitutional factors as discussed below 
are likely the primary reasons, at least for some of the cytokines. 
Firstly, cytokine genes are expressed at very low level. This is seen in the results 
of IL-2, IL-4, and IL-13 in this study. These undetectable cytokines by ELISA were all at 
very low gene expression levels (Figs. 6.8 and 6.10); moreover, IL-13 gene expression 
was not even detected by the real-time quantitative cDNA PCR. This is consistent with 
previous studies (Barnes et al., 1993a; Schauf et al., 1993). Therefore, these cytokines 
were either undetectable (Barnes et al., 1993b; Swaminathan et al., 1999) or at very low 
concentrations in unstimulated blood (Verbon et al., 1999; Dheda et al., 2005). With the 
exception of IL-4, it is not known whether these cytokines are biologically active at 
undetectable low concentration except IL-4. IL-4 is thought to be biologically active at 
very low concentration (reviewed by Brown and Hural, 1997 and Rook et al., 2005b). In 
addition, IL-4 appears to be present at significant different concentrations between people
in developed and developing countries because it is consistently not detectable in 
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tuberculosis patients from developed countries but easily detected in those from 
developing countries (reviewed by Rook et al., 2005b). Although IL-5 gene expression 
was not measured in the present study, a previous study (Barnes et al., 1993b) has shown 
that both IL-5 protein and mRNA were not detectable in vivo, suggesting that IL-5 is 
likely a member of the cytokines that express in vivo at very low level. 
Secondly, cytokines are mainly produced at the local site of disease, particularly 
in the case of IL-12 and TNF-α. IL-12 is a heterodimeric 70-kDa protein composed of 
two subunits (35 kDa light chain, p35 and 40 kDa heavy chain, p40) linked by a disulfide 
bond (Kobayashi et al., 1989; Stern et al., 1990). Although IL-12 is thought to be a major 
player in the protective immunity against tuberculosis, this concept is mainly based on 
evidence from in vitro stimulation studies with human cells, from individuals with IL-12 
receptor gene defects, and from gene knock-out mouse studies (reviewed by van Crevel 
et al., 2002). In keeping with the findings of the present study, the biologically active IL-
12p70 has never been detected from the serum or plasma of tuberculosis patients in 
previous studies (Zhang et al., 1994; Verbon et al., 1999) although it has been 
demonstrated to be present in tuberculous pleural fluid (Zhang et al., 1994). However, the 
IL-12p40 subunit is easily detected from the blood of tuberculosis patients (Zhang et al., 
1994; Verbon et al., 1999). IL-12p40, however, does not essentially reflect the presence 
of IL-12p70 because this subunit is shared by another different interleukin, known as IL-
23, which is an inducer of Th17 cells and cytokine (IL-17) (reviewed by Langrish et al., 
2004). These findings suggest that IL-12 may be only produced at the site of disease and 
hardly spread into the circulating system. In addition, the absence of circulating IL-12p70 
from tuberculosis patients may imply the presence of a novel pathogenic mechanism for 
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tuberculosis because it has been found that the absence of IL-12p70 can promot an 
increase in the number of IL-17-producing Ag-specific CD4 T cells both in vitro and in 
vivo (Khader et al., 2005) while IL-17 is a mediator of inflammatory responses and 
increased levels of IL-17 has been associated with several inflammatory conditions and 
tissue damage (reviewed by Witowski et al., 2004).
Although TNF-α is present at much higher concentration in local fluids (pleural 
fluid and bronchoalveolar lavage fluid) of disease sites than in blood  (Barnes et al., 
1990; Tsao et al., 1999a, 1999b; Gursel et al., 1995; Olobo et al., 2001), there have been 
many reported studies from South Korea (Kim et al., 1991), Turkey (Gursel et al., 1995; 
Cagatay yet al., 2005), South Africa (Bekker et al., 1998), Argentina (Dlugovitzky et al., 
1999; Fiorenza et al., 2005), Spain (Poveda et al., 1999), Taiwan (Tsao et al., 1999a, 
1999b), and Brazil (Ribeiro-Rodrigues et al., 2002), in which TNF-α is detected in either 
serum or plasma from tuberculosis patients. However, other studies, for example from the 
Netherlands (Juffermans et al., 1998) and Ethiopia (Olobo et al., 2001) that have found 
TNF-α to be undetectable in the sera of tuberculosis patients. The South Korean study 
(Kim et al., 1991) has shown that TNF-α concentration in lungs seems an important 
factor to affect TNF-α concentration in bloodstream; no serum TNF-α was detected if 
TNF-α concentration in lungs is low. We did not measure the cytokines in lungs, but a 
low level expression of TNF-α is likely a reason why it is not detected in our patients.
IL-10 is a potent anti-inflammatory and immunosuppressive cytokine which can 
inhibit the production of many cytokines, such as IFN-, TNF-α, IL-2, IL-4, IL-6, IL-12, 
IL-18, etc.  (reviewed by Moore et al., 2001). Like IL-12 and TNF-α, IL-10 appears to be 
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produced mainly at the site of disease (Olobo et al., 2001). It has been shown that serum 
IL-10 is elevated in tuberculosis patients compared to healthy controls (Dlugovitzky et 
al., 1997; Verbon et al., 1999; Morosini et al., 2003; Vankayalapati et al., 2003). 
However, in the studies performed by Verbon et al. (1999) and by Olobo et al. (2001) in 
which IL-10 measurement of each individual patient is presented, serum IL-10 was 
detected in only about 17% (14/81) and 42% (10/24) of the tuberculosis patients, 
respectively; moreover, serum IL-10 was also elevated in the contacts and healthy 
controls in the study by Olobo et al. (2001) but not in the study by Verbon et al. (1999). 
Therefore, the elevated serum IL-10 in tuberculosis patients demonstrated in these studies 
does not essentially mean that it was due to tuberculosis. In addition, because serum IL-
10 level does not parallel M. tuberculosis-induced IL-10 production by PBMC in vitro in 
the same patients, it has been speculated that the IL-10 in bloodstream is due to leakage 
of IL-10 from tissue into the circulation (Vankayalapati et al., 2003). Therefore, possibly 
similarly as TNF-α, a low level expression of IL-10 is likely a reason why it is not 
detected in our patients.
Although it is possible to conduct ex vivo stimulation of cells to increase cytokine 
production, this may not yield an accurate reflection of the cytokine balance present in 
vivo (Rook et al., 2001). Indeed, a recent study has shown that the concentrations of IFN-
, IL-18, and IL-10 in serum do not parallel cytokine levels produced by in vitro M. 
tuberculosis-stimulated PBMCs regardless of they are from tuberculosis patients or from 
healthy tuberculin reactors (Vankayalapati et al., 2003). However, a major shortcoming 
in our cytokine experiments is that we did not set up healthy subject controls.   
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6.4.4 Relationship between clinical parameters and cytokines
We have shown that pulmonary tuberculosis patients with fever had higher plasma IFN-
and TGF-1 compared to those without fever. This confirmed the previous finding that 
active tuberculosis patients with fever showed higher serum IFN- than those without 
fever (Verbon et al., 1999). But we did not find a significant higher level of IL-6 in the 
patients with fever, a result that is not consistent with the Verbon study (Verbon et al., 
1999). This may be due to the small sample size. Fever is a systemic biological response 
to exogenous pyrogens mediated by endogenous pyrogens, namely proinflammatory 
cytokines including IL-1, IL-6, TNF- and interferons (Netea et al., 2000a). IL-1, IL-6, 
and TNF- are potent endogenous pyrogens; IL-6 seems at the critical position in the 
cascade of cytokines acting as endogenous pyrogens in the pathogenesis of fever, IL-1 
and TNF- function as pyrogen through IL-6. IFN- may be pyrogenic through induction 
of IL-1 and TNF (Netea et al., 2000a). In the present study, IFN-, IL-6, IL-18, and TGF-
1 were all higher in tuberculosis patients with fever, suggesting stronger inflammatory 
responses in these patients. 
IFN- gene expression level was significantly higher in non-cavitary tuberculosis 
than was in cavitary tuberculosis. Conversely, IL-4 gene expression level was 
significantly lower in non-cavitary disease than was in cavitary disease. More 
interestingly, the IFN- : IL-4 cDNA copy number ratio was significantly correlated with 
non-cavitary disease. Our findings agree well with previous studies (Seah et al., 2000; 
van Crevel et al., 2000; Mazzarella et al., 2003; Bai et al., 2004). In the in vivo study by 
Seah et al. (2000), both higher IL-4 gene expression in PBMC and lower IFN- : IL-4 
cDNA copy number ratio were found to be related with more extensive radiographic 
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abnormality and with pulmonary cavities. In another in vivo study by Mazzarella et al. 
(2003), a predominant Th1 cellular immune response was observed in the lungs of non-
cavitary tuberculosis patients, while cavitary involved lung segments exhibit the presence 
of Th2 lymphocyte subset. In the study by van Crevel et al. (2000), in vitro stimulated 
CD4+ and CD8+ T cells from cavitary tuberculosis patients produced higher IL-4 than 
those from non-cavitary tuberculosis patients. Bai et al. (2004) have recently reported that 
IL-4 and IL-13 decreased in well-formed pulmonary granulomas of tuberculosis patients, 
suggesting that the absence of IL-4 and IL-13 is essential for granuloma formation.  In 
addition, in BALB/c mouse model of tuberculosis, progressive disease and reactivation of 
latent infection (Hernandez-Pando et al., 1996a, 1996b) are both associated with 
increased production of IL-4. In IL-4 gene knockout (KO) BALB/c mice, IL-4 was found 
to have modestly detrimental effects on the antibacterial efficacy of the Th1 response, 
and larger effects on the toxicity of TNF- and on fibrosis (Hernadez-Pando et al., 2004). 
Moreover, overexpression of IL-4 intensified tissue damage in experimental infection 
(Lukacs et al., 1997).
Taken together, our observations that IL-4 expression was significantly elevated 
in patients infected with non-Beijing strains but not in those infected with Beijing strains 
and these non-Beijing patients had more febrile and cavitary disease strongly suggest that 
IL-4 plays a pathogenic role in tuberculosis, especially in development of cavitary 
disease. Hence, although there are some KO mouse studies do not support a pathogenic 
role for IL-4 in tuberculosis disease (North, 1998; Jung et al., 2002), Rook et al. (2004) 
have argued that overproduction of IL-4 is a cause instead of an effect in tuberculosis and 
thought that IL-4 is a pathogenic factor for fibrosis in lung.
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The significant inverse correlation between IFN- : IL-4 cDNA copy number ratio 
and cavitary tuberculosis suggests that Th1 and Th2 immunity must maintain some extent 
of balance. If the balance is impaired, active disease would be developed from latent 
infection (Ordway et al., 2004) or cavitary disease would be developed (van Crevel et al., 
2000, and this study). In this study, all the cavitary tuberculosis had an IFN- : IL-4 
cDNA copy number ratio less than 10, and the low ratio was not only due to increased 
IL-4 (Th2 immunity) gene expression but also due to reduced IFN- (Th1 immunity) 
gene expression. This further suggests the pathogenic role of IL-4 because the reduced 
IFN- gene expression was likely a result of down regulation by over expressed IL-4.
6.4.5 Conclusions
This study suggests that the M. tuberculosis Beijing genotype strains may clinically not 
be as virulent as previously expected in tuberculosis patients; the less symptomatic and 
cavitary disease caused by Beijing strains suggests that they may be clinically less 
virulent. Importantly, the less symptomatic and/or severe disease associated with Beijing 
strains may result in delay for consultation and/or clinical overlook in the identification 
of patient, thus increasing the risk of transmission. This could be a reason accounting for 
the high prevalence and more involvement of Beijing strains in transmission.
Th1 immune response is comparable in patients infected with M. tuberculosis
Beijing versus non-Beijing strains. A Th2-polarized immunity was observed in patients 
infected with non-Beijing strains, though in contrast with previous in vitro findings 
(Manca et al., 2004). This observation, corroborating with previous findings in human 
tuberculosis studies (Seah et al., 2000; van Crevel et al., 2000; Mazzarella et al., 2003; 
135
Bai et al., 2004), can be a rational immunological basis with which to interpret the 
clinical features of our subjects. Taken together, all the findings from our study and from 
the others indicate the intriguing complexity of tuberculosis immunity; it may vary 
markedly in different hosts. This has implications for interpreting results from different 
hosts and the importance of in vivo study in tuberculosis patients as the final determinant.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS OF RESEARCH
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7.1 Genotyping of M. tuberculosis
Key factors in the control of tuberculosis are rapid detection, adequate therapy, and 
contact tracing to arrest further transmission. Genotyping of M. tuberculosis isolates is 
useful molecular epidemiological means to study transmission and to trace 
epidemiologically-related cases. As such, typing all M. tuberculosis isolates using IS6110
RFLP typing has been performed routinely in many developed countries, such as The 
Netherlands, Denmark, and Norway. In the USA, more than 25 states perform this typing. 
In other countries, such as Germany, Italy, France and Spain, routine typing is mostly 
reserved for resistant isolates (van Soolingen et al., 2003). An international IS6110 RFLP 
database has been set up in The Netherlands which has greatly facilitated tuberculosis 
studies conducted either in that country (van Soolingen et al., 1999; van Deuketom et al., 
2004, 2005) or abroad (Suffys et al., 2000; Siddiqi et al., 2001). Due to resource 
limitations, routine typing of M. tuberculosis isolates in the developing world remains 
impossible in spite of the fact that the vast majority of tuberculosis cases are in 
developing countries. In Singapore, it has been suggested that strain-typing should be 
adopted as a molecular epidemiological measure to enhance the control of tuberculosis 
(Chee and James, 2003).
Since its advent, it has been suggested that MIRU-VNTR typing could be applied 
directly on clinical specimens (Mazars et al., 2001; Supply et al., 2001), like 
spoligotyping. However, such application has not been reported until this study. The 
automated, high throughput format of MIRU-VNTR typing based on a genetic analyzer 
to detect fluorescent dye labeled PCR products has shown excellent sensitivity using 
either slab gel electrophoresis (Supply et al., 2001) or capillary electrophoresis (Sun et 
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al., 2004a) because of the employment of sensitive fluorescence detection technology. 
Indeed, in this study, using only 2 l of total DNA samples extracted directly from 
sputum in each PCR reaction, we were able to amplify the MIRU-VNTR locus sequences 
and successfully typed 41 of 42 culture-proven tuberculosis isolates. This indicates the 
great potential of MIRU-VNTR typing to be used as the first line, “real-time” M. 
tuberculosis genotyping method, or maybe as a diagnostic method.
Our work has demonstrated the feasibility of typing M. tuberculosis isolates as a 
routine using MIRU-VNTR typing as the first-line modality and reserving IS6110 RFLP 
typing as a secondary modality to subdivide isolates that are clustered in MIRU-VNTR 
typing. With direct application to clinical specimens, such as sputum, labor-intensive 
subculturing (for IS6110 RFLP) will only be required for selected isolates that are 
clustered by MIRU-VNTR typing. This will greatly reduce the workloads of subculturing 
isolates and provide “real-time” typing results for most of patients. Furthermore, MIRU-
VNTR typing may be also used as a rapid detection method.
7.2 Prevalence of Beijing genotype over time in Singapore
It has been reported that the Beijing genotype of M. tuberculosis is emerging in Vietnam 
(Anh et al., 2000), in Russia (Drobniewski et al., 2005), and in The Netherlands (Glynn et 
al., 2005). Therefore, it is of local and global interest to confirm the emerging trend of 
this genotype because it has important implications for the control or even vaccine design 
of tuberculosis. Comparison of the genotyping results of our two sets of samples that 
were separated by an interval of 10 years, suggests that there has been no major change in 
the prevalence of the Beijing genotype. In 1994, Beijing strains accounted for 
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approximately 54% (196/364, see Chapter 2) of new drug-susceptible tuberculosis, and 
10 years later it was approximately 59% (17/29, see Chapter 6) in local residents. The 
proportions of Beijing strains in the two samples were not different (p = 0.43). However, 
the two sampling populations were different in that the isolates collected in 1994 
(Chapters 2) represented the then population of drug-susceptible M. tuberculosis, whereas 
the samples collected in 2004 and 2005 (Chapter 6) represented patients with clinically 
evident (and predominantly smear positive) tuberculosis who were hospitalized for 
investigation and initiation of treatment. Thus this comparison needed to be interpreted 
with caution.
7.3 M. tuberculosis Beijing genotype: New perspectives
One salient finding in this project is that Beijing strains appeared to cause less 
symptomatic disease compared to non-Beijing strains. Possibly because of this, patients 
infected with Beijing strains took longer to be identified, which may increase the 
likelihood of spreading the bacilli. This might be a ‘selective advantage’ associated with 
the highly prevalence of M. tuberculosis Beijing strains. Due to the weaknesses of our 
study as discussed in Chapter 6, a larger, well-designed molecular epidemiological study 
is needed to confirm this finding. In such a study the correlation of the time between 
disease onset and being diagnosed with transmission clusters defined by M. tuberculosis
DNA fingerprints should be investigated on the basis of excluding the effects from 
demographic and socioeconomic factors of study subjects that may affect patient’s will to 
seek medical attention.
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One hypothesis is that the Beijing genotype is an ‘escape variant’ from the 
immune protection provided by BCG vaccination, so BCG vaccination can provide 
protection to other genotype strains but not against this ‘Beijing variant’ (van Soolingen 
et al., 1995). Because of the very high coverage of BCG vaccination in areas with high 
prevalence of Beijing strains, no association between BCG vaccination and Beijing 
strains has been established until recently. A recent multicentre study, involved in The 
Netherlands, Vietnam, and Hong Kong, has demonstrated an association, albeit rather 
weak, between BCG vaccination and Beijing genotype strains (Kremer et al., 2005). 
However, based on our observations, we postulate that the M. tuberculosis Beijing 
genotype may be an “attenuated variant” resulted from the interaction between its 
progenitor and the immune defense of BCG vaccination. Alternatively, BCG vaccination 
may provide some extent of protection against the virulence of Beijing strains, thus they 
cause less symptomatic and less severe disease. In view of the high virulence of Beijing 
strains in mice (Manca et al., 2001; López et al., 2003) and in in vitro cultured cells 
(Manca et al., 2004), as well as their rapid spreading in areas without or with low BCG 
coverage (Caminero et al., 2001; Glynn et al., 2005), the latter is perhaps more plausible. 
Future studies on this aspect would be interesting.
7.4 The pathogenic role of IL-4 in tuberculosis
As an anti-inflammatory cytokine, IL-4 is deleterious in intracellular infection, such as 
suppression of Th1 response (Biedermann et al., 2001), suppression of macrophage 
activation (van Crevel et al., 2002), switch of signaling via TLR-2 and down regulation 
of iNOS (Bogdan et al., 1994). In human tuberculosis, it has been found that IL-4 can 
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suppress the production of IL-2 and is predominant in active disease (Lucey et al., 1996).  
Studies have also demonstrated that increased IL-4 production is associated with 
advanced radiological disease (Seah et al., 2000), with cavitary disease (van Crevel et al., 
2000), and with progression from latent infection to active disease (Ordway et al., 2004). 
All these data suggest a pathogenic role for IL-4 in tuberculosis. However, evidence from 
mouse studies are contradictory. In BALB/c mice infected with M. tuberculosis, 
progressive disease and reactivation of latent infection are both associated with increased 
production of IL-4 (Hernandez Pando et al., 1996a, 1996b), and overexpression of IL-4 
intensified tissue damage in experimental infection (Lukacs et al., 1997). These are in 
agreement with the findings from humans. On the other hand, results from studies with 
KO mice do not support a pathogenic role for IL-4 in mouse tuberculosis (North, 1998; 
Jung et al., 2002). Our study represented the first in vivo human study that has 
demonstrated the different IL-4 responses in patients infected with Beijing and non-
Beijing strains. In the patients infected with non-Beijing strains, IL-4 expressed markedly 
higher and that was correlated with severe disease, such as fever and cavitation. These 
linkages among etiological pathogen, disease development mediator, and disease 
presentation strongly suggest that IL-4 is a pathogenic factor in tuberculosis. The 
establishment of IL-4 as a pathogenic cytokine in tuberculosis has important implications 
for therapy and for vaccine design. Studies on this direction are essential to shed more 
light on issues, such as in what way M. tuberculosis overactivates IL-4 expression, and 
how IL-4 causes disease.
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Figure 2.1. Spoligotyping patterns of the 364 drug-susceptible isolates. A total of 118 
distinct spoligotyping patterns were generated. The patterns were grouped by the families 
of M. tuberculosis based on the common characteristics of spoligotypes of each family. 
The S family is a novel clone defined in this study (see Chapter 3).














































































































































Table 2.3.    MIRU-VNTR patterns of drug-susceptible isolates 
Families Pattern MIRU-VNTR loci No.of 
No. 2 4 10 16 20 23 24 26 27 31 39 40 isolates
Beijing
1 2 0 3 3 2 5 1 7 3 5 2 3 1
2 2 0 3 3 2 5 1 7 3 5 3 3 2
3 2 2 1 3 2 5 1 7 3 5 3 3 1
4 2 2 1 3 2 7 1 7 3 5 3 4 1
5 2 2 2 2 2 5 1 7 3 5 4 3 1
6 2 2 2 3 2 5 1 1 3 3 2 2 1
7 2 2 2 3 2 5 1 5 2 3 2 2 1
8 2 2 2 3 2 5 1 5 3 3 4 2 2
9 2 2 2 3 2 5 1 6 3 5 4 3 2
10 2 2 2 3 2 5 1 7 1 5 4 1 1
11 2 2 2 3 2 5 1 7 3 3 4 3 1
12 2 2 2 3 2 5 1 7 3 5 2 3 3
13 2 2 2 3 2 5 1 7 3 5 3 3 10
14 2 2 2 3 2 5 1 7 3 5 4 3 17
15 2 2 2 3 2 5 1 9 3 5 4 3 2
16 2 2 3 1 2 5 1 7 3 4 3 3 1
17 2 2 3 2 2 5 1 5 1 5 3 3 2
18 2 2 3 2 2 5 1 5 2 5 2 2 1
19 2 2 3 2 2 5 1 7 3 5 3 3 4
20 2 2 3 3 1 5 1 7 3 5 3 3 1
21 2 2 3 3 2 5 1 1 3 4 3 3 1
22 2 2 3 3 2 5 1 1 3 5 3 3 1
23 2 2 3 3 2 5 1 2 3 5 2 2 1
24 2 2 3 3 2 5 1 2 3 5 3 3 1
25 2 2 3 3 2 5 1 4 3 4 3 3 1
26 2 2 3 3 2 5 1 4 3 5 2 3 1
27 2 2 3 3 2 5 1 5 3 4 3 3 1
28 2 2 3 3 2 5 1 5 3 4 3 4 1
29 2 2 3 3 2 5 1 5 3 5 2 3 1
30 2 2 3 3 2 5 1 5 3 5 3 3 3
31 2 2 3 3 2 5 1 6 2 5 3 3 1
32 2 2 3 3 2 5 1 6 3 2 1 3 1
33 2 2 3 3 2 5 1 6 3 5 3 2 2
34 2 2 3 3 2 5 1 6 3 5 3 3 14
35 2 2 3 3 2 5 1 6 3 5 3 4 1
36 2 2 3 3 2 5 1 7 1 5 3 1 3
37 2 2 3 3 2 5 1 7 3 1 2 3 1
38 2 2 3 3 2 5 1 7 3 2 1 3 1
39 2 2 3 3 2 5 1 7 3 2 2 1 1
40 2 2 3 3 2 5 1 7 3 3 3 1 1
183
                         Table 2.3. continued
Families Pattern MIRU-VNTR loci No.of 
No. 2 4 10 16 20 23 24 26 27 31 39 40 isolates
Beijing
41 2 2 3 3 2 5 1 7 3 4 3 3 6
42 2 2 3 3 2 5 1 7 3 5 1 3 4
43 2 2 3 3 2 5 1 7 3 5 2 3 8
44 2 2 3 3 2 5 1 7 3 5 3 1 1
45 2 2 3 3 2 5 1 7 3 5 3 2 7
46 2 2 3 3 2 5 1 7 3 5 3 3 58
47 2 2 3 3 2 5 1 7 3 5 3 4 2
48 2 2 3 3 2 5 1 7 3 5 4 3 3
49 2 2 3 3 2 5 1 7 3 5 5 3 1
50 2 2 3 3 2 5 1 7 3 6 3 1 1
51 2 2 3 3 2 5 1 7 3 6 3 3 2
52 2 2 3 3 2 5 1 8 3 5 3 1 1
53 2 2 3 3 2 5 1 8 3 5 3 3 5
54 2 2 3 3 2 6 1 1 2 4 2 4 1
55 2 2 3 3 2 6 1 7 3 5 3 3 2
56 2 3 3 3 2 5 1 7 3 5 3 2 1
CAS
57 1 2 4 4 2 5 1 8 3 5 3 4 1
58 2 2 7 4 2 5 1 1 3 4 3 4 1
EAI
59 2 1 5 3 2 6 2 2 3 4 3 4 1
60 2 2 4 1 2 5 1 2 3 5 3 3 1
61 2 2 4 2 2 6 2 2 3 4 3 2 1
62 2 2 4 3 2 4 2 2 3 4 2 2 1
63 2 2 4 3 2 6 2 2 2 4 3 2 1
64 2 3 4 3 2 4 2 2 3 5 2 3 1
65 2 3 4 3 2 6 2 2 3 3 3 2 1
66 2 3 4 3 2 6 2 2 3 4 3 4 1
67 2 4 4 3 2 5 1 2 2 2 2 2 1
68 2 4 4 3 2 6 2 2 1 5 3 2 1
69 2 4 4 3 2 6 2 2 3 4 3 1 1
70 2 5 3 3 2 4 2 2 3 6 3 3 1
71 2 5 4 1 2 6 2 2 3 4 2 2 1
72 2 5 4 1 2 6 2 2 3 5 3 4 1
73 2 5 4 2 2 5 2 2 3 5 3 3 1
74 2 5 4 2 2 5 3 2 3 2 3 3 1
75 2 5 4 2 2 6 2 2 3 4 2 5 1
76 2 5 4 3 1 6 2 2 3 4 3 2 1
77 2 5 4 3 2 1 2 2 3 4 1 4 1
78 2 5 4 3 2 1 2 2 3 5 1 3 1
184
                          
                                    Table 2.3. continued
Families Pattern MIRU-VNTR loci No.of 
No. 2 4 10 16 20 23 24 26 27 31 39 40 isolates
EAI
79 2 5 4 3 2 2 2 2 3 4 1 2 1
80 2 5 4 3 2 3 2 2 3 5 3 3 1
81 2 5 4 3 2 4 2 2 3 4 2 2 1
82 2 5 4 3 2 4 2 2 3 5 2 2 1
83 2 5 4 3 2 6 2 2 1 1 3 4 1
84 2 5 4 3 2 6 2 2 1 4 2 2 1
85 2 5 4 3 2 6 2 2 2 3 4 2 1
86 2 5 4 3 2 6 2 2 3 2 3 2 1
87 2 5 4 3 2 6 2 2 3 2 3 4 1
88 2 5 4 3 2 6 2 2 3 4 1 2 1
89 2 5 4 3 2 6 2 2 3 4 2 2 4
90 2 5 4 3 2 6 2 2 3 4 3 1 2
91 2 5 4 3 2 6 2 2 3 4 3 2 13
92 2 5 4 3 2 6 2 2 3 4 3 4 2
93 2 5 4 3 2 6 2 2 3 4 4 4 1
94 2 5 4 3 2 6 2 2 3 5 1 4 1
95 2 5 4 3 2 6 2 2 3 5 3 2 1
96 2 5 4 3 2 6 2 2 3 5 4 4 1
97 2 5 4 3 2 7 2 2 3 4 3 4 1
98 2 5 5 3 2 6 2 5 3 4 3 2 1
99 2 5 6 3 2 6 2 7 3 5 1 3 1
100 2 6 4 1 2 5 1 2 3 5 3 3 1
101 2 6 4 2 2 5 2 2 3 5 3 2 1
102 2 6 4 2 2 5 2 2 3 5 2 3 2
103 2 6 4 3 1 6 2 2 3 4 3 2 1
104 2 6 4 3 2 6 2 2 3 4 3 2 3
105 2 6 4 3 2 6 2 2 3 4 4 2 1
106 2 6 4 3 2 6 2 2 4 6 3 5 1
107 2 7 4 2 2 4 2 2 3 4 3 4 1
108 2 7 4 2 2 5 2 2 3 5 3 3 1
109 2 7 4 3 2 6 2 2 2 1 4 4 1
110 2 7 4 3 2 6 2 2 3 4 3 4 1
111 2 9 4 3 2 6 2 2 3 5 3 3 1
112 3 2 4 2 2 5 2 2 3 5 3 3 1
113 3 9 4 2 2 5 2 2 3 4 3 3 1
114 2 5 4 3 1 12 2 2 3 4 2 3 1
115 2 5 4 3 2 10 2 2 3 3 3 3 1
116 2 1 4 3 2 4 2 2 3 5 3 3 1
117 2 5 4 3 2 6 2 2 3 4 2 2 1
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                        Table 2.3. continued
Families Pattern MIRU-VNTR loci No.of 
No. 2 4 10 16 20 23 24 26 27 31 39 40 isolates
Haarlem
118 2 2 0 3 2 5 1 4 3 3 2 3 1
119 2 2 2 2 2 5 1 5 3 3 2 2 1
120 2 2 2 3 2 4 1 5 3 3 2 3 1
121 2 2 2 3 2 5 1 4 3 2 2 3 1
122 2 2 2 3 2 5 1 5 1 3 2 3 1
123 2 2 2 3 2 5 1 5 3 2 2 3 2
124 2 2 2 3 2 5 1 5 3 3 2 3 6
125 2 2 2 3 2 5 1 6 3 3 2 3 1
126 2 2 2 4 2 5 1 4 3 3 2 4 1
127 2 2 4 3 2 5 1 4 3 3 2 3 1
128 2 2 5 1 2 5 1 1 3 3 2 2 3
129 2 2 5 3 2 5 1 4 3 3 2 3 1
130 2 2 5 3 2 5 1 5 3 3 2 3 2
131 2 2 6 3 2 5 1 5 3 3 2 3 2
132 2 2 6 4 2 3 1 5 3 3 2 4 1
133 2 2 7 2 2 5 1 1 3 3 2 2 1
134 2 3 2 3 2 5 1 6 3 3 2 1 1
135 2 3 2 3 2 5 1 5 3 3 2 3 2
LAM
136 1 2 4 3 2 6 1 5 2 2 2 6 1
137 2 2 2 2 2 4 1 5 3 2 2 3 1
138 2 2 3 3 1 6 1 5 3 2 2 6 1
139 2 2 4 4 2 4 1 4 3 2 2 1 1
140 2 3 2 3 2 5 1 3 2 3 2 2 1
141 2 4 2 3 2 5 1 5 2 2 2 1 1
S
142 2 2 3 2 2 5 1 7 3 4 3 3 1
143 2 2 5 2 2 5 1 7 3 4 3 3 3
144 2 2 6 2 2 5 1 7 3 4 3 3 1
145 2 2 7 2 2 5 1 7 3 4 3 3 3
146 2 2 7 2 2 5 1 7 3 4 3 4 1
147 2 2 8 2 2 5 1 6 3 4 3 3 1
148 2 2 8 2 2 5 1 7 3 4 2 2 1
149 2 2 8 2 2 5 1 7 3 4 3 2 1
150 2 2 8 2 2 5 1 7 3 4 3 3 1
151 2 2 8 2 2 5 1 7 3 4 4 3 2
152 2 2 9 2 2 5 1 7 3 4 3 3 1
186
                           Table 2.3. continued
Families Pattern MIRU-VNTR loci No.of 
No. 2 4 10 16 20 23 24 26 27 31 39 40 isolates
T
153 2 1 2 2 2 5 1 1 2 3 2 3 1
154 2 2 2 2 2 5 1 1 3 3 2 2 2
155 2 2 2 3 2 5 1 5 3 3 2 2 1
156 2 2 2 4 2 5 1 6 3 3 2 2 1
157 2 2 2 4 2 6 1 5 3 3 2 2 1
158 2 2 3 3 2 5 1 5 3 3 2 1 1
159 2 2 4 3 2 5 1 5 3 3 2 3 1
160 2 2 5 1 2 5 1 1 1 2 2 2 2
161 2 2 5 1 2 5 1 1 3 1 2 2 1
162 2 3 4 3 2 5 1 5 2 3 3 2 1
163 2 3 4 3 2 5 1 5 3 3 2 3 1
164 2 4 2 3 2 4 1 1 2 3 2 2 1
165 2 4 2 3 2 4 1 5 2 3 2 2 3
166 2 4 2 3 2 4 1 5 3 3 2 1 1
167 2 4 2 3 2 4 1 5 3 3 2 2 1
168 2 4 2 3 2 5 1 2 2 3 2 2 2
169 2 4 2 3 2 5 1 3 2 2 2 2 1
170 2 4 2 3 2 5 1 4 2 3 2 3 1
171 2 4 2 3 2 5 1 4 2 4 2 2 1
172 2 4 2 3 2 5 1 5 2 3 2 1 1
173 2 4 2 3 2 5 1 5 2 3 2 2 7
X
174 2 2 4 3 2 5 1 5 3 3 3 2 1
175 2 2 4 3 2 5 1 6 3 3 2 4 1
176 2 2 4 4 2 5 1 2 3 3 2 3 1
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